head,relation,tail
NCT01639248,has_title,A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Local
NCT01639248,has_status,COMPLETED
NCT01639248,has_phase,
NCT01639248,sponsored_by,"CASI Pharmaceuticals, Inc."
NCT01639248,tests,ENMD-2076
ENMD-2076,has_type,DRUG
NCT02580448,has_title,"A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy"
NCT02580448,has_status,COMPLETED
NCT02580448,has_phase,
NCT02580448,sponsored_by,Innocrin Pharmaceutical
NCT02580448,tests,Seviteronel
Seviteronel,has_type,DRUG
NCT03639948,has_title,Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast
NCT03639948,has_status,ACTIVE_NOT_RECRUITING
NCT03639948,has_phase,
NCT03639948,sponsored_by,University of Kansas Medical Center
NCT03639948,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03639948,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT03639948,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03639948,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT03414684,has_title,A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple
NCT03414684,has_status,ACTIVE_NOT_RECRUITING
NCT03414684,has_phase,
NCT03414684,sponsored_by,Dana-Farber Cancer Institute
NCT03414684,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03414684,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT04592484,has_title,"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Inject"
NCT04592484,has_status,COMPLETED
NCT04592484,has_phase,
NCT04592484,sponsored_by,Codiak BioSciences
NCT04592484,tests,CDK-002
CDK-002,has_type,BIOLOGICAL
NCT01662284,has_title,A Phase 1/2 Study of 124I-NM404 in Subjects With Advanced Solid Malignancies
NCT01662284,has_status,TERMINATED
NCT01662284,has_phase,
NCT01662284,sponsored_by,"University of Wisconsin, Madison"
NCT01662284,tests,124I-NM404
124I-NM404,has_type,DRUG
NCT01094184,has_title,Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-Line Treatment of Pa
NCT01094184,has_status,COMPLETED
NCT01094184,has_phase,
NCT01094184,sponsored_by,Hoffmann-La Roche
NCT01094184,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01094184,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01094184,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT04067102,has_title,Albumin Bound (Nab)-Paclitaxel Combined With Carboplatin Versus Paclitaxel Combined With Carboplatin
NCT04067102,has_status,WITHDRAWN
NCT04067102,has_phase,
NCT04067102,sponsored_by,Hebei Medical University Fourth Hospital
NCT04067102,tests,Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,has_type,DRUG
NCT04067102,tests,paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide,has_type,DRUG
NCT04514484,has_title,Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
NCT04514484,has_status,ACTIVE_NOT_RECRUITING
NCT04514484,has_phase,
NCT04514484,sponsored_by,National Cancer Institute (NCI)
NCT04514484,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04514484,tests,Cabozantinib S-malate
Cabozantinib S-malate,has_type,DRUG
NCT04514484,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT04514484,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT04514484,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03125902,has_title,"A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-P"
NCT03125902,has_status,COMPLETED
NCT03125902,has_phase,
NCT03125902,sponsored_by,Hoffmann-La Roche
NCT03125902,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
NCT03125902,tests,Atezolizumab Placebo
Atezolizumab Placebo,has_type,DRUG
NCT03125902,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05460702,has_title,Evaluation of the Relationship Between Stage I-II Breast Cancer Subtypes and Soluble Immune Checkpoi
NCT05460702,has_status,COMPLETED
NCT05460702,has_phase,
NCT05460702,sponsored_by,Istanbul Training and Research Hospital
NCT05460702,tests,Soluble immune checkpoints
Soluble immune checkpoints,has_type,DIAGNOSTIC_TEST
NCT05955521,has_title,Development of a Prognostic and Predictive Biomarker for Locally Advanced Breast Cancer Patients Tre
NCT05955521,has_status,ACTIVE_NOT_RECRUITING
NCT05955521,has_phase,
NCT05955521,sponsored_by,Samsung Medical Center
NCT05955521,tests,exosome and ctDNA evaluation
exosome and ctDNA evaluation,has_type,PROCEDURE
NCT02850302,has_title,
NCT02850302,has_status,COMPLETED
NCT02850302,has_phase,
NCT02850302,sponsored_by,Centre Georges Francois Leclerc
NCT02850302,tests,PET with FDG
PET with FDG,has_type,OTHER
NCT02850302,tests,Tumor exome analysis
Tumor exome analysis,has_type,OTHER
NCT03742102,has_title,"A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durval"
NCT03742102,has_status,ACTIVE_NOT_RECRUITING
NCT03742102,has_phase,
NCT03742102,sponsored_by,AstraZeneca
NCT03742102,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03742102,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT03742102,tests,Oleclumab
Oleclumab,has_type,DRUG
NCT03742102,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03742102,tests,Trastuzumab deruxtecan
Trastuzumab deruxtecan,has_type,DRUG
NCT03742102,tests,Datopotamab deruxtecan
Datopotamab deruxtecan,has_type,DRUG
NCT03340402,has_title,Pilot Study of Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer
NCT03340402,has_status,WITHDRAWN
NCT03340402,has_phase,
NCT03340402,sponsored_by,Massachusetts General Hospital
NCT03340402,tests,Accelerated Partial Breast Irradiation
Accelerated Partial Breast Irradiation,has_type,RADIATION
NCT03340402,tests,AlignRT
AlignRT,has_type,DEVICE
NCT00546364,has_title,IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Plus Capecitabine or C
NCT00546364,has_status,TERMINATED
NCT00546364,has_phase,
NCT00546364,sponsored_by,R-Pharm
NCT00546364,tests,"Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2"
"Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2",has_type,DRUG
NCT00546364,tests,"Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2"
"Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2",has_type,DRUG
NCT00546364,tests,"Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2"
"Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2",has_type,DRUG
NCT01234402,has_title,"An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirum"
NCT01234402,has_status,COMPLETED
NCT01234402,has_phase,
NCT01234402,sponsored_by,Eli Lilly and Company
NCT01234402,tests,Ramucirumab DP
Ramucirumab DP,has_type,BIOLOGICAL
NCT01234402,tests,IMC-18F1
IMC-18F1,has_type,BIOLOGICAL
NCT01234402,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06264921,has_title,"A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminar"
NCT06264921,has_status,ACTIVE_NOT_RECRUITING
NCT06264921,has_phase,
NCT06264921,sponsored_by,"NiKang Therapeutics, Inc."
NCT06264921,tests,NKT3447
NKT3447,has_type,DRUG
NCT04521621,has_title,A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab
NCT04521621,has_status,TERMINATED
NCT04521621,has_phase,
NCT04521621,sponsored_by,Merck Sharp & Dohme LLC
NCT04521621,tests,Gebasaxturev
Gebasaxturev,has_type,BIOLOGICAL
NCT04521621,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04849364,has_title,"A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients "
NCT04849364,has_status,TERMINATED
NCT04849364,has_phase,
NCT04849364,sponsored_by,"Bryan Schneider, MD"
NCT04849364,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04849364,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04849364,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04849364,tests,Inavolisib
Inavolisib,has_type,DRUG
NCT02936102,has_title,"A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combinati"
NCT02936102,has_status,TERMINATED
NCT02936102,has_phase,
NCT02936102,sponsored_by,Novartis Pharmaceuticals
NCT02936102,tests,FAZ053
FAZ053,has_type,DRUG
NCT02936102,tests,PDR001
PDR001,has_type,DRUG
NCT01071564,has_title,A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Plus Pan-Notch Inhibit
NCT01071564,has_status,TERMINATED
NCT01071564,has_phase,
NCT01071564,sponsored_by,National Cancer Institute (NCI)
NCT01071564,tests,Gamma-Secretase Inhibitor RO4929097
Gamma-Secretase Inhibitor RO4929097,has_type,DRUG
NCT01071564,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01071564,tests,Pharmacogenomic Study
Pharmacogenomic Study,has_type,OTHER
NCT01071564,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01071564,tests,Vismodegib
Vismodegib,has_type,DRUG
NCT02900664,has_title,"Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynami"
NCT02900664,has_status,COMPLETED
NCT02900664,has_phase,
NCT02900664,sponsored_by,Novartis Pharmaceuticals
NCT02900664,tests,PDR001
PDR001,has_type,BIOLOGICAL
NCT02900664,tests,ACZ885
ACZ885,has_type,BIOLOGICAL
NCT02900664,tests,CJM112
CJM112,has_type,BIOLOGICAL
NCT02900664,tests,TMT212
TMT212,has_type,DRUG
NCT02900664,tests,EGF816
EGF816,has_type,DRUG
NCT00203502,has_title,Primary Systemic Therapy Using Sequential Docetaxel/Cyclophosphamide/Bevacizumab Followed by Doxorub
NCT00203502,has_status,COMPLETED
NCT00203502,has_phase,
NCT00203502,sponsored_by,University of Arkansas
NCT00203502,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00203502,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00203502,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01045421,has_title,"A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Non"
NCT01045421,has_status,COMPLETED
NCT01045421,has_phase,
NCT01045421,sponsored_by,"Millennium Pharmaceuticals, Inc."
NCT01045421,tests,MLN8237 (Alisertib)
MLN8237 (Alisertib),has_type,DRUG
NCT05336721,has_title,"An Open Labelled, Multicenter-phase II Study of Chiauranib Combine With Capecitabine in Advanced Tri"
NCT05336721,has_status,TERMINATED
NCT05336721,has_phase,
NCT05336721,sponsored_by,"Chipscreen Biosciences, Ltd."
NCT05336721,tests,Chiauranib
Chiauranib,has_type,DRUG
NCT05336721,tests,capecitabine
capecitabine,has_type,DRUG
NCT02124902,has_title,A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery
NCT02124902,has_status,TERMINATED
NCT02124902,has_phase,
NCT02124902,sponsored_by,Washington University School of Medicine
NCT02124902,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02124902,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02124902,tests,FDG-PET/MR
FDG-PET/MR,has_type,PROCEDURE
NCT04916002,has_title,"A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With I"
NCT04916002,has_status,TERMINATED
NCT04916002,has_phase,
NCT04916002,sponsored_by,Regeneron Pharmaceuticals
NCT04916002,tests,vidutolimod
vidutolimod,has_type,DRUG
NCT04916002,tests,cemiplimab
cemiplimab,has_type,DRUG
NCT01207102,has_title,"A Phase II Study of Abraxane® and Carboplatin as First-line Treatment for ""Triple Negative"" (Demonst"
NCT01207102,has_status,TERMINATED
NCT01207102,has_phase,
NCT01207102,sponsored_by,Duke University
NCT01207102,tests,Abraxane
Abraxane,has_type,DRUG
NCT01207102,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01015521,has_title,A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positi
NCT01015521,has_status,WITHDRAWN
NCT01015521,has_phase,
NCT01015521,sponsored_by,Tigris Pharmaceuticals
NCT01015521,tests,Aminoflavone Prodrug
Aminoflavone Prodrug,has_type,DRUG
NCT03945721,has_title,A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Brea
NCT03945721,has_status,ACTIVE_NOT_RECRUITING
NCT03945721,has_phase,
NCT03945721,sponsored_by,Massachusetts General Hospital
NCT03945721,tests,Niraparib
Niraparib,has_type,DRUG
NCT03945721,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT01837602,has_title,Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Br
NCT01837602,has_status,COMPLETED
NCT01837602,has_phase,
NCT01837602,sponsored_by,University of Pennsylvania
NCT01837602,tests,cMet RNA CAR T cells
cMet RNA CAR T cells,has_type,BIOLOGICAL
NCT04549584,has_title,Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
NCT04549584,has_status,TERMINATED
NCT04549584,has_phase,
NCT04549584,sponsored_by,Seoul National University Hospital
NCT04549584,tests,Vimentin/pan CK stain
Vimentin/pan CK stain,has_type,DIAGNOSTIC_TEST
NCT00749502,has_title,A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies
NCT00749502,has_status,COMPLETED
NCT00749502,has_phase,
NCT00749502,sponsored_by,"Tesaro, Inc."
NCT00749502,tests,MK-4827
MK-4827,has_type,DRUG
NCT02876302,has_title,Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Neg
NCT02876302,has_status,ACTIVE_NOT_RECRUITING
NCT02876302,has_phase,
NCT02876302,sponsored_by,Dana-Farber Cancer Institute
NCT02876302,tests,Ruxolitinib
Ruxolitinib,has_type,DRUG
NCT02876302,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02876302,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02876302,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01147484,has_title,"A Phase II Study of Foretinib in Patients With Estrogen Receptor (ER), Progesterone Receptor (PR), a"
NCT01147484,has_status,COMPLETED
NCT01147484,has_phase,
NCT01147484,sponsored_by,NCIC Clinical Trials Group
NCT01147484,tests,Foretinib
Foretinib,has_type,DRUG
NCT02402764,has_title,Investigator-Initiated Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Metastatic
NCT02402764,has_status,COMPLETED
NCT02402764,has_phase,
NCT02402764,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT02402764,tests,Selinexor
Selinexor,has_type,DRUG
NCT02926690,has_title,"A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics"
NCT02926690,has_status,ACTIVE_NOT_RECRUITING
NCT02926690,has_phase,
NCT02926690,sponsored_by,"OncoTherapy Science, Inc."
NCT02926690,tests,OTS167PO
OTS167PO,has_type,DRUG
NCT04134884,has_title,A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ H
NCT04134884,has_status,COMPLETED
NCT04134884,has_phase,
NCT04134884,sponsored_by,Kathy Miller
NCT04134884,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04134884,tests,ASTX727
ASTX727,has_type,DRUG
NCT05694364,has_title,A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Adv
NCT05694364,has_status,ACTIVE_NOT_RECRUITING
NCT05694364,has_phase,
NCT05694364,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05694364,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT05694364,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05694364,tests,PRGN-3007
PRGN-3007,has_type,BIOLOGICAL
NCT04925284,has_title,A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent an
NCT04925284,has_status,COMPLETED
NCT04925284,has_phase,
NCT04925284,sponsored_by,Exelixis
NCT04925284,tests,XB002
XB002,has_type,DRUG
NCT04925284,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT04925284,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT04927884,has_title,Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment 
NCT04927884,has_status,TERMINATED
NCT04927884,has_phase,
NCT04927884,sponsored_by,"ImmunityBio, Inc."
NCT04927884,tests,N-803
N-803,has_type,BIOLOGICAL
NCT04927884,tests,PD-L1 t-haNK
PD-L1 t-haNK,has_type,BIOLOGICAL
NCT04927884,tests,Sacituzumab Govitecan-Hziy
Sacituzumab Govitecan-Hziy,has_type,DRUG
NCT04927884,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01250379,has_title,A Phase III Randomized Study Evaluating the Efficacy and Safety of Continued and Re-induced Bevacizu
NCT01250379,has_status,COMPLETED
NCT01250379,has_phase,
NCT01250379,sponsored_by,Hoffmann-La Roche
NCT01250379,tests,bevacizumab [Avastin]
bevacizumab [Avastin],has_type,DRUG
NCT01250379,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT00691379,has_title,Weekly Paclitaxel-carboplatin Plus Bevacizumab as First Line Therapy for Patients With Triple Negati
NCT00691379,has_status,COMPLETED
NCT00691379,has_phase,
NCT00691379,sponsored_by,Hellenic Oncology Research Group
NCT00691379,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00691379,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00691379,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04803084,has_title,Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment in Breast Cancer
NCT04803084,has_status,SUSPENDED
NCT04803084,has_phase,
NCT04803084,sponsored_by,Laura Kennedy
NCT04803084,tests,Tempus assay
Tempus assay,has_type,OTHER
NCT04803084,tests,Advanced pathology 1
Advanced pathology 1,has_type,OTHER
NCT04803084,tests,Advanced pathology 2
Advanced pathology 2,has_type,OTHER
NCT03777579,has_title,"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of JS001 (Anti-PD-1 Antibody) in Comb"
NCT03777579,has_status,SUSPENDED
NCT03777579,has_phase,
NCT03777579,sponsored_by,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd."
NCT03777579,tests,JS001，an engineered anti-PD-1 antibody
JS001，an engineered anti-PD-1 antibody,has_type,DRUG
NCT03777579,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT03777579,tests,Placebo
Placebo,has_type,DRUG
NCT03457779,has_title,Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative (TN) Breast Canc
NCT03457779,has_status,COMPLETED
NCT03457779,has_phase,
NCT03457779,sponsored_by,Baylor Research Institute
NCT03457779,tests,Glucose
Glucose,has_type,DIETARY_SUPPLEMENT
NCT01779479,has_title,"Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus W"
NCT01779479,has_status,COMPLETED
NCT01779479,has_phase,
NCT01779479,sponsored_by,GBG Forschungs GmbH
NCT01779479,tests,Cabacitaxel
Cabacitaxel,has_type,DRUG
NCT01779479,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02161679,has_title,Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Rela
NCT02161679,has_status,WITHDRAWN
NCT02161679,has_phase,
NCT02161679,sponsored_by,Gilead Sciences
NCT02161679,tests,IMMU-132 infusion is administered to participants in one arm for the study
IMMU-132 infusion is administered to participants in one arm for the study,has_type,DRUG
NCT02161679,tests,IMMU-132 plus Carboplatin infusion
IMMU-132 plus Carboplatin infusion,has_type,DRUG
NCT03383679,has_title,A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recur
NCT03383679,has_status,COMPLETED
NCT03383679,has_phase,
NCT03383679,sponsored_by,UNICANCER
NCT03383679,tests,Darolutamide
Darolutamide,has_type,DRUG
NCT03383679,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT00633464,has_title,Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatmen
NCT00633464,has_status,COMPLETED
NCT00633464,has_phase,
NCT00633464,sponsored_by,R-Pharm
NCT00633464,tests,ixabepilone
ixabepilone,has_type,DRUG
NCT00633464,tests,ixabepilone + cetuximab
ixabepilone + cetuximab,has_type,DRUG
NCT05252390,has_title,Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or En
NCT05252390,has_status,TERMINATED
NCT05252390,has_phase,
NCT05252390,sponsored_by,Nuvation Bio Inc.
NCT05252390,tests,NUV-868
NUV-868,has_type,DRUG
NCT05252390,tests,Olaparib
Olaparib,has_type,DRUG
NCT05252390,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT01194908,has_title,Phase I/II Trial of Tamoxifen Following Epigenetic Regeneration of Estrogen Receptor Using Decitabin
NCT01194908,has_status,TERMINATED
NCT01194908,has_phase,
NCT01194908,sponsored_by,Emory University
NCT01194908,tests,"Decitabine, LBH589, Tamoxifen"
"Decitabine, LBH589, Tamoxifen",has_type,DRUG
NCT03449108,has_title,Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured 
NCT03449108,has_status,ACTIVE_NOT_RECRUITING
NCT03449108,has_phase,
NCT03449108,sponsored_by,M.D. Anderson Cancer Center
NCT03449108,tests,Aldesleukin
Aldesleukin,has_type,BIOLOGICAL
NCT03449108,tests,Autologous Tumor Infiltrating Lymphocytes LN-145
Autologous Tumor Infiltrating Lymphocytes LN-145,has_type,BIOLOGICAL
NCT03449108,tests,Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Autologous Tumor Infiltrating Lymphocytes LN-145-S1,has_type,BIOLOGICAL
NCT03449108,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03449108,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT03449108,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT03449108,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03449108,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03449108,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT00733408,has_title,Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly 
NCT00733408,has_status,COMPLETED
NCT00733408,has_phase,
NCT00733408,sponsored_by,University of Washington
NCT00733408,tests,paclitaxel albumin-stabilized nanoparticle formulation
paclitaxel albumin-stabilized nanoparticle formulation,has_type,DRUG
NCT00733408,tests,bevacizumab
bevacizumab,has_type,BIOLOGICAL
NCT00733408,tests,erlotinib hydrochloride
erlotinib hydrochloride,has_type,DRUG
NCT02370238,has_title,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Repar"
NCT02370238,has_status,COMPLETED
NCT02370238,has_phase,
NCT02370238,sponsored_by,Dompé Farmaceutici S.p.A
NCT02370238,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT02370238,tests,Reparixin
Reparixin,has_type,DRUG
NCT02370238,tests,placebo
placebo,has_type,DRUG
NCT04596150,has_title,"A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine"
NCT04596150,has_status,COMPLETED
NCT04596150,has_phase,
NCT04596150,sponsored_by,CytomX Therapeutics
NCT04596150,tests,CX-2009
CX-2009,has_type,DRUG
NCT04596150,tests,CX-072
CX-072,has_type,DRUG
NCT04291950,has_title,Epigenetics of Triple-Negative Breast Cancer in Overweight and Obese Hispanic and Non-Hispanic White
NCT04291950,has_status,WITHDRAWN
NCT04291950,has_phase,
NCT04291950,sponsored_by,University of Arizona
NCT04291950,tests,Needle core biopsy
Needle core biopsy,has_type,PROCEDURE
NCT02897050,has_title,Phase II Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With 
NCT02897050,has_status,SUSPENDED
NCT02897050,has_phase,
NCT02897050,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT02897050,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02897050,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02897050,tests,Cyclophosphamide (tablet)
Cyclophosphamide (tablet),has_type,DRUG
NCT02897050,tests,Fluorouracil
Fluorouracil,has_type,DRUG
NCT02897050,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02897050,tests,Cyclophosphamide (injection)
Cyclophosphamide (injection),has_type,DRUG
NCT02259114,has_title,"A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Termin"
NCT02259114,has_status,COMPLETED
NCT02259114,has_phase,
NCT02259114,sponsored_by,"Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)"
NCT02259114,tests,Birabresib
Birabresib,has_type,DRUG
NCT05809895,has_title,"AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Evaluating the Efficacy"
NCT05809895,has_status,WITHDRAWN
NCT05809895,has_phase,
NCT05809895,sponsored_by,Novartis Pharmaceuticals
NCT05809895,tests,Ociperlimab
Ociperlimab,has_type,DRUG
NCT05809895,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT05809895,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05809895,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05809895,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05809895,tests,Placebo
Placebo,has_type,DRUG
NCT05809895,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05809895,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02263495,has_title,"A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemci"
NCT02263495,has_status,COMPLETED
NCT02263495,has_phase,
NCT02263495,sponsored_by,Asan Medical Center
NCT02263495,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02263495,tests,Eribulin
Eribulin,has_type,DRUG
NCT02263495,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03634150,has_title,"A Phase 1b, Open-Label, Dose-Confirmation Study Evaluating the Safety, and Clinical Effects of Intra"
NCT03634150,has_status,WITHDRAWN
NCT03634150,has_phase,
NCT03634150,sponsored_by,Immune System Key Ltd
NCT03634150,tests,"Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties."
"Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.",has_type,BIOLOGICAL
NCT03301350,has_title,A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosp
NCT03301350,has_status,COMPLETED
NCT03301350,has_phase,
NCT03301350,sponsored_by,"University of Wisconsin, Madison"
NCT03301350,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03301350,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03301350,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT03301350,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03301350,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT03301350,tests,Filgrastim
Filgrastim,has_type,DRUG
NCT04690855,has_title,"A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy an"
NCT04690855,has_status,TERMINATED
NCT04690855,has_phase,
NCT04690855,sponsored_by,"Mylin A. Torres, MD"
NCT04690855,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT04690855,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04690855,tests,Radiation
Radiation,has_type,RADIATION
NCT03098550,has_title,Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumum
NCT03098550,has_status,COMPLETED
NCT03098550,has_phase,
NCT03098550,sponsored_by,Bristol-Myers Squibb
NCT03098550,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03098550,tests,Daratumumab
Daratumumab,has_type,BIOLOGICAL
NCT03775850,has_title,A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With A
NCT03775850,has_status,COMPLETED
NCT03775850,has_phase,
NCT03775850,sponsored_by,"Evelo Biosciences, Inc."
NCT03775850,tests,EDP1503
EDP1503,has_type,BIOLOGICAL
NCT03775850,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05654623,has_title,"A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PART"
NCT05654623,has_status,ACTIVE_NOT_RECRUITING
NCT05654623,has_phase,
NCT05654623,sponsored_by,Pfizer
NCT05654623,tests,ARV-471
ARV-471,has_type,DRUG
NCT05654623,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT01375023,has_title,Allogenic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total
NCT01375023,has_status,TERMINATED
NCT01375023,has_phase,
NCT01375023,sponsored_by,European Institute of Oncology
NCT01375023,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT01375023,tests,Anti-Thymocyte Globulin
Anti-Thymocyte Globulin,has_type,BIOLOGICAL
NCT02838823,has_title,"A Phase I,Open,Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of"
NCT02838823,has_status,COMPLETED
NCT02838823,has_phase,
NCT02838823,sponsored_by,"Shanghai Junshi Bioscience Co., Ltd."
NCT02838823,tests,humanized anti-PD-1 monoclonal antibody toripalimab
humanized anti-PD-1 monoclonal antibody toripalimab,has_type,BIOLOGICAL
NCT04177108,has_title,"A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With A"
NCT04177108,has_status,COMPLETED
NCT04177108,has_phase,
NCT04177108,sponsored_by,Hoffmann-La Roche
NCT04177108,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04177108,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT04177108,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04177108,tests,Placebo for Atezolizumab
Placebo for Atezolizumab,has_type,DRUG
NCT04177108,tests,Placebo for Ipatasertib
Placebo for Ipatasertib,has_type,DRUG
NCT00972023,has_title,A Pilot Study of Androgen Receptor as a Target for the Treatment of ER-/PR-/AR + Breast Cancer
NCT00972023,has_status,TERMINATED
NCT00972023,has_phase,
NCT00972023,sponsored_by,Barbara Ann Karmanos Cancer Institute
NCT00972023,tests,DHEA
DHEA,has_type,DRUG
NCT00972023,tests,Surgical resection
Surgical resection,has_type,PROCEDURE
NCT03243838,has_title,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative B
NCT03243838,has_status,COMPLETED
NCT03243838,has_phase,
NCT03243838,sponsored_by,Guangdong Provincial People's Hospital
NCT03243838,tests,Apatinib
Apatinib,has_type,DRUG
NCT03752723,has_title,"A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics a"
NCT03752723,has_status,COMPLETED
NCT03752723,has_phase,
NCT03752723,sponsored_by,"Genexine, Inc."
NCT03752723,tests,GX-I7
GX-I7,has_type,DRUG
NCT03752723,tests,Pembrolizumab(KEYTRUDA®)
Pembrolizumab(KEYTRUDA®),has_type,DRUG
NCT03752723,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04915755,has_title,A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and Safety of Niraparib to Placebo 
NCT04915755,has_status,ACTIVE_NOT_RECRUITING
NCT04915755,has_phase,
NCT04915755,sponsored_by,GlaxoSmithKline
NCT04915755,tests,Niraparib
Niraparib,has_type,DRUG
NCT04915755,tests,Placebo
Placebo,has_type,DRUG
NCT02658214,has_title,A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combinati
NCT02658214,has_status,COMPLETED
NCT02658214,has_phase,
NCT02658214,sponsored_by,AstraZeneca
NCT02658214,tests,paclitaxel + carboplatin
paclitaxel + carboplatin,has_type,DRUG
NCT02658214,tests,carboplatin + etoposide
carboplatin + etoposide,has_type,DRUG
NCT02658214,tests,gemcitabine + carboplatin
gemcitabine + carboplatin,has_type,DRUG
NCT02658214,tests,nab-paclitaxel (paclitaxel-albumin) + carboplatin
nab-paclitaxel (paclitaxel-albumin) + carboplatin,has_type,DRUG
NCT02658214,tests,oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid),has_type,DRUG
NCT02658214,tests,durvalumab
durvalumab,has_type,BIOLOGICAL
NCT02658214,tests,tremelimumab
tremelimumab,has_type,BIOLOGICAL
NCT02658214,tests,nab-paclitaxel (paclitaxel-albumin) + gemcitabine
nab-paclitaxel (paclitaxel-albumin) + gemcitabine,has_type,DRUG
NCT02658214,tests,cisplatin + 5-fluorouracil (5FU)
cisplatin + 5-fluorouracil (5FU),has_type,DRUG
NCT01889238,has_title,"A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ENZALUTA"
NCT01889238,has_status,COMPLETED
NCT01889238,has_phase,
NCT01889238,sponsored_by,Pfizer
NCT01889238,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT05520723,has_title,"Multicenter, Open-label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan's Tole"
NCT05520723,has_status,ACTIVE_NOT_RECRUITING
NCT05520723,has_phase,
NCT05520723,sponsored_by,MedSIR
NCT05520723,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT05520723,tests,Loperamide
Loperamide,has_type,DRUG
NCT05520723,tests,Granulocyte Colony-Stimulating Factor
Granulocyte Colony-Stimulating Factor,has_type,DRUG
NCT02423603,has_title,"A Phase II, Double-blind, Randomised, Placebo-controlled Study of the AKT Inhibitor AZD5363 in Combi"
NCT02423603,has_status,COMPLETED
NCT02423603,has_phase,
NCT02423603,sponsored_by,Queen Mary University of London
NCT02423603,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02423603,tests,AZD5363
AZD5363,has_type,DRUG
NCT02423603,tests,Placebo
Placebo,has_type,DRUG
NCT02688803,has_title,Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three
NCT02688803,has_status,COMPLETED
NCT02688803,has_phase,
NCT02688803,sponsored_by,Ottawa Hospital Research Institute
NCT02688803,tests,Dose dense AC-P
Dose dense AC-P,has_type,DRUG
NCT02688803,tests,Dose dense AC
Dose dense AC,has_type,DRUG
NCT02688803,tests,FEC-D
FEC-D,has_type,DRUG
NCT04508803,has_title,Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer: a muLti-centEr Pha
NCT04508803,has_status,COMPLETED
NCT04508803,has_phase,
NCT04508803,sponsored_by,Fudan University
NCT04508803,tests,HX008，Niraparib
HX008，Niraparib,has_type,DRUG
NCT04508803,tests,HX008，Niraparib
HX008，Niraparib,has_type,DRUG
NCT04508803,tests,HX008，Niraparib，Trastuzumab
HX008，Niraparib，Trastuzumab,has_type,DRUG
NCT04508803,tests,HX008，Niraparib，Pyrrolitinib
HX008，Niraparib，Pyrrolitinib,has_type,DRUG
NCT03002103,has_title,"An Open-label, Randomized, Controlled Phase III Trial Evaluating the Efficacy and Safety of EndoTAG®"
NCT03002103,has_status,SUSPENDED
NCT03002103,has_phase,
NCT03002103,sponsored_by,"SynCore Biotechnology Co., Ltd."
NCT03002103,tests,EndoTAG-1
EndoTAG-1,has_type,DRUG
NCT03002103,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03002103,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
NCT05132790,has_title,Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) Combined Neo
NCT05132790,has_status,ACTIVE_NOT_RECRUITING
NCT05132790,has_phase,
NCT05132790,sponsored_by,Shengjing Hospital
NCT05132790,tests,SHR-1316 at a dose 20mg/kg q3w
SHR-1316 at a dose 20mg/kg q3w,has_type,DRUG
NCT05132790,tests,"SHR6390 at a dose of 150mg orally, daily"
"SHR6390 at a dose of 150mg orally, daily",has_type,DRUG
NCT05132790,tests,SBRT
SBRT,has_type,RADIATION
NCT01587703,has_title,"A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmaco"
NCT01587703,has_status,COMPLETED
NCT01587703,has_phase,
NCT01587703,sponsored_by,GlaxoSmithKline
NCT01587703,tests,GSK525762
GSK525762,has_type,DRUG
NCT04031703,has_title,Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant 
NCT04031703,has_status,COMPLETED
NCT04031703,has_phase,
NCT04031703,sponsored_by,Fudan University
NCT04031703,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04031703,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04031703,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04031703,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04031703,tests,5-fluorouracil
5-fluorouracil,has_type,DRUG
NCT04031703,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02734290,has_title,"A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Che"
NCT02734290,has_status,ACTIVE_NOT_RECRUITING
NCT02734290,has_phase,
NCT02734290,sponsored_by,Providence Health & Services
NCT02734290,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02734290,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02734290,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02834403,has_title,Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally
NCT02834403,has_status,COMPLETED
NCT02834403,has_phase,
NCT02834403,sponsored_by,The Methodist Hospital Research Institute
NCT02834403,tests,L-NMMA
L-NMMA,has_type,DRUG
NCT02834403,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02834403,tests,Amlodipine
Amlodipine,has_type,DRUG
NCT02834403,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT02834403,tests,Enteric-coated aspirin
Enteric-coated aspirin,has_type,DRUG
NCT05609903,has_title,Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Tr
NCT05609903,has_status,COMPLETED
NCT05609903,has_phase,
NCT05609903,sponsored_by,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT05609903,tests,Atezolizumab in combination with nab-paclitaxel
Atezolizumab in combination with nab-paclitaxel,has_type,DRUG
NCT03154190,has_title,St. Judes-Stanford Comprehensive Support Initiative
NCT03154190,has_status,COMPLETED
NCT03154190,has_phase,
NCT03154190,sponsored_by,Stanford University
NCT03154190,tests,Best Practice
Best Practice,has_type,OTHER
NCT03154190,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03154190,tests,Supportive Care
Supportive Care,has_type,PROCEDURE
NCT03154190,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT01351103,has_title,"A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent "
NCT01351103,has_status,COMPLETED
NCT01351103,has_phase,
NCT01351103,sponsored_by,Novartis Pharmaceuticals
NCT01351103,tests,LGK974
LGK974,has_type,DRUG
NCT01351103,tests,PDR001
PDR001,has_type,BIOLOGICAL
NCT05198843,has_title,Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative I
NCT05198843,has_status,TERMINATED
NCT05198843,has_phase,
NCT05198843,sponsored_by,National Cancer Institute (NCI)
NCT05198843,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT05198843,tests,Icosapent Ethyl
Icosapent Ethyl,has_type,DIETARY_SUPPLEMENT
NCT03291938,has_title,A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Sol
NCT03291938,has_status,COMPLETED
NCT03291938,has_phase,
NCT03291938,sponsored_by,M.D. Anderson Cancer Center
NCT03291938,tests,Oxidative Phosphorylation Inhibitor IACS-010759
Oxidative Phosphorylation Inhibitor IACS-010759,has_type,DRUG
NCT03291938,tests,Pharmacodynamic Study
Pharmacodynamic Study,has_type,OTHER
NCT03291938,tests,Pharmacokinetic Study
Pharmacokinetic Study,has_type,OTHER
NCT03577743,has_title,Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
NCT03577743,has_status,COMPLETED
NCT03577743,has_phase,
NCT03577743,sponsored_by,Assiut University
NCT03577743,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05889390,has_title,"[A Prospective, Randomized Trial to Assess the Added Value of Concomitant Modulated Electro-hyperthe"
NCT05889390,has_status,ACTIVE_NOT_RECRUITING
NCT05889390,has_phase,
NCT05889390,sponsored_by,Semmelweis University
NCT05889390,tests,Oncotherm EHY-2030
Oncotherm EHY-2030,has_type,DEVICE
NCT05889390,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05889390,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05889390,tests,Cyclophosphamide/Doxorubicin
Cyclophosphamide/Doxorubicin,has_type,DRUG
NCT05889390,tests,Breast cancer removal surgery
Breast cancer removal surgery,has_type,PROCEDURE
NCT01391143,has_title,A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
NCT01391143,has_status,COMPLETED
NCT01391143,has_phase,
NCT01391143,sponsored_by,MacroGenics
NCT01391143,tests,MGA271
MGA271,has_type,BIOLOGICAL
NCT01969643,has_title,"A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in"
NCT01969643,has_status,COMPLETED
NCT01969643,has_phase,
NCT01969643,sponsored_by,Seagen Inc.
NCT01969643,tests,ladiratuzumab vedotin
ladiratuzumab vedotin,has_type,DRUG
NCT01969643,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04584112,has_title,"A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolum"
NCT04584112,has_status,COMPLETED
NCT04584112,has_phase,
NCT04584112,sponsored_by,Hoffmann-La Roche
NCT04584112,tests,Tiragolumab
Tiragolumab,has_type,DRUG
NCT04584112,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04584112,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04584112,tests,Tiragolumab
Tiragolumab,has_type,DRUG
NCT04584112,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04584112,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04584112,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04584112,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04584112,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04584112,tests,Granulocyte colony-stimulating factor (G-CSF)
Granulocyte colony-stimulating factor (G-CSF),has_type,DRUG
NCT04584112,tests,Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Granulocyte-macrophage colony-stimulating factor (GM-CSF),has_type,DRUG
NCT03709446,has_title,A Phase I/II Trial of Leflunomide in Women With Previously Treated Metastatic Triple Negative Cancer
NCT03709446,has_status,ACTIVE_NOT_RECRUITING
NCT03709446,has_phase,
NCT03709446,sponsored_by,Joseph Sparano
NCT03709446,tests,Leflunomide
Leflunomide,has_type,DRUG
NCT03901469,has_title,A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breas
NCT03901469,has_status,TERMINATED
NCT03901469,has_phase,
NCT03901469,sponsored_by,Zenith Epigenetics
NCT03901469,tests,ZEN003694
ZEN003694,has_type,DRUG
NCT03901469,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT05374512,has_title,"A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's C"
NCT05374512,has_status,ACTIVE_NOT_RECRUITING
NCT05374512,has_phase,
NCT05374512,sponsored_by,AstraZeneca
NCT05374512,tests,Dato-DXd
Dato-DXd,has_type,DRUG
NCT05374512,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05374512,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05374512,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05374512,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05374512,tests,Eribulin mesylate
Eribulin mesylate,has_type,DRUG
NCT01031446,has_title,"A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer"
NCT01031446,has_status,COMPLETED
NCT01031446,has_phase,
NCT01031446,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT01031446,tests,cisplatin
cisplatin,has_type,DRUG
NCT01031446,tests,everolimus
everolimus,has_type,DRUG
NCT01031446,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01031446,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT02890069,has_title,"Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynami"
NCT02890069,has_status,COMPLETED
NCT02890069,has_phase,
NCT02890069,sponsored_by,Novartis Pharmaceuticals
NCT02890069,tests,PDR001
PDR001,has_type,BIOLOGICAL
NCT02890069,tests,LCL161
LCL161,has_type,DRUG
NCT02890069,tests,Everolimus
Everolimus,has_type,DRUG
NCT02890069,tests,Panobinostat
Panobinostat,has_type,DRUG
NCT02890069,tests,QBM076
QBM076,has_type,DRUG
NCT02890069,tests,HDM201
HDM201,has_type,DRUG
NCT02447003,has_title,A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative B
NCT02447003,has_status,COMPLETED
NCT02447003,has_phase,
NCT02447003,sponsored_by,Merck Sharp & Dohme LLC
NCT02447003,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03620643,has_title,"Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobula"
NCT03620643,has_status,ACTIVE_NOT_RECRUITING
NCT03620643,has_phase,
NCT03620643,sponsored_by,Royal Marsden NHS Foundation Trust
NCT03620643,tests,Crizotinib Oral Capsule [Xalkori]
Crizotinib Oral Capsule [Xalkori],has_type,DRUG
NCT03620643,tests,Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]
Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic],has_type,DRUG
NCT05300412,has_title,"The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer: a Cross-sectional, Obse"
NCT05300412,has_status,COMPLETED
NCT05300412,has_phase,
NCT05300412,sponsored_by,University Clinical Centre of Kosova
NCT02993068,has_title,Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
NCT02993068,has_status,SUSPENDED
NCT02993068,has_phase,
NCT02993068,sponsored_by,M.D. Anderson Cancer Center
NCT02993068,tests,Educational Intervention
Educational Intervention,has_type,OTHER
NCT02993068,tests,Genetic Counseling
Genetic Counseling,has_type,OTHER
NCT02993068,tests,Genetic Counseling
Genetic Counseling,has_type,OTHER
NCT02993068,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02993068,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT03801369,has_title,"A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumeti"
NCT03801369,has_status,TERMINATED
NCT03801369,has_phase,
NCT03801369,sponsored_by,"Gordon Mills, MD, PhD"
NCT03801369,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT03801369,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT03801369,tests,Ceralasertib
Ceralasertib,has_type,DRUG
NCT03801369,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT03801369,tests,Olaparib
Olaparib,has_type,DRUG
NCT03801369,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03801369,tests,Selumetinib
Selumetinib,has_type,DRUG
NCT02957968,has_title,T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast C
NCT02957968,has_status,ACTIVE_NOT_RECRUITING
NCT02957968,has_phase,
NCT02957968,sponsored_by,Virginia Commonwealth University
NCT02957968,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02957968,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02957968,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02957968,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02957968,tests,Decitabine
Decitabine,has_type,DRUG
NCT02957968,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03849469,has_title,A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and 
NCT03849469,has_status,COMPLETED
NCT03849469,has_phase,
NCT03849469,sponsored_by,"Xencor, Inc."
NCT03849469,tests,XmAb®22841
XmAb®22841,has_type,BIOLOGICAL
NCT03849469,tests,Pembrolizumab (Keytruda®)
Pembrolizumab (Keytruda®),has_type,BIOLOGICAL
NCT02120469,has_title,Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cance
NCT02120469,has_status,COMPLETED
NCT02120469,has_phase,
NCT02120469,sponsored_by,City of Hope Medical Center
NCT02120469,tests,everolimus
everolimus,has_type,DRUG
NCT02120469,tests,eribulin mesylate
eribulin mesylate,has_type,DRUG
NCT02120469,tests,pharmacological study
pharmacological study,has_type,OTHER
NCT02120469,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT04664972,has_title,Comparing TP (Docetaxel + Cisplatin) and TAC (Docetaxel + Doxorubicin + Cyclophosphamide) in Neoadju
NCT04664972,has_status,COMPLETED
NCT04664972,has_phase,
NCT04664972,sponsored_by,Henan Cancer Hospital
NCT04664972,tests,Docetaxel +doxorubicin+ cyclophosphamide
Docetaxel +doxorubicin+ cyclophosphamide,has_type,DRUG
NCT04664972,tests,Docetaxel +Cisplatin
Docetaxel +Cisplatin,has_type,DRUG
NCT02644369,has_title,Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
NCT02644369,has_status,ACTIVE_NOT_RECRUITING
NCT02644369,has_phase,
NCT02644369,sponsored_by,"University Health Network, Toronto"
NCT02644369,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04906369,has_title,Optimizing Treatment of Metastatic Breast Cancer Through Real-Time Disease Monitoring
NCT04906369,has_status,SUSPENDED
NCT04906369,has_phase,
NCT04906369,sponsored_by,Mayo Clinic
NCT04906369,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT01176669,has_title,A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Meta
NCT01176669,has_status,COMPLETED
NCT01176669,has_phase,
NCT01176669,sponsored_by,Fudan University
NCT01176669,tests,Apatinib
Apatinib,has_type,DRUG
NCT04504669,has_title,"A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Effica"
NCT04504669,has_status,COMPLETED
NCT04504669,has_phase,
NCT04504669,sponsored_by,AstraZeneca
NCT04504669,tests,AZD8701
AZD8701,has_type,DRUG
NCT04504669,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT06465069,has_title,"A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants Wit"
NCT06465069,has_status,SUSPENDED
NCT06465069,has_phase,
NCT06465069,sponsored_by,Eli Lilly and Company
NCT06465069,tests,LY4052031
LY4052031,has_type,DRUG
NCT02513472,has_title,"An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribul"
NCT02513472,has_status,COMPLETED
NCT02513472,has_phase,
NCT02513472,sponsored_by,Eisai Inc.
NCT02513472,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT02513472,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03579472,has_title,A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TN
NCT03579472,has_status,TERMINATED
NCT03579472,has_phase,
NCT03579472,sponsored_by,M.D. Anderson Cancer Center
NCT03579472,tests,Bintrafusp Alfa
Bintrafusp Alfa,has_type,DRUG
NCT03579472,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT04789668,has_title,Phase I/II Trial of BINTRAFUSP ALFA (M7824) and Pimasertib for Treatment of Intracranial Metastases
NCT04789668,has_status,COMPLETED
NCT04789668,has_phase,
NCT04789668,sponsored_by,M.D. Anderson Cancer Center
NCT04789668,tests,Bintrafusp Alfa
Bintrafusp Alfa,has_type,DRUG
NCT04789668,tests,Pimasertib
Pimasertib,has_type,DRUG
NCT04789668,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT02755272,has_title,A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in
NCT02755272,has_status,ACTIVE_NOT_RECRUITING
NCT02755272,has_phase,
NCT02755272,sponsored_by,Fox Chase Cancer Center
NCT02755272,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02755272,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02755272,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04770272,has_title,An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono A
NCT04770272,has_status,COMPLETED
NCT04770272,has_phase,
NCT04770272,sponsored_by,Palleos Healthcare GmbH
NCT04770272,tests,Atezolizumab 840 MG in 14 ML Injection
Atezolizumab 840 MG in 14 ML Injection,has_type,DRUG
NCT04770272,tests,Atezolizumab 1200 MG in 20 ML Injection
Atezolizumab 1200 MG in 20 ML Injection,has_type,DRUG
NCT04770272,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04770272,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04770272,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04770272,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04770272,tests,Biopsy Arm A
Biopsy Arm A,has_type,PROCEDURE
NCT04770272,tests,Biopsy Arm B
Biopsy Arm B,has_type,PROCEDURE
NCT04770272,tests,Surgery
Surgery,has_type,PROCEDURE
NCT05194072,has_title,A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
NCT05194072,has_status,TERMINATED
NCT05194072,has_phase,
NCT05194072,sponsored_by,"Seagen, a wholly owned subsidiary of Pfizer"
NCT05194072,tests,Felmetatug Vedotin
Felmetatug Vedotin,has_type,DRUG
NCT05194072,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03150810,has_title,"A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination "
NCT03150810,has_status,COMPLETED
NCT03150810,has_phase,
NCT03150810,sponsored_by,BeiGene
NCT03150810,tests,Pamiparib
Pamiparib,has_type,DRUG
NCT03150810,tests,Temozolomide
Temozolomide,has_type,DRUG
NCT03917381,has_title,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN10"
NCT03917381,has_status,ACTIVE_NOT_RECRUITING
NCT03917381,has_phase,
NCT03917381,sponsored_by,Genmab
NCT03917381,tests,Acasunlimab
Acasunlimab,has_type,BIOLOGICAL
NCT03917381,tests,Acasunlimab in combination with docetaxel (in a single expansion cohort)
Acasunlimab in combination with docetaxel (in a single expansion cohort),has_type,BIOLOGICAL
NCT03917381,tests,Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Acasunlimab in combination with pembrolizumab (in a separate expansion cohort),has_type,BIOLOGICAL
NCT03917381,tests,Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts),has_type,BIOLOGICAL
NCT05390710,has_title,A PhI Dose Escalation Study of LAE005+Afuresertib+Nab_Paclitaxel in Advanced Solid Tumors and PhII S
NCT05390710,has_status,COMPLETED
NCT05390710,has_phase,
NCT05390710,sponsored_by,Laekna Limited
NCT05390710,tests,LAE005 + Afuresertib + Nab-Paclitaxel
LAE005 + Afuresertib + Nab-Paclitaxel,has_type,COMBINATION_PRODUCT
NCT02457910,has_title,"A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in P"
NCT02457910,has_status,TERMINATED
NCT02457910,has_phase,
NCT02457910,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT02457910,tests,Biomarker Analysis
Biomarker Analysis,has_type,OTHER
NCT02457910,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02457910,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02457910,tests,Taselisib
Taselisib,has_type,DRUG
NCT01467310,has_title,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
NCT01467310,has_status,COMPLETED
NCT01467310,has_phase,
NCT01467310,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT01467310,tests,GSK1120212
GSK1120212,has_type,DRUG
NCT00130533,has_title,"Multicenter, Open-label, Randomized Phase III to Evaluate Efficacy of Maintenance Treatment With Cap"
NCT00130533,has_status,COMPLETED
NCT00130533,has_phase,
NCT00130533,sponsored_by,Spanish Breast Cancer Research Group
NCT00130533,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03394287,has_title,"A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Tria"
NCT03394287,has_status,COMPLETED
NCT03394287,has_phase,
NCT03394287,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT03394287,tests,SHR-1210
SHR-1210,has_type,DRUG
NCT03394287,tests,Apatinib
Apatinib,has_type,DRUG
NCT05093387,has_title,A Pilot Study of SGT-53 With Carboplatin and Pembrolizumab in Metastatic Triple Negative Inflammator
NCT05093387,has_status,WITHDRAWN
NCT05093387,has_phase,
NCT05093387,sponsored_by,Northwestern University
NCT05093387,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05093387,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05093387,tests,Transferrin Receptor-Targeted Liposomal p53 cDNA
Transferrin Receptor-Targeted Liposomal p53 cDNA,has_type,GENETIC
NCT01997333,has_title,"A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB O"
NCT01997333,has_status,COMPLETED
NCT01997333,has_phase,
NCT01997333,sponsored_by,Celldex Therapeutics
NCT01997333,tests,CDX-011
CDX-011,has_type,DRUG
NCT01997333,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT01251874,has_title,A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negat
NCT01251874,has_status,ACTIVE_NOT_RECRUITING
NCT01251874,has_phase,
NCT01251874,sponsored_by,National Cancer Institute (NCI)
NCT01251874,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT01251874,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01251874,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT01251874,tests,Fluorothymidine F-18
Fluorothymidine F-18,has_type,OTHER
NCT01251874,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,PROCEDURE
NCT01251874,tests,Veliparib
Veliparib,has_type,DRUG
NCT05333874,has_title,CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stag
NCT05333874,has_status,ACTIVE_NOT_RECRUITING
NCT05333874,has_phase,
NCT05333874,sponsored_by,"Rutgers, The State University of New Jersey"
NCT05333874,tests,Neoadjuvant chemotherapy administered before surgical extraction of a tumor
Neoadjuvant chemotherapy administered before surgical extraction of a tumor,has_type,DRUG
NCT05333874,tests,Observational
Observational,has_type,OTHER
NCT02348320,has_title,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA
NCT02348320,has_status,COMPLETED
NCT02348320,has_phase,
NCT02348320,sponsored_by,Washington University School of Medicine
NCT02348320,tests,Personalized polyepitope DNA vaccine
Personalized polyepitope DNA vaccine,has_type,BIOLOGICAL
NCT04455620,has_title,"Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Sa"
NCT04455620,has_status,TERMINATED
NCT04455620,has_phase,
NCT04455620,sponsored_by,BioNTech SE
NCT04455620,tests,BNT151
BNT151,has_type,BIOLOGICAL
NCT02000882,has_title,Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Breast Cancer Patients With Br
NCT02000882,has_status,COMPLETED
NCT02000882,has_phase,
NCT02000882,sponsored_by,US Oncology Research
NCT02000882,tests,BKM120
BKM120,has_type,DRUG
NCT02000882,tests,capecitabine
capecitabine,has_type,DRUG
NCT02000882,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02659631,has_title,A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WI
NCT02659631,has_status,TERMINATED
NCT02659631,has_phase,
NCT02659631,sponsored_by,Pfizer
NCT02659631,tests,PF-06671008
PF-06671008,has_type,DRUG
NCT02659631,tests,PF-06671008
PF-06671008,has_type,DRUG
NCT03621982,has_title,"A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerabilit"
NCT03621982,has_status,TERMINATED
NCT03621982,has_phase,
NCT03621982,sponsored_by,ADC Therapeutics S.A.
NCT03621982,tests,ADCT-301
ADCT-301,has_type,DRUG
NCT03621982,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT01975831,has_title,"A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With"
NCT01975831,has_status,COMPLETED
NCT01975831,has_phase,
NCT01975831,sponsored_by,Ludwig Institute for Cancer Research
NCT01975831,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT01975831,tests,Tremelimumab
Tremelimumab,has_type,DRUG
NCT02689427,has_title,A Phase IIB Study of Neoadjuvant ZT Regimen (Enzalutamide Therapy in Combination With Weekly Paclita
NCT02689427,has_status,COMPLETED
NCT02689427,has_phase,
NCT02689427,sponsored_by,M.D. Anderson Cancer Center
NCT02689427,tests,Axillary Lymph Node Dissection
Axillary Lymph Node Dissection,has_type,PROCEDURE
NCT02689427,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02689427,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02689427,tests,Lymph Node Biopsy
Lymph Node Biopsy,has_type,PROCEDURE
NCT02689427,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02689427,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT07018427,has_title,"Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated Unresectable Locally Advanced, Re"
NCT07018427,has_status,ACTIVE_NOT_RECRUITING
NCT07018427,has_phase,
NCT07018427,sponsored_by,Peking University Cancer Hospital & Institute
NCT07018427,tests,Sacituzumab Govitecan Monotherapy or Combination Therapy
Sacituzumab Govitecan Monotherapy or Combination Therapy,has_type,DRUG
NCT02929576,has_title,"A Phase 3, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Comb"
NCT02929576,has_status,WITHDRAWN
NCT02929576,has_phase,
NCT02929576,sponsored_by,Pfizer
NCT02929576,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02929576,tests,Placebo
Placebo,has_type,DRUG
NCT02929576,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03077776,has_title,Tracking Triple-negative Breast Cancer Evolution Through Therapy
NCT03077776,has_status,ACTIVE_NOT_RECRUITING
NCT03077776,has_phase,
NCT03077776,sponsored_by,UNICANCER
NCT03077776,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT03077776,tests,Biopsy (optional)
Biopsy (optional),has_type,PROCEDURE
NCT03077776,tests,Biopsy (metastatic)
Biopsy (metastatic),has_type,PROCEDURE
NCT02027376,has_title,"A Phase Ib Dose Escalation, Open Label, Multicenter Study Evaluating LDE225 (Sonidegib) in Combinati"
NCT02027376,has_status,COMPLETED
NCT02027376,has_phase,
NCT02027376,sponsored_by,Spanish Breast Cancer Research Group
NCT02027376,tests,LDE225
LDE225,has_type,DRUG
NCT02027376,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01805076,has_title,"Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Brea"
NCT01805076,has_status,ACTIVE_NOT_RECRUITING
NCT01805076,has_phase,
NCT01805076,sponsored_by,Alliance for Clinical Trials in Oncology
NCT01805076,tests,Breast surgery
Breast surgery,has_type,PROCEDURE
NCT01805076,tests,Magnetic resonance imaging
Magnetic resonance imaging,has_type,PROCEDURE
NCT01805076,tests,Mammography
Mammography,has_type,PROCEDURE
NCT01891227,has_title,Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastati
NCT01891227,has_status,COMPLETED
NCT01891227,has_phase,
NCT01891227,sponsored_by,Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT01891227,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT01891227,tests,Bendamustine
Bendamustine,has_type,DRUG
NCT01740427,has_title,"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LE"
NCT01740427,has_status,COMPLETED
NCT01740427,has_phase,
NCT01740427,sponsored_by,Pfizer
NCT01740427,tests,PD-0332991
PD-0332991,has_type,DRUG
NCT01740427,tests,Letrozole
Letrozole,has_type,DRUG
NCT01740427,tests,Placebo
Placebo,has_type,DRUG
NCT01740427,tests,Letrozole
Letrozole,has_type,DRUG
NCT04085276,has_title,"A Randomized, Double-Blind, Multicenter, Phase III Study of Toripalimab(JS001) in Combination With N"
NCT04085276,has_status,ACTIVE_NOT_RECRUITING
NCT04085276,has_phase,
NCT04085276,sponsored_by,"Shanghai Junshi Bioscience Co., Ltd."
NCT04085276,tests,JS001
JS001,has_type,DRUG
NCT04085276,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT04085276,tests,Placebo
Placebo,has_type,DRUG
NCT04085276,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT05756166,has_title,Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (
NCT05756166,has_status,TERMINATED
NCT05756166,has_phase,
NCT05756166,sponsored_by,Roswell Park Cancer Institute
NCT05756166,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT05756166,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05756166,tests,Celecoxib
Celecoxib,has_type,DRUG
NCT05756166,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05756166,tests,Interferon Alpha-2
Interferon Alpha-2,has_type,BIOLOGICAL
NCT05756166,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT05756166,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05756166,tests,Rintatolimod
Rintatolimod,has_type,DRUG
NCT02535026,has_title,"Epidemiological, Prospective and Observational Study on the HER2 Status in Breast Invasive Carcinoma"
NCT02535026,has_status,COMPLETED
NCT02535026,has_phase,
NCT02535026,sponsored_by,Hoffmann-La Roche
NCT04442126,has_title,A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patie
NCT04442126,has_status,TERMINATED
NCT04442126,has_phase,
NCT04442126,sponsored_by,Numab Therapeutics AG
NCT04442126,tests,NM21-1480
NM21-1480,has_type,BIOLOGICAL
NCT01347866,has_title,"A Multi-arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of T"
NCT01347866,has_status,TERMINATED
NCT01347866,has_phase,
NCT01347866,sponsored_by,Pfizer
NCT01347866,tests,PF-05212384
PF-05212384,has_type,DRUG
NCT01347866,tests,PD-0325901
PD-0325901,has_type,DRUG
NCT01347866,tests,PF-05212384
PF-05212384,has_type,DRUG
NCT01347866,tests,irinotecan
irinotecan,has_type,DRUG
NCT01576666,has_title,"A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 1"
NCT01576666,has_status,COMPLETED
NCT01576666,has_phase,
NCT01576666,sponsored_by,Novartis Pharmaceuticals
NCT01576666,tests,LDE225
LDE225,has_type,DRUG
NCT01576666,tests,BKM120
BKM120,has_type,DRUG
NCT03175666,has_title,NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC W
NCT03175666,has_status,WITHDRAWN
NCT03175666,has_phase,
NCT03175666,sponsored_by,"ImmunityBio, Inc."
NCT03175666,tests,avelumab
avelumab,has_type,BIOLOGICAL
NCT03175666,tests,bevacizumab
bevacizumab,has_type,BIOLOGICAL
NCT03175666,tests,capecitabine
capecitabine,has_type,DRUG
NCT03175666,tests,cisplatin
cisplatin,has_type,DRUG
NCT03175666,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT03175666,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT03175666,tests,Leucovorin
Leucovorin,has_type,DRUG
NCT03175666,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT03175666,tests,Lovaza
Lovaza,has_type,DRUG
NCT03175666,tests,Stereotactic Body Radiation Therapy
Stereotactic Body Radiation Therapy,has_type,RADIATION
NCT03175666,tests,ALT-803
ALT-803,has_type,BIOLOGICAL
NCT03175666,tests,ETBX-011
ETBX-011,has_type,BIOLOGICAL
NCT03175666,tests,ETBX-051
ETBX-051,has_type,BIOLOGICAL
NCT03175666,tests,ETBX-061
ETBX-061,has_type,BIOLOGICAL
NCT03175666,tests,GI-4000
GI-4000,has_type,BIOLOGICAL
NCT03175666,tests,GI-6207
GI-6207,has_type,BIOLOGICAL
NCT03175666,tests,GI-6301
GI-6301,has_type,BIOLOGICAL
NCT03175666,tests,haNK
haNK,has_type,BIOLOGICAL
NCT03911973,has_title,Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA
NCT03911973,has_status,ACTIVE_NOT_RECRUITING
NCT03911973,has_phase,
NCT03911973,sponsored_by,Kari Wisinski
NCT03911973,tests,Gedatolisib
Gedatolisib,has_type,DRUG
NCT03911973,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT01750073,has_title,A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast Ca
NCT01750073,has_status,ACTIVE_NOT_RECRUITING
NCT01750073,has_phase,
NCT01750073,sponsored_by,University of Nebraska
NCT01750073,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01750073,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT01750073,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01750073,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01750073,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT01750073,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT01750073,tests,Trastuzumab
Trastuzumab,has_type,BIOLOGICAL
NCT00817531,has_title,"A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple"
NCT00817531,has_status,TERMINATED
NCT00817531,has_phase,
NCT00817531,sponsored_by,Baylor Breast Care Center
NCT00817531,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT02474173,has_title,"Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients Wi"
NCT02474173,has_status,TERMINATED
NCT02474173,has_phase,
NCT02474173,sponsored_by,National Cancer Institute (NCI)
NCT02474173,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02474173,tests,Onalespib
Onalespib,has_type,DRUG
NCT02474173,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02474173,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT04556773,has_title,"A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Sa"
NCT04556773,has_status,ACTIVE_NOT_RECRUITING
NCT04556773,has_phase,
NCT04556773,sponsored_by,AstraZeneca
NCT04556773,tests,Trastuzumab deruxtecan
Trastuzumab deruxtecan,has_type,DRUG
NCT04556773,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT04556773,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04556773,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT04556773,tests,Anastrozole
Anastrozole,has_type,DRUG
NCT04556773,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT04556773,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03243331,has_title,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
NCT03243331,has_status,COMPLETED
NCT03243331,has_phase,
NCT03243331,sponsored_by,Kathy Miller
NCT03243331,tests,Gedatolisib
Gedatolisib,has_type,DRUG
NCT03243331,tests,PTK7-ADC
PTK7-ADC,has_type,DRUG
NCT03970382,has_title,"A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-e"
NCT03970382,has_status,SUSPENDED
NCT03970382,has_phase,
NCT03970382,sponsored_by,"PACT Pharma, Inc."
NCT03970382,tests,NeoTCR-P1 adoptive cell therapy
NeoTCR-P1 adoptive cell therapy,has_type,BIOLOGICAL
NCT03970382,tests,nivolumab
nivolumab,has_type,BIOLOGICAL
NCT03970382,tests,IL-2
IL-2,has_type,BIOLOGICAL
NCT02244580,has_title,"Evaluation of the MammaTyperTM Kit, Ref 90020/90021 Performed on Clinical Material Obtained From Pat"
NCT02244580,has_status,COMPLETED
NCT02244580,has_phase,
NCT02244580,sponsored_by,BioNTech Diagnostics GmbH
NCT02244580,tests,MammaTyper™
MammaTyper™,has_type,DEVICE
NCT03109080,has_title,"A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced"
NCT03109080,has_status,COMPLETED
NCT03109080,has_phase,
NCT03109080,sponsored_by,Institut Curie
NCT03109080,tests,Olaparib
Olaparib,has_type,DRUG
NCT03109080,tests,Radiation therapy
Radiation therapy,has_type,RADIATION
NCT03168880,has_title,A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly 
NCT03168880,has_status,ACTIVE_NOT_RECRUITING
NCT03168880,has_phase,
NCT03168880,sponsored_by,Tata Memorial Hospital
NCT03168880,tests,Paclitaxel + Carboplatin
Paclitaxel + Carboplatin,has_type,DRUG
NCT03168880,tests,Paclitaxel only
Paclitaxel only,has_type,DRUG
NCT02041429,has_title,Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Neg
NCT02041429,has_status,COMPLETED
NCT02041429,has_phase,
NCT02041429,sponsored_by,Dana-Farber Cancer Institute
NCT02041429,tests,Ruxolitinib
Ruxolitinib,has_type,DRUG
NCT02041429,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02620280,has_title,Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer
NCT02620280,has_status,COMPLETED
NCT02620280,has_phase,
NCT02620280,sponsored_by,Fondazione Michelangelo
NCT02620280,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02620280,tests,Abraxane
Abraxane,has_type,DRUG
NCT02620280,tests,MPDL3280A
MPDL3280A,has_type,DRUG
NCT02620280,tests,Surgery
Surgery,has_type,PROCEDURE
NCT02620280,tests,Anthra
Anthra,has_type,DRUG
NCT04032080,has_title,Pilot Clinical Trial of Treatment With LY3023414 and Prexasertib to Inhibit Homologous Recombination
NCT04032080,has_status,COMPLETED
NCT04032080,has_phase,
NCT04032080,sponsored_by,Baylor Research Institute
NCT04032080,tests,Drug 1: LY3023414
Drug 1: LY3023414,has_type,COMBINATION_PRODUCT
NCT02708680,has_title,"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Wi"
NCT02708680,has_status,COMPLETED
NCT02708680,has_phase,
NCT02708680,sponsored_by,Syndax Pharmaceuticals
NCT02708680,tests,Entinostat
Entinostat,has_type,DRUG
NCT02708680,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02708680,tests,Placebo
Placebo,has_type,DRUG
NCT04595565,has_title,"Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Prim"
NCT04595565,has_status,ACTIVE_NOT_RECRUITING
NCT04595565,has_phase,
NCT04595565,sponsored_by,GBG Forschungs GmbH
NCT04595565,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04595565,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04595565,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT04595565,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT00479674,has_title,"A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in ""Triple Negative"" (Demonstrating No Ex"
NCT00479674,has_status,COMPLETED
NCT00479674,has_phase,
NCT00479674,sponsored_by,Duke University
NCT00479674,tests,Abraxane
Abraxane,has_type,DRUG
NCT00479674,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00479674,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04464174,has_title,"A Multicenter, Open-Label, Non-Comparative, Three-Arm, Phase IIa Trial of Ipatasertib (GDC-0068) in "
NCT04464174,has_status,COMPLETED
NCT04464174,has_phase,
NCT04464174,sponsored_by,MedSIR
NCT04464174,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT04464174,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04464174,tests,Eribulin
Eribulin,has_type,DRUG
NCT04464174,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04464174,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02266420,has_title,Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm 
NCT02266420,has_status,COMPLETED
NCT02266420,has_phase,
NCT02266420,sponsored_by,Institut Claudius Regaud
NCT02266420,tests,Blood samples of 10 mL
Blood samples of 10 mL,has_type,PROCEDURE
NCT02622074,has_title,A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination 
NCT02622074,has_status,COMPLETED
NCT02622074,has_phase,
NCT02622074,sponsored_by,Merck Sharp & Dohme LLC
NCT02622074,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02622074,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02622074,tests,Anthracycline (doxorubicin)
Anthracycline (doxorubicin),has_type,DRUG
NCT02622074,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02622074,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02622074,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05062174,has_title,Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study
NCT05062174,has_status,WITHDRAWN
NCT05062174,has_phase,
NCT05062174,sponsored_by,Indiana University
NCT05062174,tests,Mifepristone 200 MG
Mifepristone 200 MG,has_type,DRUG
NCT05062174,tests,Prophylactic mastectomy
Prophylactic mastectomy,has_type,PROCEDURE
NCT02954874,has_title,"A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adju"
NCT02954874,has_status,ACTIVE_NOT_RECRUITING
NCT02954874,has_phase,
NCT02954874,sponsored_by,National Cancer Institute (NCI)
NCT02954874,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT02954874,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02954874,tests,Patient Observation
Patient Observation,has_type,OTHER
NCT02954874,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02954874,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT02954874,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT02954874,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT04613674,has_title,"A Multicentre, Randomized, Double-blind, Parallel-controlled Phase Ⅲ Study to Evaluate Camrelizumab "
NCT04613674,has_status,COMPLETED
NCT04613674,has_phase,
NCT04613674,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT04613674,tests,Camrelizumab Plus Chemotherapy
Camrelizumab Plus Chemotherapy,has_type,DRUG
NCT04613674,tests,placebo+chemotherapy
placebo+chemotherapy,has_type,DRUG
NCT03576131,has_title,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN10"
NCT03576131,has_status,TERMINATED
NCT03576131,has_phase,
NCT03576131,sponsored_by,Genmab
NCT03576131,tests,GEN1029 (HexaBody®-DR5/DR5)
GEN1029 (HexaBody®-DR5/DR5),has_type,BIOLOGICAL
NCT04105582,has_title,Phase I Clinical Study of Immunotherapy With Personalized Synthetic Vaccines in Patients With Triple
NCT04105582,has_status,COMPLETED
NCT04105582,has_phase,
NCT04105582,sponsored_by,Universidad Nacional de Colombia
NCT04105582,tests,Neo-antigen pulsed Dendritic cell
Neo-antigen pulsed Dendritic cell,has_type,BIOLOGICAL
NCT05460273,has_title,"Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advan"
NCT05460273,has_status,ACTIVE_NOT_RECRUITING
NCT05460273,has_phase,
NCT05460273,sponsored_by,AstraZeneca
NCT05460273,tests,Datopotamab Deruxtecan (Dato-DXd)
Datopotamab Deruxtecan (Dato-DXd),has_type,DRUG
NCT00912444,has_title,"A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docet"
NCT00912444,has_status,TERMINATED
NCT00912444,has_phase,
NCT00912444,sponsored_by,Shanghai Jiao Tong University School of Medicine
NCT00912444,tests,"Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide"
"Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide",has_type,DRUG
NCT00912444,tests,"Docetaxel, cyclophosphamide"
"Docetaxel, cyclophosphamide",has_type,DRUG
NCT01836640,has_title,Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patie
NCT01836640,has_status,TERMINATED
NCT01836640,has_phase,
NCT01836640,sponsored_by,Dartmouth-Hitchcock Medical Center
NCT02125344,has_title,"A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) "
NCT02125344,has_status,COMPLETED
NCT02125344,has_phase,
NCT02125344,sponsored_by,GBG Forschungs GmbH
NCT02125344,tests,non-pegylated liposomal doxorubicin
non-pegylated liposomal doxorubicin,has_type,DRUG
NCT02125344,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02125344,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02125344,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02125344,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02125344,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT02125344,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02125344,tests,Ferric carboxymaltose
Ferric carboxymaltose,has_type,DRUG
NCT05209529,has_title,Neoadjuvant Olaparib and Durvalumab for Patients With BRCA-associated Triple Negative Breast Cancer
NCT05209529,has_status,WITHDRAWN
NCT05209529,has_phase,
NCT05209529,sponsored_by,European Organisation for Research and Treatment of Cancer - EORTC
NCT05209529,tests,olaparib
olaparib,has_type,DRUG
NCT05209529,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT02530489,has_title,"Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibit"
NCT02530489,has_status,COMPLETED
NCT02530489,has_phase,
NCT02530489,sponsored_by,M.D. Anderson Cancer Center
NCT02530489,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02530489,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT06371989,has_title,Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders 
NCT06371989,has_status,COMPLETED
NCT06371989,has_phase,
NCT06371989,sponsored_by,Hospital Universitario 12 de Octubre
NCT06371989,tests,Image guided vacuum assisted biopsy
Image guided vacuum assisted biopsy,has_type,PROCEDURE
NCT03644589,has_title,A Phase II Trial Evaluating Safety and Efficacy of Pembrolizumab and Cisplatin in Patients With Adva
NCT03644589,has_status,WITHDRAWN
NCT03644589,has_phase,
NCT03644589,sponsored_by,University of Washington
NCT03644589,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03644589,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT05712889,has_title,"An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor"
NCT05712889,has_status,COMPLETED
NCT05712889,has_phase,
NCT05712889,sponsored_by,"Vincerx Pharma, Inc."
NCT05712889,tests,VIP236 (Q3W)
VIP236 (Q3W),has_type,DRUG
NCT05712889,tests,VIP236 (Q2W)
VIP236 (Q2W),has_type,DRUG
NCT02657889,has_title,Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With A
NCT02657889,has_status,COMPLETED
NCT02657889,has_phase,
NCT02657889,sponsored_by,"Tesaro, Inc."
NCT02657889,tests,niraparib
niraparib,has_type,DRUG
NCT02657889,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT03367689,has_title,A Two-stage Simon Design Phase II Study for NOn-BRCA Metastatic BReast Cancer (MBC) Patients With Ho
NCT03367689,has_status,TERMINATED
NCT03367689,has_phase,
NCT03367689,sponsored_by,MedSIR
NCT03367689,tests,Olaparib
Olaparib,has_type,DRUG
NCT03997968,has_title,"A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell M"
NCT03997968,has_status,COMPLETED
NCT03997968,has_phase,
NCT03997968,sponsored_by,"Cyteir Therapeutics, Inc."
NCT03997968,tests,CYT-0851
CYT-0851,has_type,DRUG
NCT03997968,tests,CYT-0851 in combination with gemcitabine
CYT-0851 in combination with gemcitabine,has_type,DRUG
NCT03997968,tests,CYT-0851 in combination with capecitabine
CYT-0851 in combination with capecitabine,has_type,DRUG
NCT03997968,tests,CYT-0851 in combination with rituximab and bendamustine
CYT-0851 in combination with rituximab and bendamustine,has_type,DRUG
NCT03974204,has_title,Benefit of Analyzing Exosomes in the Cerebrospinal Fluid During the Medical Care of Breast Cancer Pa
NCT03974204,has_status,WITHDRAWN
NCT03974204,has_phase,
NCT03974204,sponsored_by,Centre Oscar Lambret
NCT03974204,tests,Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment
Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment,has_type,PROCEDURE
NCT03974204,tests,"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""Lack of evidence"" according to EANO-ESMO classification"
"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""Lack of evidence"" according to EANO-ESMO classification",has_type,PROCEDURE
NCT03974204,tests,"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""confirmed"", ""probable"" or ""possible"", leading to leptomeningeal metastase specific treatment"
"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""confirmed"", ""probable"" or ""possible"", leading to leptomeningeal metastase specific treatment",has_type,PROCEDURE
NCT04216472,has_title,"A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory "
NCT04216472,has_status,ACTIVE_NOT_RECRUITING
NCT04216472,has_phase,
NCT04216472,sponsored_by,M.D. Anderson Cancer Center
NCT04216472,tests,Alpelisib
Alpelisib,has_type,DRUG
NCT04216472,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT01421472,has_title,"A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer"
NCT01421472,has_status,COMPLETED
NCT01421472,has_phase,
NCT01421472,sponsored_by,Merrimack Pharmaceuticals
NCT01421472,tests,MM-121
MM-121,has_type,DRUG
NCT01421472,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03292172,has_title,"Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and C"
NCT03292172,has_status,TERMINATED
NCT03292172,has_phase,
NCT03292172,sponsored_by,Hoffmann-La Roche
NCT03292172,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03292172,tests,RO6870810
RO6870810,has_type,DRUG
NCT00608972,has_title,"A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metas"
NCT00608972,has_status,COMPLETED
NCT00608972,has_phase,
NCT00608972,sponsored_by,"Rutgers, The State University of New Jersey"
NCT00608972,tests,Doxil
Doxil,has_type,DRUG
NCT00608972,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00608972,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05111067,has_title,Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity
NCT05111067,has_status,COMPLETED
NCT05111067,has_phase,
NCT05111067,sponsored_by,Nova Scotia Health Authority
NCT05111067,tests,DNA and whole transcriptome mRNA sequencing
DNA and whole transcriptome mRNA sequencing,has_type,GENETIC
NCT00528567,has_title,"An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in ""Triple Ne"
NCT00528567,has_status,COMPLETED
NCT00528567,has_phase,
NCT00528567,sponsored_by,Hoffmann-La Roche
NCT00528567,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00528567,tests,Standard adjuvant chemotherapy
Standard adjuvant chemotherapy,has_type,DRUG
NCT02488967,has_title,A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followe
NCT02488967,has_status,ACTIVE_NOT_RECRUITING
NCT02488967,has_phase,
NCT02488967,sponsored_by,NRG Oncology
NCT02488967,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02488967,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02488967,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT02488967,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02488967,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03970967,has_title,A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatmen
NCT03970967,has_status,TERMINATED
NCT03970967,has_phase,
NCT03970967,sponsored_by,Alpha Tau Medical LTD.
NCT03970967,tests,Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT),has_type,DEVICE
NCT01745367,has_title,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Study Comparing Tivozanib Hydrochloride in C"
NCT01745367,has_status,TERMINATED
NCT01745367,has_phase,
NCT01745367,sponsored_by,"AVEO Pharmaceuticals, Inc."
NCT01745367,tests,Tivozanib Hydrochloride
Tivozanib Hydrochloride,has_type,DRUG
NCT01745367,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01745367,tests,Placebo
Placebo,has_type,DRUG
NCT03829501,has_title,"A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and"
NCT03829501,has_status,TERMINATED
NCT03829501,has_phase,
NCT03829501,sponsored_by,Kymab Limited
NCT03829501,tests,Alomfilimab
Alomfilimab,has_type,DRUG
NCT03829501,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT01045304,has_title,"Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibit"
NCT01045304,has_status,COMPLETED
NCT01045304,has_phase,
NCT01045304,sponsored_by,Sanofi
NCT01045304,tests,Iniparib
Iniparib,has_type,DRUG
NCT01045304,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT01045304,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02768701,has_title,Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Neg
NCT02768701,has_status,COMPLETED
NCT02768701,has_phase,
NCT02768701,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT02768701,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02768701,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03256344,has_title,A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Tripl
NCT03256344,has_status,COMPLETED
NCT03256344,has_phase,
NCT03256344,sponsored_by,Amgen
NCT03256344,tests,Talimogene Laherparepvec
Talimogene Laherparepvec,has_type,BIOLOGICAL
NCT03256344,tests,Atezolizumab
Atezolizumab,has_type,BIOLOGICAL
NCT04434040,has_title,A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Tripl
NCT04434040,has_status,ACTIVE_NOT_RECRUITING
NCT04434040,has_phase,
NCT04434040,sponsored_by,Dana-Farber Cancer Institute
NCT04434040,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04434040,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT01461044,has_title,"An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER"
NCT01461044,has_status,COMPLETED
NCT01461044,has_phase,
NCT01461044,sponsored_by,Hoffmann-La Roche
NCT01910844,has_title,
NCT01910844,has_status,TERMINATED
NCT01910844,has_phase,
NCT01910844,sponsored_by,Centre Jean Perrin
NCT01910844,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01910844,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02807844,has_title,"A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With A"
NCT02807844,has_status,COMPLETED
NCT02807844,has_phase,
NCT02807844,sponsored_by,Novartis Pharmaceuticals
NCT02807844,tests,MCS110
MCS110,has_type,DRUG
NCT02807844,tests,PDR001
PDR001,has_type,DRUG
NCT03366844,has_title,Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Can
NCT03366844,has_status,ACTIVE_NOT_RECRUITING
NCT03366844,has_phase,
NCT03366844,sponsored_by,Stephen Shiao
NCT03366844,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03366844,tests,RT Boost
RT Boost,has_type,RADIATION
NCT01930292,has_title,A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 
NCT01930292,has_status,TERMINATED
NCT01930292,has_phase,
NCT01930292,sponsored_by,Debiopharm International SA
NCT01930292,tests,Part A: Debio 1143
Part A: Debio 1143,has_type,DRUG
NCT01930292,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01930292,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01930292,tests,Part B: Debio 1143
Part B: Debio 1143,has_type,DRUG
NCT01520389,has_title,A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
NCT01520389,has_status,COMPLETED
NCT01520389,has_phase,
NCT01520389,sponsored_by,Merrimack Pharmaceuticals
NCT01520389,tests,MM-151
MM-151,has_type,DRUG
NCT01520389,tests,MM-151 + irinotecan
MM-151 + irinotecan,has_type,DRUG
NCT01167192,has_title,Effect of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Bre
NCT01167192,has_status,TERMINATED
NCT01167192,has_phase,
NCT01167192,sponsored_by,Washington University School of Medicine
NCT01167192,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01167192,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01167192,tests,Radiation therapy
Radiation therapy,has_type,RADIATION
NCT01167192,tests,Mastectomy (recommended but not mandatory)
Mastectomy (recommended but not mandatory),has_type,PROCEDURE
NCT00918892,has_title,Assessment of Candidate Protein Expression in Human Breast Cancer Specimens
NCT00918892,has_status,COMPLETED
NCT00918892,has_phase,
NCT00918892,sponsored_by,Case Comprehensive Cancer Center
NCT00918892,tests,gene expression analysis
gene expression analysis,has_type,GENETIC
NCT00918892,tests,immunohistochemistry staining method
immunohistochemistry staining method,has_type,OTHER
NCT00918892,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT00827567,has_title,A Phase II Trial of RAD001 in Triple Negative Metastatic Breast Cancer
NCT00827567,has_status,TERMINATED
NCT00827567,has_phase,
NCT00827567,sponsored_by,Milton S. Hershey Medical Center
NCT00827567,tests,RAD 001
RAD 001,has_type,DRUG
NCT04464967,has_title,"A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety and Anti-Tumor Activity of Ex Viv"
NCT04464967,has_status,WITHDRAWN
NCT04464967,has_phase,
NCT04464967,sponsored_by,"NKGen Biotech, Inc."
NCT04464967,tests,SNK01
SNK01,has_type,BIOLOGICAL
NCT04464967,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04464967,tests,Cetuximab
Cetuximab,has_type,DRUG
NCT04331067,has_title,Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in P
NCT04331067,has_status,ACTIVE_NOT_RECRUITING
NCT04331067,has_phase,
NCT04331067,sponsored_by,Washington University School of Medicine
NCT04331067,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04331067,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04331067,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT04331067,tests,Cabiralizumab
Cabiralizumab,has_type,BIOLOGICAL
NCT04331067,tests,Tumor biopsy
Tumor biopsy,has_type,PROCEDURE
NCT04331067,tests,Bone marrow
Bone marrow,has_type,PROCEDURE
NCT04331067,tests,Blood draw
Blood draw,has_type,PROCEDURE
NCT04249167,has_title,Cryoablation and Anti-PD-L1 Immunotherapy for Triple Negative Breast Cancer (TNBC)
NCT04249167,has_status,WITHDRAWN
NCT04249167,has_phase,
NCT04249167,sponsored_by,Mayo Clinic
NCT04249167,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04249167,tests,Cryosurgery
Cryosurgery,has_type,PROCEDURE
NCT04249167,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04445844,has_title,IRENE Study: Phase 2 Study of INCMGA00012 and the Oncolytic Virus Pelareorep in Metastatic Triple Ne
NCT04445844,has_status,ACTIVE_NOT_RECRUITING
NCT04445844,has_phase,
NCT04445844,sponsored_by,"Mridula George, MD"
NCT04445844,tests,Pelareorep
Pelareorep,has_type,BIOLOGICAL
NCT04445844,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT04445844,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04445844,tests,Retifanlimab
Retifanlimab,has_type,BIOLOGICAL
NCT02157792,has_title,"An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M662"
NCT02157792,has_status,COMPLETED
NCT02157792,has_phase,
NCT02157792,sponsored_by,"EMD Serono Research & Development Institute, Inc."
NCT02157792,tests,M6620
M6620,has_type,DRUG
NCT02157792,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02157792,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02157792,tests,Etoposide
Etoposide,has_type,DRUG
NCT02157792,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02157792,tests,Irinotecan
Irinotecan,has_type,DRUG
NCT03122444,has_title,A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Previously Untr
NCT03122444,has_status,COMPLETED
NCT03122444,has_phase,
NCT03122444,sponsored_by,The University of Texas Health Science Center at San Antonio
NCT03122444,tests,Imipramine
Imipramine,has_type,DRUG
NCT04149444,has_title,A Phase 2 Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
NCT04149444,has_status,WITHDRAWN
NCT04149444,has_phase,
NCT04149444,sponsored_by,AHS Cancer Control Alberta
NCT04149444,tests,Trifluridine/Tipiracil
Trifluridine/Tipiracil,has_type,DRUG
NCT02003092,has_title,"A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Meta"
NCT02003092,has_status,TERMINATED
NCT02003092,has_phase,
NCT02003092,sponsored_by,"Rexahn Pharmaceuticals, Inc."
NCT02003092,tests,RX-5902
RX-5902,has_type,DRUG
NCT00580112,has_title,"Phase II, Multicenter, Open-label, Clinical Trial of Trabectedin (Yondelis) in Metastatic Breast Can"
NCT00580112,has_status,COMPLETED
NCT00580112,has_phase,
NCT00580112,sponsored_by,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C."
NCT00580112,tests,Dexamethasone
Dexamethasone,has_type,DRUG
NCT00580112,tests,Trabectedin
Trabectedin,has_type,DRUG
NCT01105312,has_title,Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic 
NCT01105312,has_status,COMPLETED
NCT01105312,has_phase,
NCT01105312,sponsored_by,Alliance for Clinical Trials in Oncology
NCT01105312,tests,letrozole
letrozole,has_type,DRUG
NCT01105312,tests,panobinostat
panobinostat,has_type,DRUG
NCT01105312,tests,RNA analysis
RNA analysis,has_type,GENETIC
NCT01105312,tests,microarray analysis
microarray analysis,has_type,GENETIC
NCT01105312,tests,reverse transcriptase-polymerase chain reaction
reverse transcriptase-polymerase chain reaction,has_type,GENETIC
NCT01105312,tests,enzyme-linked immunosorbent assay
enzyme-linked immunosorbent assay,has_type,OTHER
NCT01105312,tests,immunohistochemistry staining method
immunohistochemistry staining method,has_type,OTHER
NCT01105312,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT02554812,has_title,"A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODY"
NCT02554812,has_status,TERMINATED
NCT02554812,has_phase,
NCT02554812,sponsored_by,Pfizer
NCT02554812,tests,Avelumab
Avelumab,has_type,DRUG
NCT02554812,tests,Utomilumab
Utomilumab,has_type,DRUG
NCT02554812,tests,PF-04518600
PF-04518600,has_type,DRUG
NCT02554812,tests,PD 0360324
PD 0360324,has_type,DRUG
NCT02554812,tests,CMP-001
CMP-001,has_type,DRUG
NCT03055312,has_title,"A Randomized, Multicenter,Phase III Study of Bicalutamide Versus Chemotherapy in First Line Treatmen"
NCT03055312,has_status,TERMINATED
NCT03055312,has_phase,
NCT03055312,sponsored_by,Sun Yat-sen University
NCT03055312,tests,TPC
TPC,has_type,DRUG
NCT03055312,tests,Bicalutamide 150 mg
Bicalutamide 150 mg,has_type,DRUG
NCT03101280,has_title,A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With
NCT03101280,has_status,COMPLETED
NCT03101280,has_phase,
NCT03101280,sponsored_by,Hoffmann-La Roche
NCT03101280,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03101280,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT01208480,has_title,"A Phase II Trial of Neoadjuvant Bevacizumab, Docetaxel and Carboplatin for Triple Negative Breast Ca"
NCT01208480,has_status,COMPLETED
NCT01208480,has_phase,
NCT01208480,sponsored_by,Severance Hospital
NCT01208480,tests,"Avastin, docetaxel, carboplatin"
"Avastin, docetaxel, carboplatin",has_type,DRUG
NCT04762901,has_title,LCI-BRE-MTN-NIR-001: A Phase I Study of Niraparib in Combination With Standard Chemotherapy in Metas
NCT04762901,has_status,WITHDRAWN
NCT04762901,has_phase,
NCT04762901,sponsored_by,Wake Forest University Health Sciences
NCT04762901,tests,Niraparib
Niraparib,has_type,DRUG
NCT04762901,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04762901,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04762901,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04762901,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT04762901,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02484404,has_title,Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination
NCT02484404,has_status,ACTIVE_NOT_RECRUITING
NCT02484404,has_phase,
NCT02484404,sponsored_by,National Cancer Institute (NCI)
NCT02484404,tests,Olaparib
Olaparib,has_type,DRUG
NCT02484404,tests,Cediranib
Cediranib,has_type,DRUG
NCT02484404,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03094169,has_title,"Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplasti"
NCT03094169,has_status,TERMINATED
NCT03094169,has_phase,
NCT03094169,sponsored_by,Formation Biologics
NCT03094169,tests,AVID100 IV
AVID100 IV,has_type,DRUG
NCT01617668,has_title,"A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or With"
NCT01617668,has_status,COMPLETED
NCT01617668,has_phase,
NCT01617668,sponsored_by,Novartis Pharmaceuticals
NCT01617668,tests,LCL161
LCL161,has_type,DRUG
NCT01617668,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01057069,has_title,Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breas
NCT01057069,has_status,ACTIVE_NOT_RECRUITING
NCT01057069,has_phase,
NCT01057069,sponsored_by,The Netherlands Cancer Institute
NCT01057069,tests,Carboplatin and Paclitaxel
Carboplatin and Paclitaxel,has_type,DRUG
NCT01057069,tests,"Doxorubicin, cyclophosphamide"
"Doxorubicin, cyclophosphamide",has_type,DRUG
NCT01057069,tests,"Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide"
"Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide",has_type,DRUG
NCT01194869,has_title,Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclita
NCT01194869,has_status,TERMINATED
NCT01194869,has_phase,
NCT01194869,sponsored_by,Emory University
NCT01194869,tests,Sorafenib
Sorafenib,has_type,DRUG
NCT01194869,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01194869,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04368468,has_title,Study of the Modifications of the Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Tri
NCT04368468,has_status,COMPLETED
NCT04368468,has_phase,
NCT04368468,sponsored_by,Institut Claudius Regaud
NCT04368468,tests,biomarker evolution
biomarker evolution,has_type,OTHER
NCT03539965,has_title,Triple-negative Breast Cancer: a New Perspective on Predictive and Prognostic Biomarkers
NCT03539965,has_status,COMPLETED
NCT03539965,has_phase,
NCT03539965,sponsored_by,"Instituto Nacional de Cancer, Brazil"
NCT03575065,has_title,"An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatmen"
NCT03575065,has_status,COMPLETED
NCT03575065,has_phase,
NCT03575065,sponsored_by,BeiGene
NCT03575065,tests,BGB-290
BGB-290,has_type,DRUG
NCT01201265,has_title,"A Multi Centre, Pilot Phase II Trial Assessing the Efficacy and Safety of Bevacizumab + Gemcitabine "
NCT01201265,has_status,COMPLETED
NCT01201265,has_phase,
NCT01201265,sponsored_by,Hoffmann-La Roche
NCT01201265,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01201265,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01201265,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02576665,has_title,"A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients Wit"
NCT02576665,has_status,TERMINATED
NCT02576665,has_phase,
NCT02576665,sponsored_by,Tocagen Inc.
NCT02576665,tests,Toca 511
Toca 511,has_type,BIOLOGICAL
NCT02576665,tests,Toca FC
Toca FC,has_type,DRUG
NCT01337765,has_title,"A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered "
NCT01337765,has_status,COMPLETED
NCT01337765,has_phase,
NCT01337765,sponsored_by,Pfizer
NCT01337765,tests,BEZ235 + MEK162
BEZ235 + MEK162,has_type,DRUG
NCT05081492,has_title,"A Phase I, First-in-Human Study of Intratumoral Administration of CF33-hNIS-antiPDL1, A Novel Chimer"
NCT05081492,has_status,ACTIVE_NOT_RECRUITING
NCT05081492,has_phase,
NCT05081492,sponsored_by,City of Hope Medical Center
NCT05081492,tests,Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody
Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody,has_type,BIOLOGICAL
NCT02706392,has_title,Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Auto
NCT02706392,has_status,TERMINATED
NCT02706392,has_phase,
NCT02706392,sponsored_by,Fred Hutchinson Cancer Center
NCT02706392,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02706392,tests,ROR1 CAR-specific Autologous T-Lymphocytes
ROR1 CAR-specific Autologous T-Lymphocytes,has_type,BIOLOGICAL
NCT05888831,has_title,A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advance
NCT05888831,has_status,ACTIVE_NOT_RECRUITING
NCT05888831,has_phase,
NCT05888831,sponsored_by,Bristol-Myers Squibb
NCT05888831,tests,BMS-986449
BMS-986449,has_type,DRUG
NCT05888831,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT02260531,has_title,A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients 
NCT02260531,has_status,COMPLETED
NCT02260531,has_phase,
NCT02260531,sponsored_by,Dana-Farber Cancer Institute
NCT02260531,tests,Cabozantinib
Cabozantinib,has_type,DRUG
NCT02260531,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04178460,has_title,"A Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical "
NCT04178460,has_status,TERMINATED
NCT04178460,has_phase,
NCT04178460,sponsored_by,"Zai Lab (Shanghai) Co., Ltd."
NCT04178460,tests,Niraparib combined with MGD013
Niraparib combined with MGD013,has_type,DRUG
NCT03992131,has_title,"SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacoki"
NCT03992131,has_status,TERMINATED
NCT03992131,has_phase,
NCT03992131,sponsored_by,pharmaand GmbH
NCT03992131,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT03992131,tests,Lucitanib
Lucitanib,has_type,DRUG
NCT03992131,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT02338531,has_title,Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
NCT02338531,has_status,WITHDRAWN
NCT02338531,has_phase,
NCT02338531,sponsored_by,Jules Bordet Institute
NCT02338531,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT02338531,tests,Breast cancer surgery
Breast cancer surgery,has_type,PROCEDURE
NCT04373031,has_title,Induction Immunotherapy to Promote Immunologic Priming and Enhanced Response to Neoadjuvant Pembroli
NCT04373031,has_status,ACTIVE_NOT_RECRUITING
NCT04373031,has_phase,
NCT04373031,sponsored_by,Providence Health & Services
NCT04373031,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04373031,tests,IRX 2
IRX 2,has_type,DRUG
NCT03739931,has_title,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsu"
NCT03739931,has_status,ACTIVE_NOT_RECRUITING
NCT03739931,has_phase,
NCT03739931,sponsored_by,"ModernaTX, Inc."
NCT03739931,tests,mRNA-2752
mRNA-2752,has_type,BIOLOGICAL
NCT03739931,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT03822312,has_title,A Pilot Study of Digital Breast Tomosynthesis Guided Near-infrared Tomographic Optical Breast Imagin
NCT03822312,has_status,ACTIVE_NOT_RECRUITING
NCT03822312,has_phase,
NCT03822312,sponsored_by,Massachusetts General Hospital
NCT03822312,tests,DBT-TOBI
DBT-TOBI,has_type,DEVICE
NCT03822312,tests,MRI-TOBI
MRI-TOBI,has_type,DEVICE
NCT02454010,has_title,"A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advan"
NCT02454010,has_status,COMPLETED
NCT02454010,has_phase,
NCT02454010,sponsored_by,"Fujifilm Pharmaceuticals U.S.A., Inc."
NCT02454010,tests,FF21101
FF21101,has_type,BIOLOGICAL
NCT05730010,has_title,Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a 
NCT05730010,has_status,COMPLETED
NCT05730010,has_phase,
NCT05730010,sponsored_by,Indiana University
NCT03483012,has_title,A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple
NCT03483012,has_status,ACTIVE_NOT_RECRUITING
NCT03483012,has_phase,
NCT03483012,sponsored_by,Dana-Farber Cancer Institute
NCT03483012,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03483012,tests,Stereotactic radiosurgery (SRS)
Stereotactic radiosurgery (SRS),has_type,PROCEDURE
NCT01837095,has_title,"A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative "
NCT01837095,has_status,COMPLETED
NCT01837095,has_phase,
NCT01837095,sponsored_by,Polyphor Ltd.
NCT01837095,tests,POL6326
POL6326,has_type,DRUG
NCT07046195,has_title,Clinical Study of the Optimal Combination Mode of Adjuvant Radiotherapy Combined With Immunotherapy 
NCT07046195,has_status,ACTIVE_NOT_RECRUITING
NCT07046195,has_phase,
NCT07046195,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT02435680,has_title,A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple N
NCT02435680,has_status,COMPLETED
NCT02435680,has_phase,
NCT02435680,sponsored_by,Novartis Pharmaceuticals
NCT02435680,tests,MCS110
MCS110,has_type,DRUG
NCT02435680,tests,carboplatin
carboplatin,has_type,DRUG
NCT02435680,tests,gemcitabine
gemcitabine,has_type,DRUG
NCT04706962,has_title,"A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid"
NCT04706962,has_status,ACTIVE_NOT_RECRUITING
NCT04706962,has_phase,
NCT04706962,sponsored_by,Theratechnologies
NCT04706962,tests,TH1902
TH1902,has_type,DRUG
NCT03861403,has_title,A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab i
NCT03861403,has_status,TERMINATED
NCT03861403,has_phase,
NCT03861403,sponsored_by,"Leap Therapeutics, Inc."
NCT03861403,tests,TRX518
TRX518,has_type,DRUG
NCT03861403,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03861403,tests,Avelumab
Avelumab,has_type,DRUG
NCT03219268,has_title,"A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein B"
NCT03219268,has_status,COMPLETED
NCT03219268,has_phase,
NCT03219268,sponsored_by,MacroGenics
NCT03219268,tests,tebotelimab 1 mg
tebotelimab 1 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 3 mg
tebotelimab 3 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 10 mg
tebotelimab 10 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 30 mg
tebotelimab 30 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 120 mg
tebotelimab 120 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 300 mg
tebotelimab 300 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 400 mg
tebotelimab 400 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 600 mg
tebotelimab 600 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 800 mg
tebotelimab 800 mg,has_type,BIOLOGICAL
NCT03219268,tests,tebotelimab 1200 mg
tebotelimab 1200 mg,has_type,BIOLOGICAL
NCT03219268,tests,margetuximab
margetuximab,has_type,BIOLOGICAL
NCT05154201,has_title,"A Multicenter, Open-label, Phase I Clinical Study: A Dose-finding and Dose Expansion Study to Evalua"
NCT05154201,has_status,COMPLETED
NCT05154201,has_phase,
NCT05154201,sponsored_by,"Orinove, Inc."
NCT05154201,tests,ORIN1001
ORIN1001,has_type,DRUG
NCT03945604,has_title,"A Phase Ib，Open-labeled, Multi-center, Dose-exploring Trial of SHR-1210 (Anti-PD-1 Antibody) in Comb"
NCT03945604,has_status,COMPLETED
NCT03945604,has_phase,
NCT03945604,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT03945604,tests,SHR-1210 + Apatinib +Fluzoparib
SHR-1210 + Apatinib +Fluzoparib,has_type,DRUG
NCT02627430,has_title,A Phase 1 Study of PARP Inhibitor BMN 673 and HSP90 Inhibitor AT13387 for Treatment of Advanced Soli
NCT02627430,has_status,WITHDRAWN
NCT02627430,has_phase,
NCT02627430,sponsored_by,National Cancer Institute (NCI)
NCT02627430,tests,Hsp90 Inhibitor AT13387
Hsp90 Inhibitor AT13387,has_type,DRUG
NCT02627430,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02627430,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02627430,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT00930930,has_title,"A Phase II Neo-Adjuvant Study of Cisplatin, Paclitaxel With or Without RAD001 in Patients With Tripl"
NCT00930930,has_status,COMPLETED
NCT00930930,has_phase,
NCT00930930,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT00930930,tests,cisplatin
cisplatin,has_type,DRUG
NCT00930930,tests,everolimus
everolimus,has_type,DRUG
NCT00930930,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT00930930,tests,placebo
placebo,has_type,OTHER
NCT00930930,tests,Venous blood draw
Venous blood draw,has_type,PROCEDURE
NCT04320030,has_title,Pilot Feasibility Study: Inflammation and Presence of M2 Macrophages Explorations With[18F]-DPA-714 
NCT04320030,has_status,COMPLETED
NCT04320030,has_phase,
NCT04320030,sponsored_by,Institut Cancerologie de l'Ouest
NCT04320030,tests,[18F]-DPA-714 PET/CT scan
[18F]-DPA-714 PET/CT scan,has_type,DRUG
NCT03952325,has_title,"A Multicenter, Phase 2 Study of Tesetaxel Plus Three Different PD-(L)1 Inhibitors in Patients With T"
NCT03952325,has_status,TERMINATED
NCT03952325,has_phase,
NCT03952325,sponsored_by,"Odonate Therapeutics, Inc."
NCT03952325,tests,Tesetaxel
Tesetaxel,has_type,DRUG
NCT03952325,tests,Tesetaxel
Tesetaxel,has_type,DRUG
NCT03952325,tests,Tesetaxel
Tesetaxel,has_type,DRUG
NCT03952325,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03952325,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03952325,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03952325,tests,Tesetaxel
Tesetaxel,has_type,DRUG
NCT01145430,has_title,"Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gyn"
NCT01145430,has_status,COMPLETED
NCT01145430,has_phase,
NCT01145430,sponsored_by,National Cancer Institute (NCI)
NCT01145430,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01145430,tests,Pegylated Liposomal Doxorubicin Hydrochloride
Pegylated Liposomal Doxorubicin Hydrochloride,has_type,DRUG
NCT01145430,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01145430,tests,Veliparib
Veliparib,has_type,DRUG
NCT04176848,has_title,A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative B
NCT04176848,has_status,ACTIVE_NOT_RECRUITING
NCT04176848,has_phase,
NCT04176848,sponsored_by,Canadian Cancer Trials Group
NCT04176848,tests,CFI-400945
CFI-400945,has_type,DRUG
NCT04176848,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT01141530,has_title,Deep Sequencing of the Breast Cancer Transcriptome
NCT01141530,has_status,WITHDRAWN
NCT01141530,has_phase,
NCT01141530,sponsored_by,University of Arkansas
NCT01141530,tests,No intervention
No intervention,has_type,OTHER
NCT03012230,has_title,A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negati
NCT03012230,has_status,COMPLETED
NCT03012230,has_phase,
NCT03012230,sponsored_by,Mayo Clinic
NCT03012230,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03012230,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03012230,tests,Ruxolitinib Phosphate
Ruxolitinib Phosphate,has_type,DRUG
NCT04699630,has_title,A Phase II Study of U3-1402 (Patritumab Deruxtecan) in Patients With Metastatic Breast Cancer
NCT04699630,has_status,COMPLETED
NCT04699630,has_phase,
NCT04699630,sponsored_by,"SCRI Development Innovations, LLC"
NCT04699630,tests,U3-1402
U3-1402,has_type,DRUG
NCT03941730,has_title,Therapeutic Targeting of ER Beta in Triple Negative Breast Cancer
NCT03941730,has_status,ACTIVE_NOT_RECRUITING
NCT03941730,has_phase,
NCT03941730,sponsored_by,Mayo Clinic
NCT03941730,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT03941730,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT03941730,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT03941730,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,PROCEDURE
NCT03941730,tests,Therapeutic Estradiol
Therapeutic Estradiol,has_type,BIOLOGICAL
NCT05177796,has_title,Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer: A Phase II Stud
NCT05177796,has_status,WITHDRAWN
NCT05177796,has_phase,
NCT05177796,sponsored_by,M.D. Anderson Cancer Center
NCT05177796,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05177796,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05177796,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05177796,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05177796,tests,Panitumumab
Panitumumab,has_type,BIOLOGICAL
NCT05177796,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT01069796,has_title,A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel an
NCT01069796,has_status,TERMINATED
NCT01069796,has_phase,
NCT01069796,sponsored_by,ARCAGY/ GINECO GROUP
NCT01069796,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01069796,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01069796,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03498716,has_title,"A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) "
NCT03498716,has_status,TERMINATED
NCT03498716,has_phase,
NCT03498716,sponsored_by,Hoffmann-La Roche
NCT03498716,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03498716,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03498716,tests,Dose-dense Doxorubicin or dose-dense Epirubicin
Dose-dense Doxorubicin or dose-dense Epirubicin,has_type,DRUG
NCT03498716,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02567396,has_title,A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and R
NCT02567396,has_status,WITHDRAWN
NCT02567396,has_phase,
NCT02567396,sponsored_by,National Cancer Institute (NCI)
NCT02567396,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02567396,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02567396,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT00739063,has_title,"Study of Erlotinib, Small Molecule Targeting Epidermal Growth Factor Receptor (EGFR) in Treatment of"
NCT00739063,has_status,TERMINATED
NCT00739063,has_phase,
NCT00739063,sponsored_by,M.D. Anderson Cancer Center
NCT00739063,tests,Tarceva
Tarceva,has_type,DRUG
NCT02978716,has_title,"Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Tri"
NCT02978716,has_status,TERMINATED
NCT02978716,has_phase,
NCT02978716,sponsored_by,"G1 Therapeutics, Inc."
NCT02978716,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT02978716,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02978716,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02676986,has_title,Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone o
NCT02676986,has_status,COMPLETED
NCT02676986,has_phase,
NCT02676986,sponsored_by,Queen Mary University of London
NCT02676986,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02676986,tests,Exemestane
Exemestane,has_type,DRUG
NCT01495663,has_title,"A Phase 1, Multi-Center, Open-Label, Dose Escalation Study of I-131-CLR1404 in Subjects With Relapse"
NCT01495663,has_status,COMPLETED
NCT01495663,has_phase,
NCT01495663,sponsored_by,"Cellectar Biosciences, Inc."
NCT01495663,tests,I-131-CLR1404
I-131-CLR1404,has_type,DRUG
NCT02352025,has_title,A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.
NCT02352025,has_status,COMPLETED
NCT02352025,has_phase,
NCT02352025,sponsored_by,The University of Texas Health Science Center at San Antonio
NCT02352025,tests,S-equol
S-equol,has_type,DRUG
NCT02178722,has_title,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With IN"
NCT02178722,has_status,COMPLETED
NCT02178722,has_phase,
NCT02178722,sponsored_by,Incyte Corporation
NCT02178722,tests,MK-3475
MK-3475,has_type,DRUG
NCT02178722,tests,INCB024360
INCB024360,has_type,DRUG
NCT04083963,has_title,BRE-01: Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed by Doxorubicin and 
NCT04083963,has_status,ACTIVE_NOT_RECRUITING
NCT04083963,has_phase,
NCT04083963,sponsored_by,University of Illinois at Chicago
NCT04083963,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04083963,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04083963,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04083963,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01818063,has_title,"An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition o"
NCT01818063,has_status,COMPLETED
NCT01818063,has_phase,
NCT01818063,sponsored_by,Sidney Kimmel Cancer Center at Thomas Jefferson University
NCT01818063,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01818063,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01818063,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT01818063,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT01818063,tests,Veliparib
Veliparib,has_type,DRUG
NCT05774886,has_title,Pilot Study of an Implantable Microdevice to Evaluate Drug Responses in Situ in Early-stage Triple-n
NCT05774886,has_status,WITHDRAWN
NCT05774886,has_phase,
NCT05774886,sponsored_by,Dana-Farber Cancer Institute
NCT05774886,tests,Implantable Microdevice (IMD)
Implantable Microdevice (IMD),has_type,COMBINATION_PRODUCT
NCT02605486,has_title,Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastat
NCT02605486,has_status,ACTIVE_NOT_RECRUITING
NCT02605486,has_phase,
NCT02605486,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02605486,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT02605486,tests,Bicalutamide
Bicalutamide,has_type,DRUG
NCT02347163,has_title,"A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in T"
NCT02347163,has_status,TERMINATED
NCT02347163,has_phase,
NCT02347163,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT02347163,tests,Zoledronate
Zoledronate,has_type,DRUG
NCT01560663,has_title,Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II 
NCT01560663,has_status,ACTIVE_NOT_RECRUITING
NCT01560663,has_phase,
NCT01560663,sponsored_by,Miguel Martín Jiménez
NCT01560663,tests,Docetaxel- Carboplatin
Docetaxel- Carboplatin,has_type,DRUG
NCT02451735,has_title,Genetic Counseling for Breast Cancer Survivors (GC for BC)
NCT02451735,has_status,COMPLETED
NCT02451735,has_phase,
NCT02451735,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT02451735,tests,Video and Booklet
Video and Booklet,has_type,BEHAVIORAL
NCT02451735,tests,Factsheet
Factsheet,has_type,BEHAVIORAL
NCT01377363,has_title,Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
NCT01377363,has_status,COMPLETED
NCT01377363,has_phase,
NCT01377363,sponsored_by,Spanish Breast Cancer Research Group
NCT02299635,has_title,PHASE 2 STUDY OF SINGLE-AGENT PF-03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WI
NCT02299635,has_status,TERMINATED
NCT02299635,has_phase,
NCT02299635,sponsored_by,Pfizer
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT02299635,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT01931163,has_title,Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients Wi
NCT01931163,has_status,COMPLETED
NCT01931163,has_phase,
NCT01931163,sponsored_by,"Jenny C. Chang, MD"
NCT01931163,tests,Everolimus
Everolimus,has_type,DRUG
NCT03107663,has_title,A Phase I Study of Positron Emission Tomography (PET/CT) With ⁸⁹Zr-Df-IAB22M2C in Patients With Sele
NCT03107663,has_status,COMPLETED
NCT03107663,has_phase,
NCT03107663,sponsored_by,"ImaginAb, Inc."
NCT03107663,tests,⁸⁹Zr-Df-IAB22M2C Infusion
⁸⁹Zr-Df-IAB22M2C Infusion,has_type,DRUG
NCT03821935,has_title,"A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, To"
NCT03821935,has_status,ACTIVE_NOT_RECRUITING
NCT03821935,has_phase,
NCT03821935,sponsored_by,AbbVie
NCT03821935,tests,Livmoniplimab
Livmoniplimab,has_type,DRUG
NCT03821935,tests,Budigalimab
Budigalimab,has_type,DRUG
NCT02826434,has_title,A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Durv
NCT02826434,has_status,ACTIVE_NOT_RECRUITING
NCT02826434,has_phase,
NCT02826434,sponsored_by,Massachusetts General Hospital
NCT02826434,tests,PVX-410
PVX-410,has_type,BIOLOGICAL
NCT02826434,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT02826434,tests,Hiltonol
Hiltonol,has_type,DRUG
NCT00516724,has_title,"A Phase I, Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With "
NCT00516724,has_status,COMPLETED
NCT00516724,has_phase,
NCT00516724,sponsored_by,AstraZeneca
NCT00516724,tests,KU-0059436 (AZD2281)(PARP inhibitor)
KU-0059436 (AZD2281)(PARP inhibitor),has_type,DRUG
NCT00516724,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00516724,tests,KU-0059436 (AZD2281)(PARP inhibitor)
KU-0059436 (AZD2281)(PARP inhibitor),has_type,DRUG
NCT00516724,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT00516724,tests,KU-0059436 (AZD2281)(PARP inhibitor)
KU-0059436 (AZD2281)(PARP inhibitor),has_type,DRUG
NCT00516724,tests,Paclitaxel + Carboplatin
Paclitaxel + Carboplatin,has_type,DRUG
NCT03337724,has_title,"A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Pa"
NCT03337724,has_status,COMPLETED
NCT03337724,has_phase,
NCT03337724,sponsored_by,Hoffmann-La Roche
NCT03337724,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03337724,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03337724,tests,Placebo
Placebo,has_type,DRUG
NCT03197935,has_title,A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Anti
NCT03197935,has_status,COMPLETED
NCT03197935,has_phase,
NCT03197935,sponsored_by,Hoffmann-La Roche
NCT03197935,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
NCT03197935,tests,Placebo
Placebo,has_type,DRUG
NCT03197935,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03197935,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT03197935,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03197935,tests,Filgrastim
Filgrastim,has_type,DRUG
NCT03197935,tests,Pegfilgrastim
Pegfilgrastim,has_type,DRUG
NCT00540358,has_title,"A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, With or Without B"
NCT00540358,has_status,COMPLETED
NCT00540358,has_phase,
NCT00540358,sponsored_by,Sanofi
NCT00540358,tests,gemcitabine/carboplatin
gemcitabine/carboplatin,has_type,DRUG
NCT00540358,tests,iniparib
iniparib,has_type,DRUG
NCT04577963,has_title,"An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination W"
NCT04577963,has_status,TERMINATED
NCT04577963,has_phase,
NCT04577963,sponsored_by,Hutchmed
NCT04577963,tests,Fruquintinib
Fruquintinib,has_type,DRUG
NCT04577963,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT03978663,has_title,Evaluating the Use of Stereotactic Radiation Therapy Prior to Neoadjuvant Chemotherapy for High-risk
NCT03978663,has_status,ACTIVE_NOT_RECRUITING
NCT03978663,has_phase,
NCT03978663,sponsored_by,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NCT03978663,tests,Neoadjuvant radiotherapy
Neoadjuvant radiotherapy,has_type,RADIATION
NCT06590558,has_title,Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative 
NCT06590558,has_status,WITHDRAWN
NCT06590558,has_phase,
NCT06590558,sponsored_by,National Cancer Institute (NCI)
NCT06590558,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT06590558,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06590558,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT06590558,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT06590558,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT06590558,tests,Tolinapant
Tolinapant,has_type,DRUG
NCT06590558,tests,X-Ray Imaging
X-Ray Imaging,has_type,PROCEDURE
NCT02546934,has_title,"A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cispla"
NCT02546934,has_status,COMPLETED
NCT02546934,has_phase,
NCT02546934,sponsored_by,Fudan University
NCT02546934,tests,"ABX, cisplatin"
"ABX, cisplatin",has_type,DRUG
NCT02546934,tests,"Gemcitabine, Cisplatin"
"Gemcitabine, Cisplatin",has_type,DRUG
NCT02460224,has_title,"A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in"
NCT02460224,has_status,COMPLETED
NCT02460224,has_phase,
NCT02460224,sponsored_by,Novartis Pharmaceuticals
NCT02460224,tests,LAG525
LAG525,has_type,DRUG
NCT02460224,tests,PDR001
PDR001,has_type,DRUG
NCT01287624,has_title,"A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gem"
NCT01287624,has_status,COMPLETED
NCT01287624,has_phase,
NCT01287624,sponsored_by,Fudan University
NCT01287624,tests,"Gemcitabine,cisplatin"
"Gemcitabine,cisplatin",has_type,DRUG
NCT01287624,tests,"Gemcitabine, Paclitaxel"
"Gemcitabine, Paclitaxel",has_type,DRUG
NCT05101096,has_title,A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumor
NCT05101096,has_status,ACTIVE_NOT_RECRUITING
NCT05101096,has_phase,
NCT05101096,sponsored_by,Gilead Sciences
NCT05101096,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT01276496,has_title,"A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Propert"
NCT01276496,has_status,COMPLETED
NCT01276496,has_phase,
NCT01276496,sponsored_by,National Cancer Institute (NCI)
NCT01276496,tests,Cilengitide
Cilengitide,has_type,DRUG
NCT01276496,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01276496,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01276496,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT04348916,has_title,"A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic He"
NCT04348916,has_status,TERMINATED
NCT04348916,has_phase,
NCT04348916,sponsored_by,"Oncorus, Inc."
NCT04348916,tests,ONCR-177
ONCR-177,has_type,BIOLOGICAL
NCT04348916,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT00022516,has_title,"Low-dose Cytotoxics as ""Anti-angiogenesis Treatment"" Following Adjuvant Induction Chemotherapy for P"
NCT00022516,has_status,COMPLETED
NCT00022516,has_phase,
NCT00022516,sponsored_by,ETOP IBCSG Partners Foundation
NCT00022516,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00022516,tests,Methotrexate
Methotrexate,has_type,DRUG
NCT04025216,has_title,"A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chim"
NCT04025216,has_status,TERMINATED
NCT04025216,has_phase,
NCT04025216,sponsored_by,"Kite, A Gilead Company"
NCT04025216,tests,CART-TnMUC1
CART-TnMUC1,has_type,BIOLOGICAL
NCT04025216,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04025216,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT03267316,has_title,"An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a"
NCT03267316,has_status,COMPLETED
NCT03267316,has_phase,
NCT03267316,sponsored_by,Cantargia AB
NCT03267316,tests,CAN04
CAN04,has_type,BIOLOGICAL
NCT03267316,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03267316,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03267316,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03267316,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03267316,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT05498896,has_title,"A Randomised, Open-label Phase II Study to Determine the Contribution of Ipatasertib to Neoadjuvant "
NCT05498896,has_status,ACTIVE_NOT_RECRUITING
NCT05498896,has_phase,
NCT05498896,sponsored_by,Queen Mary University of London
NCT05498896,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT05498896,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT05498896,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05498896,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05498896,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05383196,has_title,A Phase 1b/2 Study of Onvansertib in Combination With Paclitaxel in Triple-negative Metastatic Breas
NCT05383196,has_status,ACTIVE_NOT_RECRUITING
NCT05383196,has_phase,
NCT05383196,sponsored_by,"Antonio Giordano, MD"
NCT05383196,tests,Onvansertib
Onvansertib,has_type,DRUG
NCT05383196,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02315196,has_title,"A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Brea"
NCT02315196,has_status,ACTIVE_NOT_RECRUITING
NCT02315196,has_phase,
NCT02315196,sponsored_by,"Rutgers, The State University of New Jersey"
NCT02315196,tests,pegylated liposomal doxorubicin hydrochloride
pegylated liposomal doxorubicin hydrochloride,has_type,DRUG
NCT02315196,tests,epirubicin hydrochloride
epirubicin hydrochloride,has_type,DRUG
NCT02315196,tests,carboplatin
carboplatin,has_type,DRUG
NCT02315196,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT02315196,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT02315196,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT02315196,tests,quality-of-life assessment
quality-of-life assessment,has_type,OTHER
NCT03729596,has_title,"A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug C"
NCT03729596,has_status,TERMINATED
NCT03729596,has_phase,
NCT03729596,sponsored_by,MacroGenics
NCT03729596,tests,vobramitamab duocarmazine
vobramitamab duocarmazine,has_type,BIOLOGICAL
NCT04243616,has_title,Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )
NCT04243616,has_status,ACTIVE_NOT_RECRUITING
NCT04243616,has_phase,
NCT04243616,sponsored_by,Medical College of Wisconsin
NCT04243616,tests,Cemiplimab
Cemiplimab,has_type,DRUG
NCT04243616,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04243616,tests,Carboplatin (not mandatory)
Carboplatin (not mandatory),has_type,DRUG
NCT04243616,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04243616,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05233696,has_title,Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With P
NCT05233696,has_status,WITHDRAWN
NCT05233696,has_phase,
NCT05233696,sponsored_by,"University of Colorado, Denver"
NCT05233696,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT05233696,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05233696,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT05233696,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03794596,has_title,"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Nega"
NCT03794596,has_status,WITHDRAWN
NCT03794596,has_phase,
NCT03794596,sponsored_by,The Christie NHS Foundation Trust
NCT03794596,tests,Avelumab
Avelumab,has_type,DRUG
NCT03794596,tests,Aspirin
Aspirin,has_type,DRUG
NCT03794596,tests,Lansoprazole (Proton Pump Inhibitor)
Lansoprazole (Proton Pump Inhibitor),has_type,DRUG
NCT04504916,has_title,A Phase 2 Study of VLS-101 in Patients With Solid Tumors
NCT04504916,has_status,TERMINATED
NCT04504916,has_phase,
NCT04504916,sponsored_by,"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)"
NCT04504916,tests,Zilovertamab vedotin
Zilovertamab vedotin,has_type,DRUG
NCT00868634,has_title,Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Loc
NCT00868634,has_status,COMPLETED
NCT00868634,has_phase,
NCT00868634,sponsored_by,iOMEDICO AG
NCT00868634,tests,capecitabine
capecitabine,has_type,DRUG
NCT00868634,tests,bevacizumab
bevacizumab,has_type,DRUG
NCT00868634,tests,capecitabine
capecitabine,has_type,DRUG
NCT00868634,tests,bevacizumab
bevacizumab,has_type,DRUG
NCT00868634,tests,vinorelbine
vinorelbine,has_type,DRUG
NCT04225117,has_title,"An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects Wi"
NCT04225117,has_status,ACTIVE_NOT_RECRUITING
NCT04225117,has_phase,
NCT04225117,sponsored_by,"Astellas Pharma Global Development, Inc."
NCT04225117,tests,enfortumab vedotin
enfortumab vedotin,has_type,DRUG
NCT04225117,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT02539017,has_title,
NCT02539017,has_status,WITHDRAWN
NCT02539017,has_phase,
NCT02539017,sponsored_by,First Affiliated Hospital Xi'an Jiaotong University
NCT02539017,tests,Chemo
Chemo,has_type,DRUG
NCT02539017,tests,Immunotherapy
Immunotherapy,has_type,BIOLOGICAL
NCT04602117,has_title,ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Pat
NCT04602117,has_status,WITHDRAWN
NCT04602117,has_phase,
NCT04602117,sponsored_by,QuantumLeap Healthcare Collaborative
NCT04602117,tests,Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel,has_type,DRUG
NCT01272141,has_title,Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally 
NCT01272141,has_status,TERMINATED
NCT01272141,has_phase,
NCT01272141,sponsored_by,Emory University
NCT01272141,tests,Lapatinib and Everolimus
Lapatinib and Everolimus,has_type,DRUG
NCT01898117,has_title,Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel W
NCT01898117,has_status,ACTIVE_NOT_RECRUITING
NCT01898117,has_phase,
NCT01898117,sponsored_by,The Netherlands Cancer Institute
NCT01898117,tests,Carbo/cyclo
Carbo/cyclo,has_type,DRUG
NCT01898117,tests,Carbo/cyclo + atezolizumab
Carbo/cyclo + atezolizumab,has_type,DRUG
NCT01898117,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01898117,tests,Paclitaxel + Atezolizumab
Paclitaxel + Atezolizumab,has_type,DRUG
NCT03742349,has_title,"A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunothe"
NCT03742349,has_status,TERMINATED
NCT03742349,has_phase,
NCT03742349,sponsored_by,Novartis Pharmaceuticals
NCT03742349,tests,spartalizumab
spartalizumab,has_type,BIOLOGICAL
NCT03742349,tests,LAG525
LAG525,has_type,BIOLOGICAL
NCT03742349,tests,NIR178
NIR178,has_type,DRUG
NCT03742349,tests,capmatinib
capmatinib,has_type,DRUG
NCT03742349,tests,MCS110
MCS110,has_type,BIOLOGICAL
NCT03742349,tests,canakinumab
canakinumab,has_type,BIOLOGICAL
NCT04799249,has_title,"A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or "
NCT04799249,has_status,COMPLETED
NCT04799249,has_phase,
NCT04799249,sponsored_by,"G1 Therapeutics, Inc."
NCT04799249,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT04799249,tests,Placebo
Placebo,has_type,DRUG
NCT04799249,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04799249,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01151449,has_title,"A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Inv"
NCT01151449,has_status,TERMINATED
NCT01151449,has_phase,
NCT01151449,sponsored_by,National Cancer Institute (NCI)
NCT01151449,tests,gamma-secretase/Notch signalling pathway inhibitor RO4929097
gamma-secretase/Notch signalling pathway inhibitor RO4929097,has_type,DRUG
NCT01151449,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT02366949,has_title,"An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerabil"
NCT02366949,has_status,COMPLETED
NCT02366949,has_phase,
NCT02366949,sponsored_by,Bayer
NCT02366949,tests,BAY1217389
BAY1217389,has_type,DRUG
NCT02366949,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06876636,has_title,"Prospective, Open-Label, Single-Arm Clinical Study of Zoledronic Acid Combined with Neoadjuvant Chem"
NCT06876636,has_status,ACTIVE_NOT_RECRUITING
NCT06876636,has_phase,
NCT06876636,sponsored_by,Xijing Hospital
NCT06876636,tests,Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T)
Zoledronic Acid Combined with Neoadjuvant Chemotherapy (EC-T),has_type,DRUG
NCT04674306,has_title,Phase I Trial of Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Patients With Non-Metastatic 
NCT04674306,has_status,ACTIVE_NOT_RECRUITING
NCT04674306,has_phase,
NCT04674306,sponsored_by,George T. Budd
NCT04674306,tests,α-lactalbumin vaccine
α-lactalbumin vaccine,has_type,BIOLOGICAL
NCT04674306,tests,Zymosan
Zymosan,has_type,BIOLOGICAL
NCT05368506,has_title,"An Early Phase I Study of the Pharmacodynamics of WEE1 Inhibitor, ZN-c3, in Metastatic Solid Tumors"
NCT05368506,has_status,WITHDRAWN
NCT05368506,has_phase,
NCT05368506,sponsored_by,OHSU Knight Cancer Institute
NCT05368506,tests,Wee1 Inhibitor ZN-c3
Wee1 Inhibitor ZN-c3,has_type,DRUG
NCT03289819,has_title,A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel 
NCT03289819,has_status,COMPLETED
NCT03289819,has_phase,
NCT03289819,sponsored_by,Institut fuer Frauengesundheit
NCT03289819,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03289819,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT03289819,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT03289819,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03733119,has_title,ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
NCT03733119,has_status,TERMINATED
NCT03733119,has_phase,
NCT03733119,sponsored_by,"University of Wisconsin, Madison"
NCT03733119,tests,Akt/ERK Inhibitor ONC201
Akt/ERK Inhibitor ONC201,has_type,DRUG
NCT03733119,tests,Methionine-Restricted Diet
Methionine-Restricted Diet,has_type,DIETARY_SUPPLEMENT
NCT01445418,has_title,A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Ca
NCT01445418,has_status,COMPLETED
NCT01445418,has_phase,
NCT01445418,sponsored_by,National Cancer Institute (NCI)
NCT01445418,tests,AZ2281 + Carboplatin
AZ2281 + Carboplatin,has_type,DRUG
NCT05750719,has_title,Impact of BRCA Mutation Status on Outcome and Response to Neoadjuvant Chemotherapy (NACT) in Triple-
NCT05750719,has_status,COMPLETED
NCT05750719,has_phase,
NCT05750719,sponsored_by,Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT05750719,tests,BRCA1/2 genetic testing
BRCA1/2 genetic testing,has_type,GENETIC
NCT03674827,has_title,"A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES A"
NCT03674827,has_status,TERMINATED
NCT03674827,has_phase,
NCT03674827,sponsored_by,Pfizer
NCT03674827,tests,PF-06936308
PF-06936308,has_type,BIOLOGICAL
NCT03596073,has_title,A Pilot Trial of Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT03596073,has_status,TERMINATED
NCT03596073,has_phase,
NCT03596073,sponsored_by,Massachusetts General Hospital
NCT03596073,tests,Topical Calcipotriene Ointment
Topical Calcipotriene Ointment,has_type,DRUG
NCT03596073,tests,Topical Vaseline
Topical Vaseline,has_type,OTHER
NCT01147016,has_title,A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvan
NCT01147016,has_status,TERMINATED
NCT01147016,has_phase,
NCT01147016,sponsored_by,Barbara Ann Karmanos Cancer Institute
NCT01147016,tests,HER2Bi-armed activated T cells
HER2Bi-armed activated T cells,has_type,BIOLOGICAL
NCT01147016,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT01147016,tests,doxorubicin hydrochloride
doxorubicin hydrochloride,has_type,DRUG
NCT01147016,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01147016,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT01147016,tests,neoadjuvant therapy
neoadjuvant therapy,has_type,PROCEDURE
NCT01147016,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT03667716,has_title,A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjec
NCT03667716,has_status,COMPLETED
NCT03667716,has_phase,
NCT03667716,sponsored_by,Compugen Ltd
NCT03667716,tests,COM701
COM701,has_type,DRUG
NCT03667716,tests,COM701 with Opdivo (Nivolumab).
COM701 with Opdivo (Nivolumab).,has_type,DRUG
NCT04540224,has_title,"The Relationship Between the Differences in Blood Cytokine Values and Disease Stage in Luminal A, Lu"
NCT04540224,has_status,COMPLETED
NCT04540224,has_phase,
NCT04540224,sponsored_by,Istanbul Training and Research Hospital
NCT04540224,tests,Flow-Cytometric analysis
Flow-Cytometric analysis,has_type,DIAGNOSTIC_TEST
NCT05620134,has_title,"A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antib"
NCT05620134,has_status,ACTIVE_NOT_RECRUITING
NCT05620134,has_phase,
NCT05620134,sponsored_by,Salubris Biotherapeutics Inc
NCT05620134,tests,JK08
JK08,has_type,DRUG
NCT05620134,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05620134,tests,Lenvatinib Pill
Lenvatinib Pill,has_type,DRUG
NCT05347134,has_title,"A Randomized, Controlled, Open-label, Multi-center Phase III Clinical Trial of SKB264 for Injection "
NCT05347134,has_status,ACTIVE_NOT_RECRUITING
NCT05347134,has_phase,
NCT05347134,sponsored_by,"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd."
NCT05347134,tests,SKB264
SKB264,has_type,DRUG
NCT02527434,has_title,"A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Sol"
NCT02527434,has_status,COMPLETED
NCT02527434,has_phase,
NCT02527434,sponsored_by,AstraZeneca
NCT02527434,tests,Tremelimumab monotherapy
Tremelimumab monotherapy,has_type,BIOLOGICAL
NCT02527434,tests,MEDI4736 monotherapy
MEDI4736 monotherapy,has_type,BIOLOGICAL
NCT02527434,tests,MEDI4736 + tremelimumab combination therapy
MEDI4736 + tremelimumab combination therapy,has_type,BIOLOGICAL
NCT02404441,has_title,Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patient
NCT02404441,has_status,COMPLETED
NCT02404441,has_phase,
NCT02404441,sponsored_by,Novartis Pharmaceuticals
NCT02404441,tests,PDR001
PDR001,has_type,BIOLOGICAL
NCT01953536,has_title,"A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide an"
NCT01953536,has_status,WITHDRAWN
NCT01953536,has_phase,
NCT01953536,sponsored_by,Endocyte
NCT01953536,tests,Vintafolide 2.5 mg
Vintafolide 2.5 mg,has_type,DRUG
NCT01953536,tests,Paclitaxel 80 mg/m^2
Paclitaxel 80 mg/m^2,has_type,DRUG
NCT01953536,tests,Etarfolatide
Etarfolatide,has_type,DRUG
NCT01953536,tests,Folic acid
Folic acid,has_type,DRUG
NCT01953536,tests,Premedication for Paclitaxel
Premedication for Paclitaxel,has_type,DRUG
NCT01618136,has_title,"An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as"
NCT01618136,has_status,COMPLETED
NCT01618136,has_phase,
NCT01618136,sponsored_by,Eisai Limited
NCT01618136,tests,E7449 alone
E7449 alone,has_type,DRUG
NCT01618136,tests,E7449 plus TMZ
E7449 plus TMZ,has_type,DRUG
NCT01618136,tests,E7449 plus carboplatin and paclitaxel
E7449 plus carboplatin and paclitaxel,has_type,DRUG
NCT03154749,has_title,Neoadjuvant Docetaxel + Carboplatin Versus Epirubicin+Cyclophosphamide Followed by Docetaxel in Trip
NCT03154749,has_status,COMPLETED
NCT03154749,has_phase,
NCT03154749,sponsored_by,Guangdong Provincial People's Hospital
NCT03154749,tests,DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe),has_type,DRUG
NCT01498536,has_title,"Fit for the Fight: Effect of a Multidisciplinary Diet and Exercise Program on Body Weight, Quality o"
NCT01498536,has_status,COMPLETED
NCT01498536,has_phase,
NCT01498536,sponsored_by,West Virginia University
NCT01498536,tests,aerobic exercise
aerobic exercise,has_type,BEHAVIORAL
NCT03358017,has_title,"Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledrona"
NCT03358017,has_status,COMPLETED
NCT03358017,has_phase,
NCT03358017,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT03358017,tests,Zoledronate
Zoledronate,has_type,DRUG
NCT03358017,tests,Atorvastatin 80mg
Atorvastatin 80mg,has_type,DRUG
NCT03358017,tests,Standard neoadjuvant cht
Standard neoadjuvant cht,has_type,DRUG
NCT01964924,has_title,"A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With G"
NCT01964924,has_status,COMPLETED
NCT01964924,has_phase,
NCT01964924,sponsored_by,National Cancer Institute (NCI)
NCT01964924,tests,Akt Inhibitor GSK2141795
Akt Inhibitor GSK2141795,has_type,DRUG
NCT01964924,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01964924,tests,Trametinib
Trametinib,has_type,DRUG
NCT03092934,has_title,A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherap
NCT03092934,has_status,COMPLETED
NCT03092934,has_phase,
NCT03092934,sponsored_by,Eli Lilly and Company
NCT03092934,tests,LY3295668
LY3295668,has_type,DRUG
NCT01083641,has_title,A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer
NCT01083641,has_status,TERMINATED
NCT01083641,has_phase,
NCT01083641,sponsored_by,"University of Wisconsin, Madison"
NCT01083641,tests,Estradiol
Estradiol,has_type,DRUG
NCT01848834,has_title,A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
NCT01848834,has_status,COMPLETED
NCT01848834,has_phase,
NCT01848834,sponsored_by,Merck Sharp & Dohme LLC
NCT01848834,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05585034,has_title,"A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Ph"
NCT05585034,has_status,ACTIVE_NOT_RECRUITING
NCT05585034,has_phase,
NCT05585034,sponsored_by,"Xencor, Inc."
NCT05585034,tests,XmAb®808
XmAb®808,has_type,BIOLOGICAL
NCT05585034,tests,Keytruda® (pembrolizumab)
Keytruda® (pembrolizumab),has_type,BIOLOGICAL
NCT04250818,has_title,Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients C
NCT04250818,has_status,SUSPENDED
NCT04250818,has_phase,
NCT04250818,sponsored_by,"Texas Tech University Health Sciences Center, El Paso"
NCT06666517,has_title,The Relationship Between the Density of Cancer-Associated Fibroblasts in the Peritumoral Stroma and 
NCT06666517,has_status,COMPLETED
NCT06666517,has_phase,
NCT06666517,sponsored_by,Haydarpasa Numune Training and Research Hospital
NCT06666517,tests,"surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines"
"surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines",has_type,PROCEDURE
NCT06666517,tests,Immunohistochemistry Analysis
Immunohistochemistry Analysis,has_type,OTHER
NCT06666517,tests,Second Biopsy
Second Biopsy,has_type,PROCEDURE
NCT03371017,has_title,"A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Saf"
NCT03371017,has_status,COMPLETED
NCT03371017,has_phase,
NCT03371017,sponsored_by,Hoffmann-La Roche
NCT03371017,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03371017,tests,Placebo
Placebo,has_type,DRUG
NCT03371017,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03371017,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03371017,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04424641,has_title,"First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN10"
NCT04424641,has_status,TERMINATED
NCT04424641,has_phase,
NCT04424641,sponsored_by,Genmab
NCT04424641,tests,GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.,has_type,BIOLOGICAL
NCT04418219,has_title,A Phase I/II Study of the SV-BR-1-GM Regimen in HLA Matched Metastatic Breast Cancer Patients in Com
NCT04418219,has_status,WITHDRAWN
NCT04418219,has_phase,
NCT04418219,sponsored_by,Thomas Jefferson University
NCT04418219,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04418219,tests,Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM
Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM,has_type,BIOLOGICAL
NCT04418219,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04418219,tests,Recombinant Interferon Alpha 2b-like Protein
Recombinant Interferon Alpha 2b-like Protein,has_type,BIOLOGICAL
NCT04418219,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04418219,tests,Quality of Life Assessment
Quality of Life Assessment,has_type,OTHER
NCT02732119,has_title,"A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane"
NCT02732119,has_status,COMPLETED
NCT02732119,has_phase,
NCT02732119,sponsored_by,Novartis Pharmaceuticals
NCT02732119,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT02732119,tests,Everolimus
Everolimus,has_type,DRUG
NCT02732119,tests,Exemestane
Exemestane,has_type,DRUG
NCT04408118,has_title,Phase II Clinical Trial to Evaluate the Efficacy and Safety of First Line Atezolizumab in Combinatio
NCT04408118,has_status,COMPLETED
NCT04408118,has_phase,
NCT04408118,sponsored_by,MedSIR
NCT04408118,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04408118,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04408118,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT04102618,has_title,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)
NCT04102618,has_status,TERMINATED
NCT04102618,has_phase,
NCT04102618,sponsored_by,Oncolytics Biotech
NCT04102618,tests,Pelareorep
Pelareorep,has_type,BIOLOGICAL
NCT04102618,tests,Letrozole
Letrozole,has_type,DRUG
NCT04102618,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04102618,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT04345913,has_title,A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination With Copanlisib in 
NCT04345913,has_status,ACTIVE_NOT_RECRUITING
NCT04345913,has_phase,
NCT04345913,sponsored_by,National Cancer Institute (NCI)
NCT04345913,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT04345913,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04345913,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT04345913,tests,Copanlisib Hydrochloride
Copanlisib Hydrochloride,has_type,DRUG
NCT04345913,tests,Eribulin Mesylate
Eribulin Mesylate,has_type,DRUG
NCT04345913,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT03875313,has_title,"A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in "
NCT03875313,has_status,TERMINATED
NCT03875313,has_phase,
NCT03875313,sponsored_by,"Calithera Biosciences, Inc"
NCT03875313,tests,CB-839
CB-839,has_type,DRUG
NCT03875313,tests,Talazoparib
Talazoparib,has_type,DRUG
NCT02162719,has_title,"A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibit"
NCT02162719,has_status,COMPLETED
NCT02162719,has_phase,
NCT02162719,sponsored_by,"Genentech, Inc."
NCT02162719,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT02162719,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02162719,tests,Placebo
Placebo,has_type,DRUG
NCT03343613,has_title,A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Ant
NCT03343613,has_status,TERMINATED
NCT03343613,has_phase,
NCT03343613,sponsored_by,Eli Lilly and Company
NCT03343613,tests,LY3381916
LY3381916,has_type,DRUG
NCT03343613,tests,LY3300054
LY3300054,has_type,DRUG
NCT02819518,has_title,"A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo "
NCT02819518,has_status,COMPLETED
NCT02819518,has_phase,
NCT02819518,sponsored_by,Merck Sharp & Dohme LLC
NCT02819518,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02819518,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02819518,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02819518,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02819518,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02819518,tests,Normale Saline Solution
Normale Saline Solution,has_type,DRUG
NCT01939418,has_title,A Phase Ib Trial of Gemcitabine and Cisplatin With RAD001 in Patients With Metastatic Triple Negativ
NCT01939418,has_status,TERMINATED
NCT01939418,has_phase,
NCT01939418,sponsored_by,"National Cancer Center, Korea"
NCT01939418,tests,RAD001
RAD001,has_type,DRUG
NCT01939418,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT01939418,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02067741,has_title,"A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Resp"
NCT02067741,has_status,TERMINATED
NCT02067741,has_phase,
NCT02067741,sponsored_by,Swiss Group for Clinical Cancer Research
NCT02067741,tests,CR1447
CR1447,has_type,DRUG
NCT05759949,has_title,"A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Ther"
NCT05759949,has_status,COMPLETED
NCT05759949,has_phase,
NCT05759949,sponsored_by,"Relay Therapeutics, Inc."
NCT05759949,tests,RLY-5836
RLY-5836,has_type,DRUG
NCT05759949,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT05759949,tests,Palbociclib
Palbociclib,has_type,DRUG
NCT05759949,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT05759949,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT06057636,has_title,Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
NCT06057636,has_status,WITHDRAWN
NCT06057636,has_phase,
NCT06057636,sponsored_by,"The University of Tennessee, Knoxville"
NCT06057636,tests,Self-Administered Hypnosis
Self-Administered Hypnosis,has_type,BEHAVIORAL
NCT06057636,tests,Self-Administered White Noise Hypnosis
Self-Administered White Noise Hypnosis,has_type,BEHAVIORAL
NCT00600249,has_title,"Phase II Pilot Study Evaluating the Neoadjuvant Combination ""Taxotere (Docetaxel) and Erbitux (Cetux"
NCT00600249,has_status,COMPLETED
NCT00600249,has_phase,
NCT00600249,sponsored_by,Centre Jean Perrin
NCT00600249,tests,Cetuximab
Cetuximab,has_type,DRUG
NCT00600249,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01623349,has_title,Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib 
NCT01623349,has_status,COMPLETED
NCT01623349,has_phase,
NCT01623349,sponsored_by,Dana-Farber Cancer Institute
NCT01623349,tests,BKM120 and Olaparib
BKM120 and Olaparib,has_type,DRUG
NCT01623349,tests,BYL719 and Olaparib
BYL719 and Olaparib,has_type,DRUG
NCT03333915,has_title,"An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese S"
NCT03333915,has_status,COMPLETED
NCT03333915,has_phase,
NCT03333915,sponsored_by,BeiGene
NCT03333915,tests,Pamiparib
Pamiparib,has_type,DRUG
NCT00813956,has_title,
NCT00813956,has_status,COMPLETED
NCT00813956,has_phase,
NCT00813956,sponsored_by,Sanofi
NCT00813956,tests,gemcitabine plus carboplatin plus BSI-201
gemcitabine plus carboplatin plus BSI-201,has_type,DRUG
NCT02509507,has_title,"A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepv"
NCT02509507,has_status,COMPLETED
NCT02509507,has_phase,
NCT02509507,sponsored_by,Amgen
NCT02509507,tests,Talimogene Laherparepvec
Talimogene Laherparepvec,has_type,DRUG
NCT02509507,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04711109,has_title,"BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to"
NCT04711109,has_status,ACTIVE_NOT_RECRUITING
NCT04711109,has_phase,
NCT04711109,sponsored_by,Alliance for Clinical Trials in Oncology
NCT04711109,tests,Denosumab
Denosumab,has_type,DRUG
NCT04711109,tests,Placebo
Placebo,has_type,DRUG
NCT04711109,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT05504707,has_title,"Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells "
NCT05504707,has_status,ACTIVE_NOT_RECRUITING
NCT05504707,has_phase,
NCT05504707,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT05504707,tests,HER2 - primed Dendritic cells
HER2 - primed Dendritic cells,has_type,BIOLOGICAL
NCT05504707,tests,HER3 - primed Dendritic cells
HER3 - primed Dendritic cells,has_type,BIOLOGICAL
NCT02876107,has_title,A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplati
NCT02876107,has_status,ACTIVE_NOT_RECRUITING
NCT02876107,has_phase,
NCT02876107,sponsored_by,M.D. Anderson Cancer Center
NCT02876107,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02876107,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02876107,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02876107,tests,Panitumumab
Panitumumab,has_type,BIOLOGICAL
NCT03853707,has_title,"A Phase I/IB Study of Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capeci"
NCT03853707,has_status,COMPLETED
NCT03853707,has_phase,
NCT03853707,sponsored_by,City of Hope Medical Center
NCT03853707,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03853707,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03853707,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03853707,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03853707,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03853707,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03853707,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04254107,has_title,A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
NCT04254107,has_status,TERMINATED
NCT04254107,has_phase,
NCT04254107,sponsored_by,Seagen Inc.
NCT04254107,tests,SEA-TGT
SEA-TGT,has_type,DRUG
NCT04254107,tests,sasanlimab
sasanlimab,has_type,DRUG
NCT04254107,tests,brentuximab vedotin
brentuximab vedotin,has_type,DRUG
NCT00721409,has_title,"PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE P"
NCT00721409,has_status,COMPLETED
NCT00721409,has_phase,
NCT00721409,sponsored_by,Pfizer
NCT00721409,tests,PD 0332991
PD 0332991,has_type,DRUG
NCT00721409,tests,letrozole
letrozole,has_type,DRUG
NCT00721409,tests,letrozole
letrozole,has_type,DRUG
NCT01990209,has_title,A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That 
NCT01990209,has_status,COMPLETED
NCT01990209,has_phase,
NCT01990209,sponsored_by,"SCRI Development Innovations, LLC"
NCT01990209,tests,Orteronel
Orteronel,has_type,DRUG
NCT05145907,has_title,"A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerabili"
NCT05145907,has_status,ACTIVE_NOT_RECRUITING
NCT05145907,has_phase,
NCT05145907,sponsored_by,"TJ Biopharma Co., Ltd."
NCT05145907,tests,TJ107 +Pembrolizumab
TJ107 +Pembrolizumab,has_type,BIOLOGICAL
NCT00707707,has_title,"Phase I/II Randomised, Double- Blind, Multi-centre Study to Assess the Efficacy of AZD2281 When Give"
NCT00707707,has_status,COMPLETED
NCT00707707,has_phase,
NCT00707707,sponsored_by,AstraZeneca
NCT00707707,tests,AZD2281
AZD2281,has_type,DRUG
NCT00707707,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02682693,has_title,Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primar
NCT02682693,has_status,COMPLETED
NCT02682693,has_phase,
NCT02682693,sponsored_by,GBG Forschungs GmbH
NCT02682693,tests,Denosumab
Denosumab,has_type,DRUG
NCT02682693,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT02682693,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02682693,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02682693,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02682693,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02682693,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT00834678,has_title,Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Br
NCT00834678,has_status,COMPLETED
NCT00834678,has_phase,
NCT00834678,sponsored_by,Ohio State University Comprehensive Cancer Center
NCT00834678,tests,bendamustine
bendamustine,has_type,DRUG
NCT00834678,tests,erlotinib
erlotinib,has_type,DRUG
NCT00834678,tests,Maintenance erlotinib
Maintenance erlotinib,has_type,DRUG
NCT03609671,has_title,A Pilot Study: Emotions Immunology and Breast Cancer
NCT03609671,has_status,COMPLETED
NCT03609671,has_phase,
NCT03609671,sponsored_by,"Luz A. Venta, MD"
NCT03609671,tests,Standard of Care + Experimental Individualized Therapy
Standard of Care + Experimental Individualized Therapy,has_type,BEHAVIORAL
NCT03609671,tests,Control: Standard of Care
Control: Standard of Care,has_type,OTHER
NCT02403271,has_title,"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With"
NCT02403271,has_status,COMPLETED
NCT02403271,has_phase,
NCT02403271,sponsored_by,Pharmacyclics LLC.
NCT02403271,tests,Ibrutinib
Ibrutinib,has_type,DRUG
NCT02403271,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03918278,has_title,"A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics"
NCT03918278,has_status,COMPLETED
NCT03918278,has_phase,
NCT03918278,sponsored_by,Merck Sharp & Dohme LLC
NCT03918278,tests,MK-0482
MK-0482,has_type,BIOLOGICAL
NCT03918278,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT03918278,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03918278,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03918278,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03918278,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03918278,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT00472693,has_title,"A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hor"
NCT00472693,has_status,COMPLETED
NCT00472693,has_phase,
NCT00472693,sponsored_by,Abramson Cancer Center at Penn Medicine
NCT00472693,tests,"Bevacizumab, Abraxane"
"Bevacizumab, Abraxane",has_type,DRUG
NCT03232593,has_title,Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)
NCT03232593,has_status,COMPLETED
NCT03232593,has_phase,
NCT03232593,sponsored_by,Hoffmann-La Roche
NCT03232593,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT00246571,has_title,"A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated,"
NCT00246571,has_status,COMPLETED
NCT00246571,has_phase,
NCT00246571,sponsored_by,Pfizer
NCT00246571,tests,SU011248
SU011248,has_type,DRUG
NCT00246571,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT04486911,has_title,"Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Treatment of Stage II-III Tripl"
NCT04486911,has_status,ACTIVE_NOT_RECRUITING
NCT04486911,has_phase,
NCT04486911,sponsored_by,Shengjing Hospital
NCT04486911,tests,"Pyrotinib maleate, SHR6390, letrozole"
"Pyrotinib maleate, SHR6390, letrozole",has_type,DRUG
NCT02449993,has_title,"Evaluation of the MammaTyper Kit, Ref 90020/90021 Performed on Clinical Material Obtained From Patie"
NCT02449993,has_status,COMPLETED
NCT02449993,has_phase,
NCT02449993,sponsored_by,BioNTech Diagnostics GmbH
NCT02449993,tests,MammaTyper™
MammaTyper™,has_type,DEVICE
NCT03872388,has_title,Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Compl
NCT03872388,has_status,TERMINATED
NCT03872388,has_phase,
NCT03872388,sponsored_by,M.D. Anderson Cancer Center
NCT03872388,tests,Atorvastatin
Atorvastatin,has_type,DRUG
NCT03872388,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03517488,has_title,A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With
NCT03517488,has_status,COMPLETED
NCT03517488,has_phase,
NCT03517488,sponsored_by,"Xencor, Inc."
NCT03517488,tests,XmAb20717
XmAb20717,has_type,BIOLOGICAL
NCT02264678,has_title,"A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetic"
NCT02264678,has_status,ACTIVE_NOT_RECRUITING
NCT02264678,has_phase,
NCT02264678,sponsored_by,AstraZeneca
NCT02264678,tests,Administration of ceralasertib
Administration of ceralasertib,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib in combination with olaparib
Administration of ceralasertib in combination with olaparib,has_type,DRUG
NCT02264678,tests,Administation of ceralasertib in combination with durvalumab
Administation of ceralasertib in combination with durvalumab,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib monotherapy
Administration of ceralasertib monotherapy,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib and olaparib
Administration of ceralasertib and olaparib,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib and durvalumab
Administration of ceralasertib and durvalumab,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib in combination with AZD5305
Administration of ceralasertib in combination with AZD5305,has_type,DRUG
NCT02264678,tests,Administration of ceralasertib in combination with carboplatin
Administration of ceralasertib in combination with carboplatin,has_type,DRUG
NCT01672671,has_title,Identification of BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Bre
NCT01672671,has_status,COMPLETED
NCT01672671,has_phase,
NCT01672671,sponsored_by,Russian Academy of Medical Sciences
NCT01672671,tests,"Doxorubicin, Paclitaxel, Cisplatin"
"Doxorubicin, Paclitaxel, Cisplatin",has_type,DRUG
NCT05099978,has_title,Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing: A-TRAIN
NCT05099978,has_status,ACTIVE_NOT_RECRUITING
NCT05099978,has_phase,
NCT05099978,sponsored_by,"National Cancer Center, Japan"
NCT05099978,tests,NGS analysis of ctDNA
NGS analysis of ctDNA,has_type,GENETIC
NCT03812393,has_title,Phase II Trial Evaluating the Efficacy and Safety of Neoadjuvant Neratinib and Chemotherapy in Early
NCT03812393,has_status,ACTIVE_NOT_RECRUITING
NCT03812393,has_phase,
NCT03812393,sponsored_by,West Cancer Center
NCT03812393,tests,Neratinib
Neratinib,has_type,DRUG
NCT04268693,has_title,Bisphenol and Phthalate Exposures in Women With Triple Negative Breast Cancer Receiving Doxorubicin 
NCT04268693,has_status,WITHDRAWN
NCT04268693,has_phase,
NCT04268693,sponsored_by,George Washington University
NCT04268693,tests,urine collection
urine collection,has_type,OTHER
NCT04139993,has_title,"A Pilot Trial of Preoperative Oral Microbiota-Based Investigational New Drug, RBX7455 to Target Immu"
NCT04139993,has_status,TERMINATED
NCT04139993,has_phase,
NCT04139993,sponsored_by,Mayo Clinic
NCT04139993,tests,Microbiota-based Formulation RBX7455
Microbiota-based Formulation RBX7455,has_type,DRUG
NCT03045393,has_title,"Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple"
NCT03045393,has_status,WITHDRAWN
NCT03045393,has_phase,
NCT03045393,sponsored_by,Duke University
NCT03045393,tests,Mirvetuximab Soravtansine (IMGN853)
Mirvetuximab Soravtansine (IMGN853),has_type,DRUG
NCT02301988,has_title,"A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combin"
NCT02301988,has_status,COMPLETED
NCT02301988,has_phase,
NCT02301988,sponsored_by,"Genentech, Inc."
NCT02301988,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT02301988,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02301988,tests,Placebo
Placebo,has_type,DRUG
NCT02158507,has_title,"An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic"
NCT02158507,has_status,COMPLETED
NCT02158507,has_phase,
NCT02158507,sponsored_by,University of Alabama at Birmingham
NCT02158507,tests,Combination of Veliparib + Lapatinib
Combination of Veliparib + Lapatinib,has_type,DRUG
NCT06889688,has_title,"A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribu"
NCT06889688,has_status,ACTIVE_NOT_RECRUITING
NCT06889688,has_phase,
NCT06889688,sponsored_by,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NCT06889688,tests,Camrelizumab+Apatinib+Eribulin
Camrelizumab+Apatinib+Eribulin,has_type,DRUG
NCT06889688,tests,Physician's choice chemotherapy
Physician's choice chemotherapy,has_type,DRUG
NCT03519178,has_title,"PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHA"
NCT03519178,has_status,TERMINATED
NCT03519178,has_phase,
NCT03519178,sponsored_by,Pfizer
NCT03519178,tests,PF-06873600
PF-06873600,has_type,DRUG
NCT03519178,tests,Endocrine Therapy 1
Endocrine Therapy 1,has_type,DRUG
NCT03519178,tests,Endocrine Therapy 2
Endocrine Therapy 2,has_type,DRUG
NCT03251378,has_title,"A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, a"
NCT03251378,has_status,COMPLETED
NCT03251378,has_phase,
NCT03251378,sponsored_by,Hutchison Medipharma Limited
NCT03251378,tests,Fruquintinib (HMPL-013)
Fruquintinib (HMPL-013),has_type,DRUG
NCT05219578,has_title,A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors
NCT05219578,has_status,TERMINATED
NCT05219578,has_phase,
NCT05219578,sponsored_by,Rubius Therapeutics
NCT05219578,tests,RTX-224
RTX-224,has_type,DRUG
NCT00463788,has_title,"Randomized Phase II Trial With Cetuximab and Cisplatin in the Treatment of ER-negative, PgR-negative"
NCT00463788,has_status,COMPLETED
NCT00463788,has_phase,
NCT00463788,sponsored_by,"Merck KGaA, Darmstadt, Germany"
NCT00463788,tests,"cetuximab, cisplatin"
"cetuximab, cisplatin",has_type,DRUG
NCT00463788,tests,cisplatin
cisplatin,has_type,DRUG
NCT03036488,has_title,"A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo P"
NCT03036488,has_status,ACTIVE_NOT_RECRUITING
NCT03036488,has_phase,
NCT03036488,sponsored_by,Merck Sharp & Dohme LLC
NCT03036488,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03036488,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03036488,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03036488,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT03036488,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT03036488,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03036488,tests,Placebo
Placebo,has_type,DRUG
NCT03036488,tests,Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim,has_type,BIOLOGICAL
NCT04879888,has_title,Estudio clínico Fase I de Inmunoterapia Con Vacunas sintéticas Personalizadas en Pacientes Con cánce
NCT04879888,has_status,COMPLETED
NCT04879888,has_phase,
NCT04879888,sponsored_by,Universidad Nacional de Colombia
NCT04879888,tests,Peptide pulsed Dendritic cell
Peptide pulsed Dendritic cell,has_type,BIOLOGICAL
NCT05274451,has_title,"A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults W"
NCT05274451,has_status,TERMINATED
NCT05274451,has_phase,
NCT05274451,sponsored_by,"Lyell Immunopharma, Inc."
NCT05274451,tests,LYL797
LYL797,has_type,BIOLOGICAL
NCT04119154,has_title,Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)
NCT04119154,has_status,COMPLETED
NCT04119154,has_phase,
NCT04119154,sponsored_by,Harvard School of Public Health (HSPH)
NCT04119154,tests,Contrast Microhalography (CEM)
Contrast Microhalography (CEM),has_type,DIAGNOSTIC_TEST
NCT04251533,has_title,"A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy "
NCT04251533,has_status,ACTIVE_NOT_RECRUITING
NCT04251533,has_phase,
NCT04251533,sponsored_by,Novartis Pharmaceuticals
NCT04251533,tests,alpelisib
alpelisib,has_type,DRUG
NCT04251533,tests,placebo
placebo,has_type,DRUG
NCT04251533,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT05918133,has_title,"A Phase Ib/II Study of PM8002 Injection Plus Nab-paclitaxel as First Line Therapy for Unresectable, "
NCT05918133,has_status,ACTIVE_NOT_RECRUITING
NCT05918133,has_phase,
NCT05918133,sponsored_by,Biotheus Inc.
NCT05918133,tests,PM8002
PM8002,has_type,DRUG
NCT05918133,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT03652077,has_title,"A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants"
NCT03652077,has_status,COMPLETED
NCT03652077,has_phase,
NCT03652077,sponsored_by,Incyte Corporation
NCT03652077,tests,INCAGN02390
INCAGN02390,has_type,DRUG
NCT04332653,has_title,An Open-label Phase 1b/2a Study of NT-I7 (efineptakin Alfa) in Combination with Pembrolizumab in Sub
NCT04332653,has_status,ACTIVE_NOT_RECRUITING
NCT04332653,has_phase,
NCT04332653,sponsored_by,NeoImmuneTech
NCT04332653,tests,NT-I7
NT-I7,has_type,DRUG
NCT04332653,tests,pembrolizumab (KEYTRUDA®)
pembrolizumab (KEYTRUDA®),has_type,DRUG
NCT01155453,has_title,"A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral "
NCT01155453,has_status,COMPLETED
NCT01155453,has_phase,
NCT01155453,sponsored_by,Novartis Pharmaceuticals
NCT01155453,tests,BKM120
BKM120,has_type,DRUG
NCT01155453,tests,GSK1120212
GSK1120212,has_type,DRUG
NCT05169853,has_title,Correlation Between Programmed Death-Ligand1 Expression and Clinical Outcomes After Neoadjuvant Syst
NCT05169853,has_status,ACTIVE_NOT_RECRUITING
NCT05169853,has_phase,
NCT05169853,sponsored_by,Ain Shams University
NCT01936961,has_title,A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tu
NCT01936961,has_status,WITHDRAWN
NCT01936961,has_phase,
NCT01936961,sponsored_by,Western Regional Medical Center
NCT01936961,tests,CTLA-4 Antibody
CTLA-4 Antibody,has_type,DRUG
NCT01936961,tests,Hypofractionated Radiotherapy
Hypofractionated Radiotherapy,has_type,RADIATION
NCT02641847,has_title,Efficacy and Safety Study of TA(E)C-GP Versus A(E)C-T for the High Risk Triple-negative Breast Cance
NCT02641847,has_status,ACTIVE_NOT_RECRUITING
NCT02641847,has_phase,
NCT02641847,sponsored_by,Fudan University
NCT02641847,tests,docetaxel
docetaxel,has_type,DRUG
NCT02641847,tests,doxorubicin or epirubicin
doxorubicin or epirubicin,has_type,DRUG
NCT02641847,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT02641847,tests,gemcitabine
gemcitabine,has_type,DRUG
NCT02641847,tests,cisplatin
cisplatin,has_type,DRUG
NCT02670577,has_title,Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: 
NCT02670577,has_status,COMPLETED
NCT02670577,has_phase,
NCT02670577,sponsored_by,Agendia
NCT02032277,has_title,"A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the "
NCT02032277,has_status,COMPLETED
NCT02032277,has_phase,
NCT02032277,sponsored_by,AbbVie
NCT02032277,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02032277,tests,Placebo
Placebo,has_type,DRUG
NCT02032277,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02032277,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02032277,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02032277,tests,Veliparib
Veliparib,has_type,DRUG
NCT02032277,tests,Placebo
Placebo,has_type,DRUG
NCT02401347,has_title,A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients Wi
NCT02401347,has_status,COMPLETED
NCT02401347,has_phase,
NCT02401347,sponsored_by,Melinda Telli
NCT02401347,tests,Talazoparib Tosylate
Talazoparib Tosylate,has_type,DRUG
NCT02983045,has_title,"A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combi"
NCT02983045,has_status,COMPLETED
NCT02983045,has_phase,
NCT02983045,sponsored_by,Nektar Therapeutics
NCT02983045,tests,Dose Escalation Doublet: Combination of NKTR-214 + nivolumab
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab,has_type,DRUG
NCT02983045,tests,Dose Expansion Doublet: Combination of NKTR-214 + nivolumab
Dose Expansion Doublet: Combination of NKTR-214 + nivolumab,has_type,DRUG
NCT02983045,tests,Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,has_type,DRUG
NCT02983045,tests,Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab,has_type,DRUG
NCT00951054,has_title,A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients W
NCT00951054,has_status,COMPLETED
NCT00951054,has_phase,
NCT00951054,sponsored_by,"Nippon Kayaku Co., Ltd."
NCT00951054,tests,NK012
NK012,has_type,DRUG
NCT03254654,has_title,"A Phase II, Single-center, Randomized Study of Vinorelbine Plus Apatinib Versus Vinorelbine as Secon"
NCT03254654,has_status,COMPLETED
NCT03254654,has_phase,
NCT03254654,sponsored_by,Fudan University
NCT03254654,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT03254654,tests,Apatinib
Apatinib,has_type,DRUG
NCT04142554,has_title,Window of Opportunity Study of Parsaclisib in Subjects With Newly Diagnosed Stage I-IIIC Triple-Nega
NCT04142554,has_status,WITHDRAWN
NCT04142554,has_phase,
NCT04142554,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT04142554,tests,Parsaclisib
Parsaclisib,has_type,DRUG
NCT02368951,has_title,"An Open-label,Phase I, Dose-escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated"
NCT02368951,has_status,TERMINATED
NCT02368951,has_phase,
NCT02368951,sponsored_by,Bayer
NCT02368951,tests,BAY1187982
BAY1187982,has_type,DRUG
NCT04909554,has_title,MRI-based Approaches for Multi-parametric Model to Early Predict Pathological Complete Response to N
NCT04909554,has_status,COMPLETED
NCT04909554,has_phase,
NCT04909554,sponsored_by,Guangdong Provincial People's Hospital
NCT00371254,has_title,Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer
NCT00371254,has_status,COMPLETED
NCT00371254,has_phase,
NCT00371254,sponsored_by,Bristol-Myers Squibb
NCT00371254,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT00371254,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT01876251,has_title,Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negativ
NCT01876251,has_status,TERMINATED
NCT01876251,has_phase,
NCT01876251,sponsored_by,Pfizer
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT01876251,tests,PF-03084014
PF-03084014,has_type,DRUG
NCT01876251,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01876251,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02547987,has_title,"CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Can"
NCT02547987,has_status,ACTIVE_NOT_RECRUITING
NCT02547987,has_phase,
NCT02547987,sponsored_by,Mothaffar Rimawi
NCT02547987,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02547987,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02393287,has_title,Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observ
NCT02393287,has_status,COMPLETED
NCT02393287,has_phase,
NCT02393287,sponsored_by,Institut Cancerologie de l'Ouest
NCT02393287,tests,Eribulin (ReProLine)
Eribulin (ReProLine),has_type,OTHER
NCT03674242,has_title,A Randomized Phase 2/3 Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemothera
NCT03674242,has_status,TERMINATED
NCT03674242,has_phase,
NCT03674242,sponsored_by,ERYtech Pharma
NCT03674242,tests,eryaspase (L-asparaginase encapsulated in red blood cells)
eryaspase (L-asparaginase encapsulated in red blood cells),has_type,DRUG
NCT03674242,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03674242,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01815242,has_title,Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy R
NCT01815242,has_status,COMPLETED
NCT01815242,has_phase,
NCT01815242,sponsored_by,West German Study Group
NCT01815242,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT01815242,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT01815242,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03277352,has_title,A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subject
NCT03277352,has_status,TERMINATED
NCT03277352,has_phase,
NCT03277352,sponsored_by,Incyte Biosciences International Sàrl
NCT03277352,tests,INCAGN01876
INCAGN01876,has_type,DRUG
NCT03277352,tests,Epacadostat
Epacadostat,has_type,DRUG
NCT03277352,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03719833,has_title,"Sentinel Lymph Node Biopsy After Neoadjuvant Oncological Treatment in Luminal B, HER-2 Positive and "
NCT03719833,has_status,ACTIVE_NOT_RECRUITING
NCT03719833,has_phase,
NCT03719833,sponsored_by,Clinical Hospital Center Rijeka
NCT01091454,has_title,Phase II Trial of Brostallicin and Cisplatin in Patients With Metastatic Triple Negative Breast Canc
NCT01091454,has_status,COMPLETED
NCT01091454,has_phase,
NCT01091454,sponsored_by,Alliance for Clinical Trials in Oncology
NCT01091454,tests,brostallicin
brostallicin,has_type,DRUG
NCT01091454,tests,cisplatin
cisplatin,has_type,DRUG
NCT01238133,has_title,A Phase 1 Study of Neoadjuvant Chemotherapy With the Gamma Secretase Inhibitor RO4929097 in Combinat
NCT01238133,has_status,TERMINATED
NCT01238133,has_phase,
NCT01238133,sponsored_by,National Cancer Institute (NCI)
NCT01238133,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01238133,tests,Gamma-Secretase Inhibitor RO4929097
Gamma-Secretase Inhibitor RO4929097,has_type,DRUG
NCT01238133,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01238133,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01238133,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01238133,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT02441933,has_title,"A Randomized, Multicenter, Open-label, Phase III Trial Comparing Anthracyclines Followed by Taxane V"
NCT02441933,has_status,ACTIVE_NOT_RECRUITING
NCT02441933,has_phase,
NCT02441933,sponsored_by,Yonsei University
NCT02441933,tests,taxane plus carboplatin
taxane plus carboplatin,has_type,DRUG
NCT02441933,tests,Taxane
Taxane,has_type,DRUG
NCT04101851,has_title,Omission of Sentinel Lymph Node Biopsy in Triple-negative and HER2-positive Breast Cancer Patients w
NCT04101851,has_status,ACTIVE_NOT_RECRUITING
NCT04101851,has_phase,
NCT04101851,sponsored_by,"Toralf Reimer, MD PhD"
NCT04101851,tests,omission of SLNB
omission of SLNB,has_type,PROCEDURE
NCT01111175,has_title,Triple Negative Breast Cancer Biomarker Study
NCT01111175,has_status,COMPLETED
NCT01111175,has_phase,
NCT01111175,sponsored_by,US Oncology Research
NCT04296175,has_title,"A Prospective, Single Center, Randomized, Open-labled Stage III Clinical Trial Comparing the Efficac"
NCT04296175,has_status,ACTIVE_NOT_RECRUITING
NCT04296175,has_phase,
NCT04296175,sponsored_by,Fudan University
NCT04296175,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04296175,tests,CTX
CTX,has_type,DRUG
NCT04296175,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04296175,tests,ddEpirubicin
ddEpirubicin,has_type,DRUG
NCT04296175,tests,ddCTX
ddCTX,has_type,DRUG
NCT04296175,tests,Paclitaxel(with carbo)
Paclitaxel(with carbo),has_type,DRUG
NCT04296175,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04441099,has_title,"A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With"
NCT04441099,has_status,TERMINATED
NCT04441099,has_phase,
NCT04441099,sponsored_by,NBE-Therapeutics AG
NCT04441099,tests,NBE-002
NBE-002,has_type,DRUG
NCT01674842,has_title,A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative
NCT01674842,has_status,COMPLETED
NCT01674842,has_phase,
NCT01674842,sponsored_by,Dana-Farber Cancer Institute
NCT01674842,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT01674842,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02812875,has_title,"A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinet"
NCT02812875,has_status,COMPLETED
NCT02812875,has_phase,
NCT02812875,sponsored_by,"Curis, Inc."
NCT02812875,tests,CA-170
CA-170,has_type,DRUG
NCT05776875,has_title,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
NCT05776875,has_status,TERMINATED
NCT05776875,has_phase,
NCT05776875,sponsored_by,Yale University
NCT05776875,tests,Atezolizumab Injection
Atezolizumab Injection,has_type,DRUG
NCT05776875,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05776875,tests,Transarterial chemoembolization
Transarterial chemoembolization,has_type,COMBINATION_PRODUCT
NCT02737475,has_title,A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimum
NCT02737475,has_status,COMPLETED
NCT02737475,has_phase,
NCT02737475,sponsored_by,Bristol-Myers Squibb
NCT02737475,tests,BMS-986178
BMS-986178,has_type,DRUG
NCT02737475,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT02737475,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT02737475,tests,Tetanus vaccine
Tetanus vaccine,has_type,BIOLOGICAL
NCT02737475,tests,DPV-001 vaccine
DPV-001 vaccine,has_type,BIOLOGICAL
NCT02737475,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00887575,has_title,Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patient
NCT00887575,has_status,COMPLETED
NCT00887575,has_phase,
NCT00887575,sponsored_by,"SCRI Development Innovations, LLC"
NCT00887575,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT00887575,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00887575,tests,Sunitinib
Sunitinib,has_type,DRUG
NCT05383170,has_title,"A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evalua"
NCT05383170,has_status,COMPLETED
NCT05383170,has_phase,
NCT05383170,sponsored_by,Cytovation AS
NCT05383170,tests,CyPep-1
CyPep-1,has_type,DRUG
NCT05383170,tests,Pembrolizumab 25 MG/ML [KEYTRUDA®]
Pembrolizumab 25 MG/ML [KEYTRUDA®],has_type,DRUG
NCT02593175,has_title,"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxe"
NCT02593175,has_status,COMPLETED
NCT02593175,has_phase,
NCT02593175,sponsored_by,M.D. Anderson Cancer Center
NCT02593175,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02593175,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02593175,tests,Panitumumab
Panitumumab,has_type,BIOLOGICAL
NCT03715959,has_title,Phi29 Motor Nanopore for Single Molecule Sensing: Breast Nipple Aspirate Fluid
NCT03715959,has_status,COMPLETED
NCT03715959,has_phase,
NCT03715959,sponsored_by,Ohio State University Comprehensive Cancer Center
NCT03715959,tests,Aspiration of Breast
Aspiration of Breast,has_type,PROCEDURE
NCT03715959,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT02685059,has_title,A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthr
NCT02685059,has_status,COMPLETED
NCT02685059,has_phase,
NCT02685059,sponsored_by,GBG Forschungs GmbH
NCT02685059,tests,MEDI4736 (Anti PD-L1)
MEDI4736 (Anti PD-L1),has_type,DRUG
NCT02685059,tests,Placebo
Placebo,has_type,DRUG
NCT02685059,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT02685059,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT02685059,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03253575,has_title,"CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observ"
NCT03253575,has_status,SUSPENDED
NCT03253575,has_phase,
NCT03253575,sponsored_by,"Mitra RxDx, Inc."
NCT03253575,tests,CANscript
CANscript,has_type,DIAGNOSTIC_TEST
NCT02672475,has_title,A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Nega
NCT02672475,has_status,COMPLETED
NCT02672475,has_phase,
NCT02672475,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT02672475,tests,Galunisertib
Galunisertib,has_type,DRUG
NCT02672475,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02672475,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01104259,has_title,Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Tr
NCT01104259,has_status,COMPLETED
NCT01104259,has_phase,
NCT01104259,sponsored_by,University of Washington
NCT01104259,tests,veliparib
veliparib,has_type,DRUG
NCT01104259,tests,cisplatin
cisplatin,has_type,DRUG
NCT01104259,tests,vinorelbine tartrate
vinorelbine tartrate,has_type,DRUG
NCT01104259,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT01104259,tests,pharmacological study
pharmacological study,has_type,OTHER
NCT02866149,has_title,Analysis of Circulating Tumor Markers in the Blood
NCT02866149,has_status,COMPLETED
NCT02866149,has_phase,
NCT02866149,sponsored_by,Institut Curie
NCT02866149,tests,Blood sampling
Blood sampling,has_type,BIOLOGICAL
NCT02866149,tests,Tumor sampling
Tumor sampling,has_type,PROCEDURE
NCT02866149,tests,Stool sampling
Stool sampling,has_type,OTHER
NCT01818999,has_title,A Phase II Trial Of Ixabepilone and Stereotactic Body Radiation Therapy (SBRT) For Patients With Tri
NCT01818999,has_status,WITHDRAWN
NCT01818999,has_phase,
NCT01818999,sponsored_by,University of Texas Southwestern Medical Center
NCT01818999,tests,IXABEPILONE
IXABEPILONE,has_type,DRUG
NCT01818999,tests,STEREOTACTIC BODY RADIATION THERAPY
STEREOTACTIC BODY RADIATION THERAPY,has_type,RADIATION
NCT02125006,has_title,"The Effect of an Inter-Disciplinary Program, Including Mindfulness-Based Stress Reduction, on Psycho"
NCT02125006,has_status,COMPLETED
NCT02125006,has_phase,
NCT02125006,sponsored_by,Ottawa Hospital Research Institute
NCT02125006,tests,Mindfulness-Based Stress Reduction
Mindfulness-Based Stress Reduction,has_type,BEHAVIORAL
NCT04335006,has_title,"A Multicentre, Open-parallel, Randomized, Controlled Phase Ⅲ Study Comparing Carelizumab Plus Nab-pa"
NCT04335006,has_status,TERMINATED
NCT04335006,has_phase,
NCT04335006,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT04335006,tests,Carelizumab
Carelizumab,has_type,DRUG
NCT04335006,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04335006,tests,Apatinib
Apatinib,has_type,DRUG
NCT04450706,has_title,FORESEE: Functional Precision Oncology for Metastatic Breast Cancer: a Feasibility Trial
NCT04450706,has_status,COMPLETED
NCT04450706,has_phase,
NCT04450706,sponsored_by,University of Utah
NCT04450706,tests,Precision Medicine
Precision Medicine,has_type,OTHER
NCT04450706,tests,Physican Decision Making
Physican Decision Making,has_type,OTHER
NCT04879849,has_title,"An Open-label, Phase 1, Dose-escalation Study to Evaluate the Safety and Preliminary Antitumor Activ"
NCT04879849,has_status,COMPLETED
NCT04879849,has_phase,
NCT04879849,sponsored_by,Takeda
NCT04879849,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04879849,tests,TAK-676
TAK-676,has_type,DRUG
NCT04879849,tests,Image-guided radiation therapy
Image-guided radiation therapy,has_type,RADIATION
NCT05451849,has_title,A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expr
NCT05451849,has_status,ACTIVE_NOT_RECRUITING
NCT05451849,has_phase,
NCT05451849,sponsored_by,TCR2 Therapeutics
NCT05451849,tests,TC-510
TC-510,has_type,BIOLOGICAL
NCT05451849,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT05451849,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04152499,has_title,"A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metasta"
NCT04152499,has_status,ACTIVE_NOT_RECRUITING
NCT04152499,has_phase,
NCT04152499,sponsored_by,Klus Pharma Inc.
NCT04152499,tests,SKB264
SKB264,has_type,DRUG
NCT02783300,has_title,"A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacody"
NCT02783300,has_status,COMPLETED
NCT02783300,has_phase,
NCT02783300,sponsored_by,GlaxoSmithKline
NCT02783300,tests,GSK3326595
GSK3326595,has_type,DRUG
NCT02783300,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03480659,has_title,"Breast Cancer Screening Using DNA Methylation Changes in Circulated Tumor, PBMC and T-cells DNA."
NCT03480659,has_status,TERMINATED
NCT03480659,has_phase,
NCT03480659,sponsored_by,HKGepitherapeutics
NCT02048059,has_title,"A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain"
NCT02048059,has_status,COMPLETED
NCT02048059,has_phase,
NCT02048059,sponsored_by,Angiochem Inc
NCT02048059,tests,ANG1005
ANG1005,has_type,DRUG
NCT02661100,has_title,A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC
NCT02661100,has_status,WITHDRAWN
NCT02661100,has_phase,
NCT02661100,sponsored_by,Case Comprehensive Cancer Center
NCT02661100,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02661100,tests,CDX-1401
CDX-1401,has_type,BIOLOGICAL
NCT02661100,tests,Poly-ICLC
Poly-ICLC,has_type,BIOLOGICAL
NCT06309459,has_title,Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma: Relationship With Prognostic Facto
NCT06309459,has_status,COMPLETED
NCT06309459,has_phase,
NCT06309459,sponsored_by,Kahramanmaras Sutcu Imam University
NCT06309459,tests,Carbonic anhydrase staining levels
Carbonic anhydrase staining levels,has_type,DIAGNOSTIC_TEST
NCT05555706,has_title,A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel 
NCT05555706,has_status,COMPLETED
NCT05555706,has_phase,
NCT05555706,sponsored_by,"Shanghai Jiaolian Drug Research and Development Co., Ltd"
NCT05555706,tests,B013+Nab-Paclitaxel
B013+Nab-Paclitaxel,has_type,DRUG
NCT04669899,has_title,Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor
NCT04669899,has_status,COMPLETED
NCT04669899,has_phase,
NCT04669899,sponsored_by,"Jounce Therapeutics, Inc."
NCT04669899,tests,JTX-8064
JTX-8064,has_type,DRUG
NCT04669899,tests,pimivalimab
pimivalimab,has_type,DRUG
NCT00674206,has_title,"A Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2NEU- (Triple Negative) Metastatic "
NCT00674206,has_status,TERMINATED
NCT00674206,has_phase,
NCT00674206,sponsored_by,Emory University
NCT00674206,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT00674206,tests,Oxaliplatin
Oxaliplatin,has_type,DRUG
NCT01276899,has_title,Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple 
NCT01276899,has_status,COMPLETED
NCT01276899,has_phase,
NCT01276899,sponsored_by,Jewish General Hospital
NCT01276899,tests,Needle core biopsies
Needle core biopsies,has_type,PROCEDURE
NCT01276899,tests,Needle core biopsies of metastatic lesion
Needle core biopsies of metastatic lesion,has_type,PROCEDURE
NCT05007106,has_title,"A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684"
NCT05007106,has_status,ACTIVE_NOT_RECRUITING
NCT05007106,has_phase,
NCT05007106,sponsored_by,Merck Sharp & Dohme LLC
NCT05007106,tests,Pembrolizumab/Vibostolimab Co-Formulation
Pembrolizumab/Vibostolimab Co-Formulation,has_type,BIOLOGICAL
NCT05007106,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05007106,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT05007106,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT05007106,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT05007106,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05007106,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT05007106,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05007106,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT05007106,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT05007106,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05007106,tests,Oxaliplatin
Oxaliplatin,has_type,DRUG
NCT05234606,has_title,"A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of SBT6290 Alone and in Combination Wit"
NCT05234606,has_status,WITHDRAWN
NCT05234606,has_phase,
NCT05234606,sponsored_by,Silverback Therapeutics
NCT05234606,tests,SBT6290
SBT6290,has_type,DRUG
NCT05234606,tests,SBT6290
SBT6290,has_type,DRUG
NCT05234606,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT01650506,has_title,Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer
NCT01650506,has_status,COMPLETED
NCT01650506,has_phase,
NCT01650506,sponsored_by,Columbia University
NCT01650506,tests,Metformin
Metformin,has_type,DRUG
NCT01650506,tests,Erlotinib
Erlotinib,has_type,DRUG
NCT01918306,has_title,A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With An
NCT01918306,has_status,TERMINATED
NCT01918306,has_phase,
NCT01918306,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT01918306,tests,cisplatin
cisplatin,has_type,DRUG
NCT01918306,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT01918306,tests,pharmacological study
pharmacological study,has_type,OTHER
NCT01918306,tests,"dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI"
"dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI",has_type,PROCEDURE
NCT01918306,tests,GDC -0941
GDC -0941,has_type,DRUG
NCT02038699,has_title,A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing o
NCT02038699,has_status,WITHDRAWN
NCT02038699,has_phase,
NCT02038699,sponsored_by,Chimerix
NCT02038699,tests,ONC201
ONC201,has_type,DRUG
NCT02685306,has_title,A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects o
NCT02685306,has_status,WITHDRAWN
NCT02685306,has_phase,
NCT02685306,sponsored_by,Peregrine Pharmaceuticals
NCT02685306,tests,Bavituximab
Bavituximab,has_type,BIOLOGICAL
NCT02685306,tests,Taxane
Taxane,has_type,DRUG
NCT04491942,has_title,A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Pl
NCT04491942,has_status,ACTIVE_NOT_RECRUITING
NCT04491942,has_phase,
NCT04491942,sponsored_by,National Cancer Institute (NCI)
NCT04491942,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT04491942,tests,Elimusertib
Elimusertib,has_type,DRUG
NCT04491942,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
NCT02938442,has_title,A Combined Phase i/II Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE™ ISA 51
NCT02938442,has_status,COMPLETED
NCT02938442,has_phase,
NCT02938442,sponsored_by,University of Arkansas
NCT02938442,tests,P10s-PADRE with MONTANIDE™ ISA 51 VG
P10s-PADRE with MONTANIDE™ ISA 51 VG,has_type,BIOLOGICAL
NCT02938442,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02938442,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02938442,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03518242,has_title,Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications
NCT03518242,has_status,COMPLETED
NCT03518242,has_phase,
NCT03518242,sponsored_by,Fred Hutchinson Cancer Center
NCT03518242,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03518242,tests,Methotrexate
Methotrexate,has_type,DRUG
NCT03518242,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03518242,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT06829199,has_title,"A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigati"
NCT06829199,has_status,WITHDRAWN
NCT06829199,has_phase,
NCT06829199,sponsored_by,Merck Sharp & Dohme LLC
NCT06829199,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT06829199,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06829199,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06829199,tests,Doxorubicin (hydrochloride)
Doxorubicin (hydrochloride),has_type,DRUG
NCT06829199,tests,Boserolimab
Boserolimab,has_type,BIOLOGICAL
NCT06829199,tests,Epirubicin Hydrochloride
Epirubicin Hydrochloride,has_type,DRUG
NCT06829199,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT06829199,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT06829199,tests,Olaparib (if approved/available locally)
Olaparib (if approved/available locally),has_type,DRUG
NCT05958199,has_title,"A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to"
NCT05958199,has_status,SUSPENDED
NCT05958199,has_phase,
NCT05958199,sponsored_by,"NextPoint Therapeutics, Inc."
NCT05958199,tests,NPX267
NPX267,has_type,DRUG
NCT04060342,has_title,"A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combinat"
NCT04060342,has_status,TERMINATED
NCT04060342,has_phase,
NCT04060342,sponsored_by,"GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc."
NCT04060342,tests,GB1275
GB1275,has_type,DRUG
NCT04060342,tests,nab-paclitaxel and gemcitabine
nab-paclitaxel and gemcitabine,has_type,DRUG
NCT04060342,tests,pembrolizumab
pembrolizumab,has_type,DRUG
NCT05097599,has_title,StrataPATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity
NCT05097599,has_status,TERMINATED
NCT05097599,has_phase,
NCT05097599,sponsored_by,Strata Oncology
NCT05097599,tests,lorlatinib
lorlatinib,has_type,DRUG
NCT05097599,tests,encorafenib + binimetinib
encorafenib + binimetinib,has_type,DRUG
NCT05097599,tests,talazoparib
talazoparib,has_type,DRUG
NCT05097599,tests,sacituzumab govitecan
sacituzumab govitecan,has_type,DRUG
NCT05097599,tests,axitinib
axitinib,has_type,DRUG
NCT05097599,tests,Fam-Trastuzumab Deruxtecan-Nxki
Fam-Trastuzumab Deruxtecan-Nxki,has_type,DRUG
NCT05097599,tests,enfortumab vedotin
enfortumab vedotin,has_type,DRUG
NCT03464942,has_title,A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereo
NCT03464942,has_status,COMPLETED
NCT03464942,has_phase,
NCT03464942,sponsored_by,"Peter MacCallum Cancer Centre, Australia"
NCT03464942,tests,SABR
SABR,has_type,RADIATION
NCT03464942,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02221999,has_title,"A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin Wit"
NCT02221999,has_status,ACTIVE_NOT_RECRUITING
NCT02221999,has_phase,
NCT02221999,sponsored_by,RenJi Hospital
NCT02221999,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02221999,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02221999,tests,Gonadotropin-releasing hormone agonist
Gonadotropin-releasing hormone agonist,has_type,DRUG
NCT02221999,tests,Letrozole
Letrozole,has_type,DRUG
NCT02485119,has_title,"An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY94-9343"
NCT02485119,has_status,COMPLETED
NCT02485119,has_phase,
NCT02485119,sponsored_by,Bayer
NCT02485119,tests,BAY94-9343
BAY94-9343,has_type,DRUG
NCT01624441,has_title,A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Pat
NCT01624441,has_status,COMPLETED
NCT01624441,has_phase,
NCT01624441,sponsored_by,National Cancer Institute (NCI)
NCT01624441,tests,Dinaciclib
Dinaciclib,has_type,DRUG
NCT01624441,tests,Epirubicin Hydrochloride
Epirubicin Hydrochloride,has_type,DRUG
NCT01624441,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01562275,has_title,"A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GD"
NCT01562275,has_status,COMPLETED
NCT01562275,has_phase,
NCT01562275,sponsored_by,"Genentech, Inc."
NCT01562275,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT01562275,tests,Cobimetinib
Cobimetinib,has_type,DRUG
NCT02225470,has_title,An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female
NCT02225470,has_status,COMPLETED
NCT02225470,has_phase,
NCT02225470,sponsored_by,"Eisai Co., Ltd."
NCT02225470,tests,E7389 (Eribulin Mesylate)
E7389 (Eribulin Mesylate),has_type,DRUG
NCT02225470,tests,Vinorelbine injection
Vinorelbine injection,has_type,DRUG
NCT01097642,has_title,Randomized Open-Label Neo-Adjuvant Phase II Study Comparing Ixabepilone (I) Vs. Ixabepilone Plus Cet
NCT01097642,has_status,COMPLETED
NCT01097642,has_phase,
NCT01097642,sponsored_by,The Methodist Hospital Research Institute
NCT01097642,tests,Cetuximab
Cetuximab,has_type,DRUG
NCT01097642,tests,Ixabepilone
Ixabepilone,has_type,DRUG
NCT02789332,has_title,A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Pacli
NCT02789332,has_status,COMPLETED
NCT02789332,has_phase,
NCT02789332,sponsored_by,GBG Forschungs GmbH
NCT02789332,tests,PwO
PwO,has_type,DRUG
NCT02789332,tests,PwCb
PwCb,has_type,DRUG
NCT02789332,tests,EC
EC,has_type,DRUG
NCT02789332,tests,Surgery after neoadjuvant Therapy
Surgery after neoadjuvant Therapy,has_type,PROCEDURE
NCT02789332,tests,Stratification
Stratification,has_type,OTHER
NCT01777932,has_title,"A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits of Bevacizumab (Avas"
NCT01777932,has_status,COMPLETED
NCT01777932,has_phase,
NCT01777932,sponsored_by,Hoffmann-La Roche
NCT00546156,has_title,A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by P
NCT00546156,has_status,COMPLETED
NCT00546156,has_phase,
NCT00546156,sponsored_by,"Ian E. Krop, MD, PhD"
NCT00546156,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT00546156,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00546156,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT00546156,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT00759785,has_title,A Study to Establish Proof-of-Biology for MK-0646 in Breast Cancer
NCT00759785,has_status,COMPLETED
NCT00759785,has_phase,
NCT00759785,sponsored_by,Merck Sharp & Dohme LLC
NCT00759785,tests,dalotuzumab (MK0646)
dalotuzumab (MK0646),has_type,DRUG
NCT03818685,has_title,"A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-oper"
NCT03818685,has_status,ACTIVE_NOT_RECRUITING
NCT03818685,has_phase,
NCT03818685,sponsored_by,Centre Leon Berard
NCT03818685,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03818685,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT03818685,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04551885,has_title,"A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subje"
NCT04551885,has_status,TERMINATED
NCT04551885,has_phase,
NCT04551885,sponsored_by,Fate Therapeutics
NCT04551885,tests,FT516
FT516,has_type,DRUG
NCT04551885,tests,Avelumab
Avelumab,has_type,DRUG
NCT04551885,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04551885,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT04551885,tests,IL-2
IL-2,has_type,DRUG
NCT01969032,has_title,Phase 2 Study of Two Consequent Chemotherapy Regimens as Induction Preoperative Therapy for Patients
NCT01969032,has_status,COMPLETED
NCT01969032,has_phase,
NCT01969032,sponsored_by,Russian Academy of Medical Sciences
NCT01969032,tests,"Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine"
"Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine",has_type,DRUG
NCT01333137,has_title,An Open-Label Randomized Phase II Trial Comparing Gemcitabine and Carboplatin With and Without P276-
NCT01333137,has_status,TERMINATED
NCT01333137,has_phase,
NCT01333137,sponsored_by,Piramal Enterprises Limited
NCT01333137,tests,Gemcitabine and Carboplatin
Gemcitabine and Carboplatin,has_type,DRUG
NCT01333137,tests,P276-00 along with Gemcitabine and carboplatin
P276-00 along with Gemcitabine and carboplatin,has_type,DRUG
NCT01009437,has_title,A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Can
NCT01009437,has_status,COMPLETED
NCT01009437,has_phase,
NCT01009437,sponsored_by,"Masonic Cancer Center, University of Minnesota"
NCT01009437,tests,ritonavir
ritonavir,has_type,DRUG
NCT01009437,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT05266937,has_title,A Phase II Trial of Atezolizumab Plus CArboplatin Plus Nab-paclitaxel as First-line Therapy in Metas
NCT05266937,has_status,ACTIVE_NOT_RECRUITING
NCT05266937,has_phase,
NCT05266937,sponsored_by,Consorzio Oncotech
NCT05266937,tests,"Atezolizumab,Paclitaxel, Carboplatin"
"Atezolizumab,Paclitaxel, Carboplatin",has_type,COMBINATION_PRODUCT
NCT02531932,has_title,A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination
NCT02531932,has_status,COMPLETED
NCT02531932,has_phase,
NCT02531932,sponsored_by,Amy Tiersten
NCT02531932,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02531932,tests,Everolimus
Everolimus,has_type,DRUG
NCT02014337,has_title,Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metasta
NCT02014337,has_status,COMPLETED
NCT02014337,has_phase,
NCT02014337,sponsored_by,Corcept Therapeutics
NCT02014337,tests,Mifepristone and Eribulin in combination
Mifepristone and Eribulin in combination,has_type,DRUG
NCT03186937,has_title,A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer
NCT03186937,has_status,TERMINATED
NCT03186937,has_phase,
NCT03186937,sponsored_by,"University of Wisconsin, Madison"
NCT03186937,tests,hominex-2
hominex-2,has_type,DIETARY_SUPPLEMENT
NCT02637375,has_title,A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
NCT02637375,has_status,WITHDRAWN
NCT02637375,has_phase,
NCT02637375,sponsored_by,University of Chicago
NCT02637375,tests,Ganetespib
Ganetespib,has_type,DRUG
NCT02637375,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02637375,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02637375,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03542175,has_title,A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients W
NCT03542175,has_status,ACTIVE_NOT_RECRUITING
NCT03542175,has_phase,
NCT03542175,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT03542175,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT03542175,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT02208375,has_title,A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the
NCT02208375,has_status,ACTIVE_NOT_RECRUITING
NCT02208375,has_phase,
NCT02208375,sponsored_by,M.D. Anderson Cancer Center
NCT02208375,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT02208375,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02208375,tests,Olaparib
Olaparib,has_type,DRUG
NCT02208375,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02208375,tests,Vistusertib
Vistusertib,has_type,DRUG
NCT01401959,has_title,Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Followi
NCT01401959,has_status,COMPLETED
NCT01401959,has_phase,
NCT01401959,sponsored_by,"SCRI Development Innovations, LLC"
NCT01401959,tests,Eribulin
Eribulin,has_type,DRUG
NCT01401959,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT01074970,has_title,PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER
NCT01074970,has_status,COMPLETED
NCT01074970,has_phase,
NCT01074970,sponsored_by,Hoosier Cancer Research Network
NCT01074970,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01074970,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT01074970,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT04691375,has_title,"A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacod"
NCT04691375,has_status,TERMINATED
NCT04691375,has_phase,
NCT04691375,sponsored_by,Ikena Oncology
NCT04691375,tests,PY314
PY314,has_type,DRUG
NCT04691375,tests,Combination Therapy: PY314 + Pembrolizumab
Combination Therapy: PY314 + Pembrolizumab,has_type,DRUG
NCT00601159,has_title,Phase Ⅱ Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple
NCT00601159,has_status,COMPLETED
NCT00601159,has_phase,
NCT00601159,sponsored_by,Fudan University
NCT00601159,tests,gemcitabine and cisplatin
gemcitabine and cisplatin,has_type,DRUG
NCT01910870,has_title,
NCT01910870,has_status,TERMINATED
NCT01910870,has_phase,
NCT01910870,sponsored_by,Centre Jean Perrin
NCT01910870,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01910870,tests,Metronomic Cyclophosphamide
Metronomic Cyclophosphamide,has_type,DRUG
NCT04718675,has_title,"Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patient"
NCT04718675,has_status,TERMINATED
NCT04718675,has_phase,
NCT04718675,sponsored_by,Kronos Bio
NCT04718675,tests,KB-0742
KB-0742,has_type,DRUG
NCT03417115,has_title,Treatment and Outcome of Patients With Breast Cancer: Clinical Research Platform for Real World Data
NCT03417115,has_status,ACTIVE_NOT_RECRUITING
NCT03417115,has_phase,
NCT03417115,sponsored_by,iOMEDICO AG
NCT05629585,has_title,"A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvaluma"
NCT05629585,has_status,ACTIVE_NOT_RECRUITING
NCT05629585,has_phase,
NCT05629585,sponsored_by,AstraZeneca
NCT05629585,tests,Dato-DXd
Dato-DXd,has_type,DRUG
NCT05629585,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT05629585,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05629585,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04958785,has_title,"A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or"
NCT04958785,has_status,TERMINATED
NCT04958785,has_phase,
NCT04958785,sponsored_by,Gilead Sciences
NCT04958785,tests,Magrolimab
Magrolimab,has_type,DRUG
NCT04958785,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT04958785,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04958785,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT02628132,has_title,"Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody"
NCT02628132,has_status,COMPLETED
NCT02628132,has_phase,
NCT02628132,sponsored_by,King Faisal Specialist Hospital & Research Center
NCT02628132,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02628132,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT04148937,has_title,A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or 
NCT04148937,has_status,COMPLETED
NCT04148937,has_phase,
NCT04148937,sponsored_by,Eli Lilly and Company
NCT04148937,tests,LY3475070
LY3475070,has_type,DRUG
NCT04148937,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04742959,has_title,"A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Re"
NCT04742959,has_status,COMPLETED
NCT04742959,has_phase,
NCT04742959,sponsored_by,"TransThera Sciences (Nanjing), Inc."
NCT04742959,tests,TT-00420
TT-00420,has_type,DRUG
NCT04742959,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,COMBINATION_PRODUCT
NCT02624700,has_title,Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative B
NCT02624700,has_status,TERMINATED
NCT02624700,has_phase,
NCT02624700,sponsored_by,Virginia Commonwealth University
NCT02624700,tests,Experimental Arm A: Pemetrexed
Experimental Arm A: Pemetrexed,has_type,DRUG
NCT02624700,tests,Experimental Arm A: Sorafenib
Experimental Arm A: Sorafenib,has_type,DRUG
NCT02624700,tests,Experimental Arm B: Pemetrexed
Experimental Arm B: Pemetrexed,has_type,DRUG
NCT02624700,tests,Experimental Arm B: Sorafenib
Experimental Arm B: Sorafenib,has_type,DRUG
NCT06052852,has_title,"A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-3042 as a Single Agent and i"
NCT06052852,has_status,ACTIVE_NOT_RECRUITING
NCT06052852,has_phase,
NCT06052852,sponsored_by,"Bolt Biotherapeutics, Inc."
NCT06052852,tests,BDC-3042
BDC-3042,has_type,DRUG
NCT06052852,tests,Cemiplimab
Cemiplimab,has_type,DRUG
NCT01349959,has_title,Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer
NCT01349959,has_status,COMPLETED
NCT01349959,has_phase,
NCT01349959,sponsored_by,National Cancer Institute (NCI)
NCT01349959,tests,Azacitidine
Azacitidine,has_type,DRUG
NCT01349959,tests,Entinostat
Entinostat,has_type,DRUG
NCT01349959,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01349959,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT05673200,has_title,Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer
NCT05673200,has_status,SUSPENDED
NCT05673200,has_phase,
NCT05673200,sponsored_by,National Cancer Institute (NCI)
NCT05673200,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT05673200,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT05673200,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05673200,tests,Decitabine and Cedazuridine
Decitabine and Cedazuridine,has_type,DRUG
NCT05673200,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT05673200,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05673200,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT01251900,has_title,BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects
NCT01251900,has_status,COMPLETED
NCT01251900,has_phase,
NCT01251900,sponsored_by,National Cancer Institute (NCI)
NCT01238952,has_title,A Phase I Study of NK012 in Combination With Carboplatin in Patients With Advanced Solid Tumors Foll
NCT01238952,has_status,COMPLETED
NCT01238952,has_phase,
NCT01238952,sponsored_by,"Nippon Kayaku Co., Ltd."
NCT01238952,tests,NK012 and carboplatin
NK012 and carboplatin,has_type,DRUG
NCT01075100,has_title,Phase II Trial of Ixabepilone Plus Carboplatin in Patients With Metastatic Breast Cancer: The ECLIPS
NCT01075100,has_status,COMPLETED
NCT01075100,has_phase,
NCT01075100,sponsored_by,US Oncology Research
NCT01075100,tests,Ixabepilone
Ixabepilone,has_type,DRUG
NCT01075100,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03012100,has_title,"Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Fo"
NCT03012100,has_status,ACTIVE_NOT_RECRUITING
NCT03012100,has_phase,
NCT03012100,sponsored_by,Academic and Community Cancer Research United
NCT03012100,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03012100,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03012100,tests,Multi-epitope Folate Receptor Alpha Peptide Vaccine
Multi-epitope Folate Receptor Alpha Peptide Vaccine,has_type,BIOLOGICAL
NCT03012100,tests,Placebo Administration
Placebo Administration,has_type,OTHER
NCT03012100,tests,Sargramostim
Sargramostim,has_type,BIOLOGICAL
NCT02950259,has_title,"A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 I"
NCT02950259,has_status,ACTIVE_NOT_RECRUITING
NCT02950259,has_phase,
NCT02950259,sponsored_by,Providence Health & Services
NCT02950259,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02950259,tests,Indomethacin
Indomethacin,has_type,DRUG
NCT02950259,tests,Omeprazole
Omeprazole,has_type,DRUG
NCT02950259,tests,Multivitamin
Multivitamin,has_type,DIETARY_SUPPLEMENT
NCT02358200,has_title,"Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carbo"
NCT02358200,has_status,TERMINATED
NCT02358200,has_phase,
NCT02358200,sponsored_by,Pamela Munster
NCT02358200,tests,BMN-673
BMN-673,has_type,DRUG
NCT02358200,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02358200,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT06190600,has_title,Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy
NCT06190600,has_status,ACTIVE_NOT_RECRUITING
NCT06190600,has_phase,
NCT06190600,sponsored_by,The Greater Poland Cancer Centre
NCT06190600,tests,High Intensity Interval Training (HIIT)
High Intensity Interval Training (HIIT),has_type,OTHER
NCT06190600,tests,"neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)"
"neoadjuvant treatment (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab)",has_type,DRUG
NCT06190600,tests,Standard Supportive Care
Standard Supportive Care,has_type,OTHER
NCT03562637,has_title,"The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simo"
NCT03562637,has_status,ACTIVE_NOT_RECRUITING
NCT03562637,has_phase,
NCT03562637,sponsored_by,"OBI Pharma, Inc"
NCT03562637,tests,adagloxad simolenin combined with OBI-821
adagloxad simolenin combined with OBI-821,has_type,BIOLOGICAL
NCT03562637,tests,Globo H IHC Assay
Globo H IHC Assay,has_type,DEVICE
NCT03562637,tests,Standard of care treatment
Standard of care treatment,has_type,OTHER
NCT02247037,has_title,Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
NCT02247037,has_status,COMPLETED
NCT02247037,has_phase,
NCT02247037,sponsored_by,Icahn School of Medicine at Mount Sinai
NCT02247037,tests,Chemotherapy
Chemotherapy,has_type,OTHER
NCT01451632,has_title,A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Can
NCT01451632,has_status,COMPLETED
NCT01451632,has_phase,
NCT01451632,sponsored_by,Merrimack Pharmaceuticals
NCT01451632,tests,MM-121
MM-121,has_type,DRUG
NCT01451632,tests,Irinotecan
Irinotecan,has_type,DRUG
NCT01451632,tests,Cetuximab
Cetuximab,has_type,DRUG
NCT00630032,has_title,"Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associ"
NCT00630032,has_status,COMPLETED
NCT00630032,has_phase,
NCT00630032,sponsored_by,UNICANCER
NCT00630032,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT00630032,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT00630032,tests,epirubicin hydrochloride
epirubicin hydrochloride,has_type,DRUG
NCT00630032,tests,fluorouracil
fluorouracil,has_type,DRUG
NCT00630032,tests,ixabepilone
ixabepilone,has_type,DRUG
NCT01790932,has_title,A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer
NCT01790932,has_status,COMPLETED
NCT01790932,has_phase,
NCT01790932,sponsored_by,Dana-Farber Cancer Institute
NCT01790932,tests,BKM120
BKM120,has_type,DRUG
NCT01234532,has_title,GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Neg
NCT01234532,has_status,TERMINATED
NCT01234532,has_phase,
NCT01234532,sponsored_by,"University of Maryland, Baltimore"
NCT01234532,tests,entinostat
entinostat,has_type,DRUG
NCT01234532,tests,anastrozole
anastrozole,has_type,DRUG
NCT01234532,tests,diagnostic laboratory biomarker analysis
diagnostic laboratory biomarker analysis,has_type,OTHER
NCT01234532,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT04454437,has_title,"A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metasta"
NCT04454437,has_status,ACTIVE_NOT_RECRUITING
NCT04454437,has_phase,
NCT04454437,sponsored_by,Gilead Sciences
NCT04454437,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT02752685,has_title,Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
NCT02752685,has_status,ACTIVE_NOT_RECRUITING
NCT02752685,has_phase,
NCT02752685,sponsored_by,NYU Langone Health
NCT02752685,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02752685,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT02506556,has_title,"A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidyl"
NCT02506556,has_status,COMPLETED
NCT02506556,has_phase,
NCT02506556,sponsored_by,"Peter MacCallum Cancer Centre, Australia"
NCT02506556,tests,BYl719
BYl719,has_type,DRUG
NCT01138085,has_title,"A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine "
NCT01138085,has_status,COMPLETED
NCT01138085,has_phase,
NCT01138085,sponsored_by,GlaxoSmithKline
NCT01138085,tests,GSK1120212
GSK1120212,has_type,DRUG
NCT01138085,tests,GSK2141795
GSK2141795,has_type,DRUG
NCT03345485,has_title,"A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-C"
NCT03345485,has_status,COMPLETED
NCT03345485,has_phase,
NCT03345485,sponsored_by,Mundipharma Research Limited
NCT03345485,tests,Tinostamustine 60mg/m2 over 30min
Tinostamustine 60mg/m2 over 30min,has_type,DRUG
NCT03345485,tests,Tinostamustine 80mg/m2 over 30min
Tinostamustine 80mg/m2 over 30min,has_type,DRUG
NCT03345485,tests,Tinostamustine 100mg/m2 over 30min
Tinostamustine 100mg/m2 over 30min,has_type,DRUG
NCT03345485,tests,Tinostamustine 60mg/m2 over 60min
Tinostamustine 60mg/m2 over 60min,has_type,DRUG
NCT03345485,tests,Tinostamustine 80mg/m2 over 60min
Tinostamustine 80mg/m2 over 60min,has_type,DRUG
NCT03345485,tests,Tinostamustine 100mg/m2 over 60min
Tinostamustine 100mg/m2 over 60min,has_type,DRUG
NCT03345485,tests,Tinostamustine 80mg/m2 over 80min
Tinostamustine 80mg/m2 over 80min,has_type,DRUG
NCT04461600,has_title,"A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Ac"
NCT04461600,has_status,TERMINATED
NCT04461600,has_phase,
NCT04461600,sponsored_by,"Ayala Pharmaceuticals, Inc,"
NCT04461600,tests,AL101
AL101,has_type,DRUG
NCT03057600,has_title,A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Pa
NCT03057600,has_status,COMPLETED
NCT03057600,has_phase,
NCT03057600,sponsored_by,"Calithera Biosciences, Inc"
NCT03057600,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03057600,tests,CB-839
CB-839,has_type,DRUG
NCT02130700,has_title,A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic
NCT02130700,has_status,COMPLETED
NCT02130700,has_phase,
NCT02130700,sponsored_by,Innocrin Pharmaceutical
NCT02130700,tests,VT-464: given orally twice daily in 28-day cycles
VT-464: given orally twice daily in 28-day cycles,has_type,DRUG
NCT02130700,tests,VT-464: given orally once daily in 28-day cycles
VT-464: given orally once daily in 28-day cycles,has_type,DRUG
NCT03499899,has_title,"A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With "
NCT03499899,has_status,COMPLETED
NCT03499899,has_phase,
NCT03499899,sponsored_by,Novartis Pharmaceuticals
NCT03499899,tests,LAG525
LAG525,has_type,DRUG
NCT03499899,tests,PDR001
PDR001,has_type,DRUG
NCT03499899,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02101385,has_title,A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemothera
NCT02101385,has_status,COMPLETED
NCT02101385,has_phase,
NCT02101385,sponsored_by,"Bryan Schneider, MD"
NCT02101385,tests,Genomically Directed Monotherapy
Genomically Directed Monotherapy,has_type,DRUG
NCT02101385,tests,Observation/Standard Therapy
Observation/Standard Therapy,has_type,OTHER
NCT03717415,has_title,"An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplati"
NCT03717415,has_status,TERMINATED
NCT03717415,has_phase,
NCT03717415,sponsored_by,"Deciphera Pharmaceuticals, LLC"
NCT03717415,tests,Rebastinib
Rebastinib,has_type,DRUG
NCT03717415,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01629615,has_title,A Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Can
NCT01629615,has_status,COMPLETED
NCT01629615,has_phase,
NCT01629615,sponsored_by,SOLTI Breast Cancer Research Group
NCT01629615,tests,BKM120
BKM120,has_type,DRUG
NCT01884285,has_title,"A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharm"
NCT01884285,has_status,COMPLETED
NCT01884285,has_phase,
NCT01884285,sponsored_by,AstraZeneca
NCT01884285,tests,Part A: AZD8186 monotherapy
Part A: AZD8186 monotherapy,has_type,DRUG
NCT01884285,tests,Part B: AZD8186 monotherapy
Part B: AZD8186 monotherapy,has_type,DRUG
NCT01884285,tests,Part C1: Abiraterone acetate combination with AZD8186
Part C1: Abiraterone acetate combination with AZD8186,has_type,DRUG
NCT01884285,tests,Part D1: AZD2014 combination with AZD8186
Part D1: AZD2014 combination with AZD8186,has_type,DRUG
NCT01884285,tests,Part D2 AZD2014 combination with AZD8186
Part D2 AZD2014 combination with AZD8186,has_type,DRUG
NCT01884285,tests,Part C2: Abiraterone acetate combination with AZD8186
Part C2: Abiraterone acetate combination with AZD8186,has_type,DRUG
NCT03387085,has_title,NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy Com
NCT03387085,has_status,TERMINATED
NCT03387085,has_phase,
NCT03387085,sponsored_by,"ImmunityBio, Inc."
NCT03387085,tests,Aldoxorubicin HCl
Aldoxorubicin HCl,has_type,DRUG
NCT03387085,tests,N-803
N-803,has_type,BIOLOGICAL
NCT03387085,tests,ETBX-011
ETBX-011,has_type,BIOLOGICAL
NCT03387085,tests,ETBX-051
ETBX-051,has_type,BIOLOGICAL
NCT03387085,tests,ETBX-061
ETBX-061,has_type,BIOLOGICAL
NCT03387085,tests,GI-4000
GI-4000,has_type,BIOLOGICAL
NCT03387085,tests,GI-6207
GI-6207,has_type,BIOLOGICAL
NCT03387085,tests,GI-6301
GI-6301,has_type,BIOLOGICAL
NCT03387085,tests,haNK for Infusion
haNK for Infusion,has_type,BIOLOGICAL
NCT03387085,tests,avelumab
avelumab,has_type,BIOLOGICAL
NCT03387085,tests,bevacizumab
bevacizumab,has_type,BIOLOGICAL
NCT03387085,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT03387085,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03387085,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03387085,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT03387085,tests,Leucovorin
Leucovorin,has_type,DRUG
NCT03387085,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT03387085,tests,SBRT
SBRT,has_type,PROCEDURE
NCT03106415,has_title,Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced o
NCT03106415,has_status,COMPLETED
NCT03106415,has_phase,
NCT03106415,sponsored_by,Mayo Clinic
NCT03106415,tests,Binimetinib
Binimetinib,has_type,DRUG
NCT03106415,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03106415,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03361800,has_title,"A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exem"
NCT03361800,has_status,TERMINATED
NCT03361800,has_phase,
NCT03361800,sponsored_by,UNC Lineberger Comprehensive Cancer Center
NCT03361800,tests,Entinostat
Entinostat,has_type,DRUG
NCT00938652,has_title,"A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine/Carboplatin, With or Without BS"
NCT00938652,has_status,COMPLETED
NCT00938652,has_phase,
NCT00938652,sponsored_by,Sanofi
NCT00938652,tests,gemcitabine/carboplatin
gemcitabine/carboplatin,has_type,DRUG
NCT00938652,tests,Iniparib
Iniparib,has_type,DRUG
NCT03121352,has_title,"Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast C"
NCT03121352,has_status,COMPLETED
NCT03121352,has_phase,
NCT03121352,sponsored_by,Case Comprehensive Cancer Center
NCT03121352,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03121352,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT03121352,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT01631552,has_title,A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cance
NCT01631552,has_status,COMPLETED
NCT01631552,has_phase,
NCT01631552,sponsored_by,Gilead Sciences
NCT01631552,tests,Sacituzumab Govitecan-hziy (SG)
Sacituzumab Govitecan-hziy (SG),has_type,DRUG
NCT03095352,has_title,"A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Comb"
NCT03095352,has_status,COMPLETED
NCT03095352,has_phase,
NCT03095352,sponsored_by,"Laura Huppert, MD, BA"
NCT03095352,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03095352,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03095352,tests,Trastuzumab
Trastuzumab,has_type,BIOLOGICAL
NCT01669252,has_title,"A Phase II, Open-label, Single-arm, Exploratory Pharmacogenomic Study of Single Agent Eribulin (HALA"
NCT01669252,has_status,COMPLETED
NCT01669252,has_phase,
NCT01669252,sponsored_by,SOLTI Breast Cancer Research Group
NCT01669252,tests,Eribulin
Eribulin,has_type,DRUG
NCT03549000,has_title,"A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PD"
NCT03549000,has_status,TERMINATED
NCT03549000,has_phase,
NCT03549000,sponsored_by,Novartis Pharmaceuticals
NCT03549000,tests,NZV930
NZV930,has_type,OTHER
NCT03549000,tests,PDR001
PDR001,has_type,OTHER
NCT03549000,tests,NIR178
NIR178,has_type,DRUG
NCT04244552,has_title,"A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokine"
NCT04244552,has_status,TERMINATED
NCT04244552,has_phase,
NCT04244552,sponsored_by,"Atreca, Inc."
NCT04244552,tests,ATRC-101
ATRC-101,has_type,BIOLOGICAL
NCT04244552,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04244552,tests,Pegylated liposomal doxorubicin (PLD)
Pegylated liposomal doxorubicin (PLD),has_type,DRUG
NCT03295552,has_title,Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer
NCT03295552,has_status,TERMINATED
NCT03295552,has_phase,
NCT03295552,sponsored_by,Shanghai Jiao Tong University School of Medicine
NCT03295552,tests,Decitabine
Decitabine,has_type,DRUG
NCT03295552,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01165385,has_title,An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With C
NCT01165385,has_status,COMPLETED
NCT01165385,has_phase,
NCT01165385,sponsored_by,UNICANCER
NCT01165385,tests,cisplatin
cisplatin,has_type,DRUG
NCT01165385,tests,Pazopanib
Pazopanib,has_type,DRUG
NCT02720185,has_title,Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epi
NCT02720185,has_status,TERMINATED
NCT02720185,has_phase,
NCT02720185,sponsored_by,"University of Wisconsin, Madison"
NCT02720185,tests,Dasatinib
Dasatinib,has_type,DRUG
NCT02720185,tests,Conventional Surgery
Conventional Surgery,has_type,PROCEDURE
NCT02720185,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02411656,has_title,A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Canc
NCT02411656,has_status,ACTIVE_NOT_RECRUITING
NCT02411656,has_phase,
NCT02411656,sponsored_by,M.D. Anderson Cancer Center
NCT02411656,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02411656,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02379585,has_title,A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Bre
NCT02379585,has_status,TERMINATED
NCT02379585,has_phase,
NCT02379585,sponsored_by,Western Regional Medical Center
NCT02379585,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02379585,tests,cyclophosphamide
cyclophosphamide,has_type,DRUG
NCT02379585,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT02379585,tests,docetaxel
docetaxel,has_type,DRUG
NCT02379585,tests,Trastuzumab
Trastuzumab,has_type,DRUG
NCT02379585,tests,Pertuzumab
Pertuzumab,has_type,DRUG
NCT04580485,has_title,"A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunot"
NCT04580485,has_status,COMPLETED
NCT04580485,has_phase,
NCT04580485,sponsored_by,Incyte Corporation
NCT04580485,tests,INCB106385
INCB106385,has_type,DRUG
NCT04580485,tests,INCMGA00012
INCMGA00012,has_type,DRUG
NCT05675085,has_title,Risk-Based Breast Screening (RIBBS) in Young Women: Personalized Imaging Protocols
NCT05675085,has_status,ACTIVE_NOT_RECRUITING
NCT05675085,has_phase,
NCT05675085,sponsored_by,Istituto Oncologico Veneto IRCCS
NCT05675085,tests,Personalized screening protocol
Personalized screening protocol,has_type,DIAGNOSTIC_TEST
NCT02445391,has_title,A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patie
NCT02445391,has_status,ACTIVE_NOT_RECRUITING
NCT02445391,has_phase,
NCT02445391,sponsored_by,ECOG-ACRIN Cancer Research Group
NCT02445391,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02445391,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02445391,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01928394,has_title,"A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subj"
NCT01928394,has_status,COMPLETED
NCT01928394,has_phase,
NCT01928394,sponsored_by,Bristol-Myers Squibb
NCT01928394,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT01928394,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT01928394,tests,Cobimetinib
Cobimetinib,has_type,DRUG
NCT02368691,has_title,"A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx"
NCT02368691,has_status,TERMINATED
NCT02368691,has_phase,
NCT02368691,sponsored_by,GTx
NCT02368691,tests,GTx-024
GTx-024,has_type,DRUG
NCT03564691,has_title,"A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With"
NCT03564691,has_status,ACTIVE_NOT_RECRUITING
NCT03564691,has_phase,
NCT03564691,sponsored_by,Merck Sharp & Dohme LLC
NCT03564691,tests,MK-4830
MK-4830,has_type,DRUG
NCT03564691,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03564691,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03564691,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT03564691,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT03564691,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03564691,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03564691,tests,MK-4830A
MK-4830A,has_type,BIOLOGICAL
NCT05181462,has_title,A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination with Gemcitab
NCT05181462,has_status,ACTIVE_NOT_RECRUITING
NCT05181462,has_phase,
NCT05181462,sponsored_by,Cantargia AB
NCT05181462,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT05181462,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT05181462,tests,Nadunolimab
Nadunolimab,has_type,DRUG
NCT04734262,has_title,"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravat"
NCT04734262,has_status,ACTIVE_NOT_RECRUITING
NCT04734262,has_phase,
NCT04734262,sponsored_by,Fudan University
NCT04734262,tests,Sitravatinib
Sitravatinib,has_type,DRUG
NCT04734262,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT04734262,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT02071862,has_title,"Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, a"
NCT02071862,has_status,COMPLETED
NCT02071862,has_phase,
NCT02071862,sponsored_by,"Calithera Biosciences, Inc"
NCT02071862,tests,CB-839
CB-839,has_type,DRUG
NCT02071862,tests,Pac-CB
Pac-CB,has_type,DRUG
NCT02071862,tests,CBE
CBE,has_type,DRUG
NCT02071862,tests,CB-Erl
CB-Erl,has_type,DRUG
NCT02071862,tests,CBD
CBD,has_type,DRUG
NCT02071862,tests,CB-Cabo
CB-Cabo,has_type,DRUG
NCT01693562,has_title,"A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects"
NCT01693562,has_status,COMPLETED
NCT01693562,has_phase,
NCT01693562,sponsored_by,MedImmune LLC
NCT01693562,tests,MEDI4736
MEDI4736,has_type,DRUG
NCT02595372,has_title,Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
NCT02595372,has_status,COMPLETED
NCT02595372,has_phase,
NCT02595372,sponsored_by,Kathy Miller
NCT02595372,tests,Omeprazole
Omeprazole,has_type,DRUG
NCT00894504,has_title,"A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast C"
NCT00894504,has_status,COMPLETED
NCT00894504,has_phase,
NCT00894504,sponsored_by,"SCRI Development Innovations, LLC"
NCT00894504,tests,Panitumumab
Panitumumab,has_type,DRUG
NCT00894504,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00894504,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT06433804,has_title,Exploring the Clinicopathological Parameters of HER2 Low Breast Cancers
NCT06433804,has_status,COMPLETED
NCT06433804,has_phase,
NCT06433804,sponsored_by,Vardhman Mahavir Medical College And Safdarjung Hospital
NCT06433804,tests,HER2 IHC
HER2 IHC,has_type,DIAGNOSTIC_TEST
NCT03197389,has_title,"Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation an"
NCT03197389,has_status,COMPLETED
NCT03197389,has_phase,
NCT03197389,sponsored_by,Universitaire Ziekenhuizen KU Leuven
NCT03197389,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03207529,has_title,Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) 
NCT03207529,has_status,COMPLETED
NCT03207529,has_phase,
NCT03207529,sponsored_by,M.D. Anderson Cancer Center
NCT03207529,tests,Alpelisib
Alpelisib,has_type,DRUG
NCT03207529,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT04081389,has_title,Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemothera
NCT04081389,has_status,COMPLETED
NCT04081389,has_phase,
NCT04081389,sponsored_by,Roswell Park Cancer Institute
NCT04081389,tests,Celecoxib
Celecoxib,has_type,DRUG
NCT04081389,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04081389,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT04081389,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT04081389,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04081389,tests,Recombinant Interferon Alfa-2b
Recombinant Interferon Alfa-2b,has_type,BIOLOGICAL
NCT04081389,tests,Rintatolimod
Rintatolimod,has_type,DRUG
NCT04395989,has_title,An Umbrella Trial Based on Molecular Pathway for Patients With Unresectable Locally Advanced or Meta
NCT04395989,has_status,ACTIVE_NOT_RECRUITING
NCT04395989,has_phase,
NCT04395989,sponsored_by,Fudan University
NCT04395989,tests,A1: Pyrotinib with nab-paclitaxel
A1: Pyrotinib with nab-paclitaxel,has_type,DRUG
NCT04395989,tests,A2: nab-paclitaxel
A2: nab-paclitaxel,has_type,DRUG
NCT04395989,tests,B1: everolimus with nab-paclitaxel
B1: everolimus with nab-paclitaxel,has_type,DRUG
NCT04395989,tests,B2: nab-paclitaxel
B2: nab-paclitaxel,has_type,DRUG
NCT04395989,tests,C1: PD-1 with nab-paclitaxel and famitinib
C1: PD-1 with nab-paclitaxel and famitinib,has_type,DRUG
NCT04395989,tests,C2: nab-paclitaxel
C2: nab-paclitaxel,has_type,DRUG
NCT04395989,tests,"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine"
"D1: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine",has_type,DRUG
NCT04395989,tests,"D2: nab-paclitaxel, with maintenance of capecitabine"
"D2: nab-paclitaxel, with maintenance of capecitabine",has_type,DRUG
NCT04395989,tests,E1: everolimus with nab-paclitaxel
E1: everolimus with nab-paclitaxel,has_type,DRUG
NCT04395989,tests,E2: nab-paclitaxel
E2: nab-paclitaxel,has_type,DRUG
NCT02455791,has_title,Pilot Study for Identification of Breast Cancer Patients for Potential Avoidance of Surgery: Accurac
NCT02455791,has_status,ACTIVE_NOT_RECRUITING
NCT02455791,has_phase,
NCT02455791,sponsored_by,M.D. Anderson Cancer Center
NCT02455791,tests,Ultrasound-Guided Biopsy
Ultrasound-Guided Biopsy,has_type,PROCEDURE
NCT02425891,has_title,"A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody)"
NCT02425891,has_status,COMPLETED
NCT02425891,has_phase,
NCT02425891,sponsored_by,Hoffmann-La Roche
NCT02425891,tests,"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody"
"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody",has_type,DRUG
NCT02425891,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT02425891,tests,Placebo
Placebo,has_type,DRUG
NCT03362060,has_title,A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Pemb
NCT03362060,has_status,ACTIVE_NOT_RECRUITING
NCT03362060,has_phase,
NCT03362060,sponsored_by,Massachusetts General Hospital
NCT03362060,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03362060,tests,PVX-410
PVX-410,has_type,BIOLOGICAL
NCT02993094,has_title,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative
NCT02993094,has_status,TERMINATED
NCT02993094,has_phase,
NCT02993094,sponsored_by,Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT02993094,tests,Ixazomib
Ixazomib,has_type,DRUG
NCT02993094,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04293094,has_title,"A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety,"
NCT04293094,has_status,COMPLETED
NCT04293094,has_phase,
NCT04293094,sponsored_by,"Volastra Therapeutics, Inc."
NCT04293094,tests,AMG 650
AMG 650,has_type,DRUG
NCT04434560,has_title,A Phase II Trial of Surgery and Stereotactic Radiosurgery With Neoadjuvant Nivolumab and Ipilimumab 
NCT04434560,has_status,TERMINATED
NCT04434560,has_phase,
NCT04434560,sponsored_by,"Sarah Sammons, MD"
NCT04434560,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT04434560,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT00542191,has_title,Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
NCT00542191,has_status,TERMINATED
NCT00542191,has_phase,
NCT00542191,sponsored_by,Leo W. Jenkins Cancer Center
NCT00542191,tests,Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin
Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin,has_type,DRUG
NCT00542191,tests,Definitive Surgery
Definitive Surgery,has_type,PROCEDURE
NCT00542191,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT03473691,has_title,Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Ad
NCT03473691,has_status,WITHDRAWN
NCT03473691,has_phase,
NCT03473691,sponsored_by,University of Virginia
NCT03473691,tests,Glembatumumab Vedotin
Glembatumumab Vedotin,has_type,DRUG
NCT05852691,has_title,"A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-P"
NCT05852691,has_status,ACTIVE_NOT_RECRUITING
NCT05852691,has_phase,
NCT05852691,sponsored_by,Hoffmann-La Roche
NCT05852691,tests,Tobemstomig
Tobemstomig,has_type,DRUG
NCT05852691,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05852691,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT04174391,has_title,Lifestyles for the Prevention of Relapses Among Women with Early Breast Cancer
NCT04174391,has_status,ACTIVE_NOT_RECRUITING
NCT04174391,has_phase,
NCT04174391,sponsored_by,University of Navarra
NCT04174391,tests,Mediterranean diet supplemented with extra-virgin olive oil
Mediterranean diet supplemented with extra-virgin olive oil,has_type,BEHAVIORAL
NCT04174391,tests,Low-fat diet
Low-fat diet,has_type,BEHAVIORAL
NCT03328494,has_title,"A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibit"
NCT03328494,has_status,COMPLETED
NCT03328494,has_phase,
NCT03328494,sponsored_by,Boston Pharmaceuticals
NCT03328494,tests,BOS172722
BOS172722,has_type,DRUG
NCT03328494,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02599194,has_title,An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy
NCT02599194,has_status,COMPLETED
NCT02599194,has_phase,
NCT02599194,sponsored_by,Andrei Iagaru
NCT02599194,tests,18F-FSPG
18F-FSPG,has_type,DRUG
NCT02599194,tests,18F-FDG
18F-FDG,has_type,DRUG
NCT02536794,has_title,A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Treme
NCT02536794,has_status,COMPLETED
NCT02536794,has_phase,
NCT02536794,sponsored_by,Northwestern University
NCT02536794,tests,Anti-B7H1 Monoclonal Antibody MEDI4736
Anti-B7H1 Monoclonal Antibody MEDI4736,has_type,BIOLOGICAL
NCT02536794,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02536794,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT02536794,tests,Tremelimumab
Tremelimumab,has_type,BIOLOGICAL
NCT03316794,has_title,An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
NCT03316794,has_status,TERMINATED
NCT03316794,has_phase,
NCT03316794,sponsored_by,AbbVie
NCT03316794,tests,SC-005
SC-005,has_type,DRUG
NCT03356860,has_title,A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting fo
NCT03356860,has_status,COMPLETED
NCT03356860,has_phase,
NCT03356860,sponsored_by,Grand Hôpital de Charleroi
NCT03356860,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03356860,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT03356860,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03356860,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT04123704,has_title,"A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer"
NCT04123704,has_status,TERMINATED
NCT04123704,has_phase,
NCT04123704,sponsored_by,Xiang Zhang
NCT04123704,tests,Sitravatinib
Sitravatinib,has_type,DRUG
NCT02635672,has_title,"An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preli"
NCT02635672,has_status,COMPLETED
NCT02635672,has_phase,
NCT02635672,sponsored_by,"Vincerx Pharma, Inc."
NCT02635672,tests,VIP152 (BAY 1251152)
VIP152 (BAY 1251152),has_type,DRUG
NCT02635672,tests,VIP152 (BAY 1251152) 30 mg
VIP152 (BAY 1251152) 30 mg,has_type,DRUG
NCT02635672,tests,Keytruda
Keytruda,has_type,DRUG
NCT02635672,tests,VIP152 (BAY 1251152) 15 mg
VIP152 (BAY 1251152) 15 mg,has_type,DRUG
NCT03358004,has_title,"An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Tw"
NCT03358004,has_status,TERMINATED
NCT03358004,has_phase,
NCT03358004,sponsored_by,Mario Negri Institute for Pharmacological Research
NCT03358004,tests,Vinorelbine Tartrate
Vinorelbine Tartrate,has_type,DRUG
NCT03358004,tests,Capecitabine 500 MG
Capecitabine 500 MG,has_type,DRUG
NCT02499367,has_title,Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-
NCT02499367,has_status,ACTIVE_NOT_RECRUITING
NCT02499367,has_phase,
NCT02499367,sponsored_by,The Netherlands Cancer Institute
NCT02499367,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT02499367,tests,Radiation therapy
Radiation therapy,has_type,RADIATION
NCT02499367,tests,Low dose doxorubicin
Low dose doxorubicin,has_type,DRUG
NCT02499367,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02499367,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01426880,has_title,A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Tri
NCT01426880,has_status,COMPLETED
NCT01426880,has_phase,
NCT01426880,sponsored_by,GBG Forschungs GmbH
NCT01426880,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01426880,tests,background treatment
background treatment,has_type,DRUG
NCT01846091,has_title,Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Gene
NCT01846091,has_status,COMPLETED
NCT01846091,has_phase,
NCT01846091,sponsored_by,Mayo Clinic
NCT01846091,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01846091,tests,Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter,has_type,BIOLOGICAL
NCT03318562,has_title,A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and H
NCT03318562,has_status,TERMINATED
NCT03318562,has_phase,
NCT03318562,sponsored_by,Effector Therapeutics
NCT03318562,tests,eFT508
eFT508,has_type,DRUG
NCT01186991,has_title,"A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety an"
NCT01186991,has_status,COMPLETED
NCT01186991,has_phase,
NCT01186991,sponsored_by,"Genentech, Inc."
NCT01186991,tests,Onartuzumab
Onartuzumab,has_type,DRUG
NCT01186991,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT01186991,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01186991,tests,Bevacizumab Placebo
Bevacizumab Placebo,has_type,DRUG
NCT01186991,tests,Onartuzumab Placebo
Onartuzumab Placebo,has_type,DRUG
NCT02187991,has_title,"A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With P"
NCT02187991,has_status,COMPLETED
NCT02187991,has_phase,
NCT02187991,sponsored_by,US Oncology Research
NCT02187991,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02187991,tests,Alisertib
Alisertib,has_type,DRUG
NCT02719691,has_title,A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibi
NCT02719691,has_status,COMPLETED
NCT02719691,has_phase,
NCT02719691,sponsored_by,"University of Colorado, Denver"
NCT02719691,tests,Alisertib
Alisertib,has_type,DRUG
NCT02719691,tests,MLN0128
MLN0128,has_type,DRUG
NCT04095689,has_title,Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patie
NCT04095689,has_status,SUSPENDED
NCT04095689,has_phase,
NCT04095689,sponsored_by,The Methodist Hospital Research Institute
NCT04095689,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT04095689,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04095689,tests,IL-12 gene therapy
IL-12 gene therapy,has_type,DRUG
NCT04807192,has_title,CMP-001 in Combination with Pre-Operative Stereotactic Body Radiation Therapy in Patients with Early
NCT04807192,has_status,ACTIVE_NOT_RECRUITING
NCT04807192,has_phase,
NCT04807192,sponsored_by,Centre Hospitalier Universitaire Vaudois
NCT04807192,tests,stereotactic body radiotherapy
stereotactic body radiotherapy,has_type,RADIATION
NCT04807192,tests,CMP-001
CMP-001,has_type,DRUG
NCT03808662,has_title,Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of R
NCT03808662,has_status,ACTIVE_NOT_RECRUITING
NCT03808662,has_phase,
NCT03808662,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT03808662,tests,Sterotactic Body Radiotherapy/SBRT
Sterotactic Body Radiotherapy/SBRT,has_type,RADIATION
NCT03808662,tests,Standard of care
Standard of care,has_type,DRUG
NCT02883062,has_title,"Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without At"
NCT02883062,has_status,COMPLETED
NCT02883062,has_phase,
NCT02883062,sponsored_by,National Cancer Institute (NCI)
NCT02883062,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02883062,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT02883062,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02883062,tests,Lumpectomy
Lumpectomy,has_type,PROCEDURE
NCT02883062,tests,Mastectomy
Mastectomy,has_type,PROCEDURE
NCT02883062,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04118062,has_title,Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication To
NCT04118062,has_status,ACTIVE_NOT_RECRUITING
NCT04118062,has_phase,
NCT04118062,sponsored_by,Institut Curie
NCT04118062,tests,Questionnaires
Questionnaires,has_type,BEHAVIORAL
NCT04118062,tests,Semi-structured individual interviews
Semi-structured individual interviews,has_type,BEHAVIORAL
NCT04118062,tests,Focus Group
Focus Group,has_type,OTHER
NCT04118062,tests,DELPHI Consensus Method
DELPHI Consensus Method,has_type,OTHER
NCT01307891,has_title,"An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Inject"
NCT01307891,has_status,COMPLETED
NCT01307891,has_phase,
NCT01307891,sponsored_by,University of Alabama at Birmingham
NCT01307891,tests,Abraxane alone
Abraxane alone,has_type,DRUG
NCT01307891,tests,Abraxane + Tigatuzumab
Abraxane + Tigatuzumab,has_type,DRUG
NCT03872791,has_title,"A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combina"
NCT03872791,has_status,COMPLETED
NCT03872791,has_phase,
NCT03872791,sponsored_by,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd"
NCT03872791,tests,KN046
KN046,has_type,BIOLOGICAL
NCT03872791,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT01232062,has_title,Study of High-dose Chemotherapy Combined With Adoptive Cellular Therapy With Dentritic and Cytokine-
NCT01232062,has_status,COMPLETED
NCT01232062,has_phase,
NCT01232062,sponsored_by,Peking University Cancer Hospital & Institute
NCT03394027,has_title,A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial 
NCT03394027,has_status,COMPLETED
NCT03394027,has_phase,
NCT03394027,sponsored_by,National Cancer Institute (NCI)
NCT03394027,tests,ONC201
ONC201,has_type,DRUG
NCT03205176,has_title,"A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Prelim"
NCT03205176,has_status,COMPLETED
NCT03205176,has_phase,
NCT03205176,sponsored_by,AstraZeneca
NCT03205176,tests,AZD5153
AZD5153,has_type,DRUG
NCT03205176,tests,Olaparib
Olaparib,has_type,DRUG
NCT03010176,has_title,"Phase 1 Open-label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monothera"
NCT03010176,has_status,COMPLETED
NCT03010176,has_phase,
NCT03010176,sponsored_by,Merck Sharp & Dohme LLC
NCT03010176,tests,Ulevostinag
Ulevostinag,has_type,DRUG
NCT03010176,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04802876,has_title,Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MR
NCT04802876,has_status,ACTIVE_NOT_RECRUITING
NCT04802876,has_phase,
NCT04802876,sponsored_by,SOLTI Breast Cancer Research Group
NCT04802876,tests,Spartalizumab
Spartalizumab,has_type,DRUG
NCT04802876,tests,Tislelizumab
Tislelizumab,has_type,DRUG
NCT05358639,has_title,A Phase I Trial of the Combination of Olaparib and Navitoclax in Women with High Grade Serous Epithe
NCT05358639,has_status,ACTIVE_NOT_RECRUITING
NCT05358639,has_phase,
NCT05358639,sponsored_by,Sunnybrook Health Sciences Centre
NCT05358639,tests,Olaparib tablet
Olaparib tablet,has_type,DRUG
NCT05358639,tests,Navitoclax
Navitoclax,has_type,DRUG
NCT06299163,has_title,A Phase 1 Study of NM32-2668 (Anti-ROR1/CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients With S
NCT06299163,has_status,TERMINATED
NCT06299163,has_phase,
NCT06299163,sponsored_by,Numab Therapeutics AG
NCT06299163,tests,NM32-2668
NM32-2668,has_type,BIOLOGICAL
NCT03316586,has_title,A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast
NCT03316586,has_status,COMPLETED
NCT03316586,has_phase,
NCT03316586,sponsored_by,Dana-Farber Cancer Institute
NCT03316586,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03316586,tests,Cabozantinib
Cabozantinib,has_type,DRUG
NCT01127763,has_title,Phase II Trial of RAD001 Plus Carboplatin in Patients With Triple-Negative Metastatic Breast Cancer
NCT01127763,has_status,COMPLETED
NCT01127763,has_phase,
NCT01127763,sponsored_by,NYU Langone Health
NCT01127763,tests,RAD001
RAD001,has_type,DRUG
NCT01127763,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03280563,has_title,"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety"
NCT03280563,has_status,COMPLETED
NCT03280563,has_phase,
NCT03280563,sponsored_by,Hoffmann-La Roche
NCT03280563,tests,"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody"
"Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody",has_type,DRUG
NCT03280563,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT03280563,tests,Entinostat
Entinostat,has_type,DRUG
NCT03280563,tests,Exemestane
Exemestane,has_type,DRUG
NCT03280563,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT03280563,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03280563,tests,Tamoxifen
Tamoxifen,has_type,DRUG
NCT03280563,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT04191135,has_title,"An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus P"
NCT04191135,has_status,ACTIVE_NOT_RECRUITING
NCT04191135,has_phase,
NCT04191135,sponsored_by,Merck Sharp & Dohme LLC
NCT04191135,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04191135,tests,Olaparib
Olaparib,has_type,DRUG
NCT04191135,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT04191135,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02432963,has_title,A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab
NCT02432963,has_status,ACTIVE_NOT_RECRUITING
NCT02432963,has_phase,
NCT02432963,sponsored_by,City of Hope Medical Center
NCT02432963,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02432963,tests,Modified Vaccinia Virus Ankara Vaccine Expressing p53
Modified Vaccinia Virus Ankara Vaccine Expressing p53,has_type,BIOLOGICAL
NCT02432963,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05382286,has_title,"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment "
NCT05382286,has_status,ACTIVE_NOT_RECRUITING
NCT05382286,has_phase,
NCT05382286,sponsored_by,Gilead Sciences
NCT05382286,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT05382286,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05382286,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05382286,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT05382286,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT05382286,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01881230,has_title,"A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination Wit"
NCT01881230,has_status,COMPLETED
NCT01881230,has_phase,
NCT01881230,sponsored_by,Celgene
NCT01881230,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT01881230,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01881230,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT04993625,has_title,Selective Avoidanve of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/T
NCT04993625,has_status,ACTIVE_NOT_RECRUITING
NCT04993625,has_phase,
NCT04993625,sponsored_by,Jeong Eon Lee
NCT04993625,tests,avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy
avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy,has_type,PROCEDURE
NCT01111825,has_title,A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Tri
NCT01111825,has_status,COMPLETED
NCT01111825,has_phase,
NCT01111825,sponsored_by,"Puma Biotechnology, Inc."
NCT01111825,tests,Temsirolimus
Temsirolimus,has_type,DRUG
NCT01111825,tests,Neratinib
Neratinib,has_type,DRUG
NCT02362230,has_title,Sun Yat-sen University Cancer Center
NCT02362230,has_status,TERMINATED
NCT02362230,has_phase,
NCT02362230,sponsored_by,Sun Yat-sen University
NCT02362230,tests,Icotinib
Icotinib,has_type,DRUG
NCT02632448,has_title,A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY28800
NCT02632448,has_status,COMPLETED
NCT02632448,has_phase,
NCT02632448,sponsored_by,Esperas Pharma Inc.
NCT02632448,tests,LY2880070
LY2880070,has_type,DRUG
NCT02632448,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02730130,has_title,A Multicenter Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in
NCT02730130,has_status,COMPLETED
NCT02730130,has_phase,
NCT02730130,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02730130,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02730130,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT02531425,has_title,Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in P
NCT02531425,has_status,COMPLETED
NCT02531425,has_phase,
NCT02531425,sponsored_by,OncoSec Medical Incorporated
NCT02531425,tests,IT-pIL12-EP
IT-pIL12-EP,has_type,BIOLOGICAL
NCT03130439,has_title,"A Phase 2 Study of Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic"
NCT03130439,has_status,TERMINATED
NCT03130439,has_phase,
NCT03130439,sponsored_by,Dana-Farber Cancer Institute
NCT03130439,tests,Abemaciclib
Abemaciclib,has_type,DRUG
NCT01319539,has_title,Pre-surgical Evaluation of MK-2206 in Patients With Operable Invasive Breast Cancer
NCT01319539,has_status,TERMINATED
NCT01319539,has_phase,
NCT01319539,sponsored_by,National Cancer Institute (NCI)
NCT01319539,tests,Akt Inhibitor MK2206
Akt Inhibitor MK2206,has_type,DRUG
NCT01319539,tests,Therapeutic Conventional Surgery
Therapeutic Conventional Surgery,has_type,PROCEDURE
NCT01319539,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01319539,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03616886,has_title,A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Olecluma
NCT03616886,has_status,ACTIVE_NOT_RECRUITING
NCT03616886,has_phase,
NCT03616886,sponsored_by,Jules Bordet Institute
NCT03616886,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03616886,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03616886,tests,MEDI4736
MEDI4736,has_type,DRUG
NCT03616886,tests,MEDI9447
MEDI9447,has_type,DRUG
NCT05830539,has_title,"A Phase Ib/II, Open-label, Multicenter Clinical Study to Evaluate the Antitumor Activities, Safety, "
NCT05830539,has_status,COMPLETED
NCT05830539,has_phase,
NCT05830539,sponsored_by,"InxMed (Shanghai) Co., Ltd."
NCT05830539,tests,IN10018+PLD
IN10018+PLD,has_type,DRUG
NCT05830539,tests,IN10018+PLD+Toripalimab
IN10018+PLD+Toripalimab,has_type,DRUG
NCT04494958,has_title,Phase IB Clinical Trial of Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer Wit
NCT04494958,has_status,COMPLETED
NCT04494958,has_phase,
NCT04494958,sponsored_by,Fundacion Oncosur
NCT04494958,tests,"Combination, Palbociclib + Binimetinib"
"Combination, Palbociclib + Binimetinib",has_type,DRUG
NCT03244358,has_title,"Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer:A Single Arm,Single Center,Phas"
NCT03244358,has_status,TERMINATED
NCT03244358,has_phase,
NCT03244358,sponsored_by,Sun Yat-sen University
NCT03244358,tests,Epalrestat
Epalrestat,has_type,DRUG
NCT02521363,has_title,Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Earl
NCT02521363,has_status,COMPLETED
NCT02521363,has_phase,
NCT02521363,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02521363,tests,KIBUR MICRODEVICE
KIBUR MICRODEVICE,has_type,DEVICE
NCT02521363,tests,anthracycline and taxane based chemotherapy
anthracycline and taxane based chemotherapy,has_type,DRUG
NCT05388435,has_title,"A Phase 1/2, Open-Label, Multicenter, Dose-Finding Study of SKL27969 to Evaluate Safety, Tolerabilit"
NCT05388435,has_status,TERMINATED
NCT05388435,has_phase,
NCT05388435,sponsored_by,"SK Life Science, Inc."
NCT05388435,tests,SKL27969
SKL27969,has_type,DRUG
NCT02018458,has_title,Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients Wit
NCT02018458,has_status,COMPLETED
NCT02018458,has_phase,
NCT02018458,sponsored_by,Baylor Research Institute
NCT02018458,tests,LA TNBC: DC vaccine+Preop chemo
LA TNBC: DC vaccine+Preop chemo,has_type,BIOLOGICAL
NCT02018458,tests,ER+/HER2-BC:DC vaccine+Preop chemo
ER+/HER2-BC:DC vaccine+Preop chemo,has_type,BIOLOGICAL
NCT03594396,has_title,Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) Before Standard Neoadjuvant Chemot
NCT03594396,has_status,ACTIVE_NOT_RECRUITING
NCT03594396,has_phase,
NCT03594396,sponsored_by,Seoul National University Hospital
NCT03594396,tests,Olaparib
Olaparib,has_type,DRUG
NCT03594396,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT02375958,has_title,"A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intrav"
NCT02375958,has_status,COMPLETED
NCT02375958,has_phase,
NCT02375958,sponsored_by,Novartis Pharmaceuticals
NCT02375958,tests,PCA062
PCA062,has_type,DRUG
NCT05069935,has_title,"A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subje"
NCT05069935,has_status,TERMINATED
NCT05069935,has_phase,
NCT05069935,sponsored_by,Fate Therapeutics
NCT05069935,tests,FT538
FT538,has_type,DRUG
NCT05069935,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT05069935,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT05069935,tests,Monoclonal antibody - Dose Escalation
Monoclonal antibody - Dose Escalation,has_type,COMBINATION_PRODUCT
NCT05069935,tests,Monoclonal antibody - Dose Expansion
Monoclonal antibody - Dose Expansion,has_type,COMBINATION_PRODUCT
NCT02750358,has_title,Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Br
NCT02750358,has_status,ACTIVE_NOT_RECRUITING
NCT02750358,has_phase,
NCT02750358,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02750358,tests,Enzalutamide
Enzalutamide,has_type,DRUG
NCT02750358,tests,assessment
assessment,has_type,BEHAVIORAL
NCT02996825,has_title,A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Ge
NCT02996825,has_status,COMPLETED
NCT02996825,has_phase,
NCT02996825,sponsored_by,City of Hope Medical Center
NCT02996825,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02996825,tests,Gemcitabine Hydrochloride
Gemcitabine Hydrochloride,has_type,DRUG
NCT02996825,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02996825,tests,Mirvetuximab Soravtansine
Mirvetuximab Soravtansine,has_type,BIOLOGICAL
NCT02996825,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01204125,has_title,"Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent a"
NCT01204125,has_status,COMPLETED
NCT01204125,has_phase,
NCT01204125,sponsored_by,Sanofi
NCT01204125,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01204125,tests,Iniparib (SAR2405550 -BSI-201)
Iniparib (SAR2405550 -BSI-201),has_type,DRUG
NCT01575522,has_title,A Phase 2 Study of ARQ 197 in Metastatic Triple-negative Breast Cancer
NCT01575522,has_status,COMPLETED
NCT01575522,has_phase,
NCT01575522,sponsored_by,National Cancer Institute (NCI)
NCT01575522,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01575522,tests,Tivantinib
Tivantinib,has_type,DRUG
NCT03544125,has_title,A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer
NCT03544125,has_status,COMPLETED
NCT03544125,has_phase,
NCT03544125,sponsored_by,OHSU Knight Cancer Institute
NCT03544125,tests,Durvalumab
Durvalumab,has_type,BIOLOGICAL
NCT03544125,tests,Olaparib
Olaparib,has_type,DRUG
NCT03241173,has_title,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination Wit"
NCT03241173,has_status,COMPLETED
NCT03241173,has_phase,
NCT03241173,sponsored_by,Incyte Biosciences International Sàrl
NCT03241173,tests,INCAGN01949
INCAGN01949,has_type,DRUG
NCT03241173,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03241173,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT05086731,has_title,THRIVE Smart - Leveraging Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Brea
NCT05086731,has_status,COMPLETED
NCT05086731,has_phase,
NCT05086731,sponsored_by,Emory University
NCT05086731,tests,Best Practice
Best Practice,has_type,OTHER
NCT05086731,tests,Informational Intervention
Informational Intervention,has_type,OTHER
NCT05086731,tests,Medical Device Usage and Evaluation
Medical Device Usage and Evaluation,has_type,OTHER
NCT05086731,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT05086731,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT03326258,has_title,Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors
NCT03326258,has_status,WITHDRAWN
NCT03326258,has_phase,
NCT03326258,sponsored_by,National Cancer Institute (NCI)
NCT03326258,tests,Glembatumumab Vedotin
Glembatumumab Vedotin,has_type,DRUG
NCT03326258,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT03326258,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03326258,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03326258,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT03184558,has_title,"A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previous"
NCT03184558,has_status,TERMINATED
NCT03184558,has_phase,
NCT03184558,sponsored_by,BerGenBio ASA
NCT03184558,tests,Bemcentinib
Bemcentinib,has_type,DRUG
NCT02222922,has_title,"A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647020 IN ADULT "
NCT02222922,has_status,COMPLETED
NCT02222922,has_phase,
NCT02222922,sponsored_by,Pfizer
NCT02222922,tests,PF-06647020 Q3W
PF-06647020 Q3W,has_type,DRUG
NCT02222922,tests,fluconazole
fluconazole,has_type,DRUG
NCT02222922,tests,PF-06647020 Q2W
PF-06647020 Q2W,has_type,DRUG
NCT02222922,tests,PF-06647020 combined with Avelumab
PF-06647020 combined with Avelumab,has_type,DRUG
NCT04224922,has_title,"A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and"
NCT04224922,has_status,COMPLETED
NCT04224922,has_phase,
NCT04224922,sponsored_by,AZ-VUB
NCT04224922,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04224922,tests,Carboplatinum
Carboplatinum,has_type,DRUG
NCT04224922,tests,Epirubicin
Epirubicin,has_type,DRUG
NCT04224922,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03800836,has_title,"A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combi"
NCT03800836,has_status,COMPLETED
NCT03800836,has_phase,
NCT03800836,sponsored_by,Hoffmann-La Roche
NCT03800836,tests,Ipatasertib
Ipatasertib,has_type,DRUG
NCT03800836,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03800836,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03800836,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT03800836,tests,AC
AC,has_type,DRUG
NCT01431196,has_title,Phase II Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negativ
NCT01431196,has_status,COMPLETED
NCT01431196,has_phase,
NCT01431196,sponsored_by,"Clinica Universidad de Navarra, Universidad de Navarra"
NCT01431196,tests,Autologous dendritic cell vaccination
Autologous dendritic cell vaccination,has_type,BIOLOGICAL
NCT01929941,has_title,"A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With"
NCT01929941,has_status,TERMINATED
NCT01929941,has_phase,
NCT01929941,sponsored_by,Incyte Corporation
NCT01929941,tests,INCB047986
INCB047986,has_type,DRUG
NCT01929941,tests,INCB047986
INCB047986,has_type,DRUG
NCT01929941,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT01929941,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT02455141,has_title,Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breas
NCT02455141,has_status,ACTIVE_NOT_RECRUITING
NCT02455141,has_phase,
NCT02455141,sponsored_by,Shanghai Jiao Tong University School of Medicine
NCT02455141,tests,Epirubicin plus Cyclophosphamide
Epirubicin plus Cyclophosphamide,has_type,DRUG
NCT02455141,tests,Taxanes
Taxanes,has_type,DRUG
NCT02455141,tests,Taxanes plus Carboplatin
Taxanes plus Carboplatin,has_type,DRUG
NCT04712396,has_title,"An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Capivasert"
NCT04712396,has_status,COMPLETED
NCT04712396,has_phase,
NCT04712396,sponsored_by,AstraZeneca
NCT04712396,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT04712396,tests,Itraconazole
Itraconazole,has_type,DRUG
NCT02926196,has_title,Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody
NCT02926196,has_status,ACTIVE_NOT_RECRUITING
NCT02926196,has_phase,
NCT02926196,sponsored_by,Istituto Oncologico Veneto IRCCS
NCT02926196,tests,MSB0010718C
MSB0010718C,has_type,DRUG
NCT05905341,has_title,"A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY,"
NCT05905341,has_status,WITHDRAWN
NCT05905341,has_phase,
NCT05905341,sponsored_by,Pfizer
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT05905341,tests,PF-07224826
PF-07224826,has_type,DRUG
NCT05905341,tests,Fulvestrant
Fulvestrant,has_type,COMBINATION_PRODUCT
NCT00986609,has_title,Pilot Study of a MUCI Peptide and Poly-ICLC Vaccine for Triple-Negative Breast Cancer
NCT00986609,has_status,COMPLETED
NCT00986609,has_phase,
NCT00986609,sponsored_by,"Joseph Baar, MD, PhD"
NCT00986609,tests,MUC-1 peptide vaccine
MUC-1 peptide vaccine,has_type,BIOLOGICAL
NCT00986609,tests,poly ICLC
poly ICLC,has_type,BIOLOGICAL
NCT00986609,tests,MUC1 peptide-poly-ICLC adjuvant vaccine
MUC1 peptide-poly-ICLC adjuvant vaccine,has_type,BIOLOGICAL
NCT00986609,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT00986609,tests,enzyme-linked immunosorbent assay
enzyme-linked immunosorbent assay,has_type,OTHER
NCT00986609,tests,flow cytometry
flow cytometry,has_type,OTHER
NCT02898207,has_title,A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Sol
NCT02898207,has_status,COMPLETED
NCT02898207,has_phase,
NCT02898207,sponsored_by,National Cancer Institute (NCI)
NCT02898207,tests,Olaparib
Olaparib,has_type,DRUG
NCT02898207,tests,Onalespib
Onalespib,has_type,DRUG
NCT03554109,has_title,An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) 
NCT03554109,has_status,WITHDRAWN
NCT03554109,has_phase,
NCT03554109,sponsored_by,"ImmunityBio, Inc."
NCT03554109,tests,Leucovorin
Leucovorin,has_type,DRUG
NCT03554109,tests,5-Fluorouracil
5-Fluorouracil,has_type,DRUG
NCT03554109,tests,Aldoxorubicin HCl
Aldoxorubicin HCl,has_type,DRUG
NCT03554109,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT03554109,tests,ETBX-011
ETBX-011,has_type,BIOLOGICAL
NCT03554109,tests,ETBX-051
ETBX-051,has_type,BIOLOGICAL
NCT03554109,tests,ETBX-061
ETBX-061,has_type,BIOLOGICAL
NCT03554109,tests,GI-4000
GI-4000,has_type,BIOLOGICAL
NCT03554109,tests,GI-6207
GI-6207,has_type,BIOLOGICAL
NCT03554109,tests,GI-6301
GI-6301,has_type,BIOLOGICAL
NCT03554109,tests,Avelumab
Avelumab,has_type,DRUG
NCT03554109,tests,ALT-803
ALT-803,has_type,BIOLOGICAL
NCT03554109,tests,haNK
haNK,has_type,BIOLOGICAL
NCT03554109,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03554109,tests,Doxorubicin HCL
Doxorubicin HCL,has_type,DRUG
NCT03554109,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01395056,has_title,Study of Chemotherapy Combined With Adoptive Cellular Therapy With Dendritic and Cytokine-induced Ki
NCT01395056,has_status,COMPLETED
NCT01395056,has_phase,
NCT01395056,sponsored_by,Peking University Cancer Hospital & Institute
NCT03304756,has_title,Phase II Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer Patients With the CAP Regi
NCT03304756,has_status,COMPLETED
NCT03304756,has_phase,
NCT03304756,sponsored_by,"Instituto Nacional de Cancer, Brazil"
NCT03304756,tests,CAP
CAP,has_type,DRUG
NCT02001519,has_title,A Phase ll Trial of Impact of Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negat
NCT02001519,has_status,COMPLETED
NCT02001519,has_phase,
NCT02001519,sponsored_by,Asan Medical Center
NCT02001519,tests,AC4-CDDP4
AC4-CDDP4,has_type,DRUG
NCT03167619,has_title,Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative B
NCT03167619,has_status,COMPLETED
NCT03167619,has_phase,
NCT03167619,sponsored_by,Duke University
NCT03167619,tests,Olaparib Oral Product
Olaparib Oral Product,has_type,DRUG
NCT03167619,tests,Olaparib Oral Product in combination with Durvalumab
Olaparib Oral Product in combination with Durvalumab,has_type,DRUG
NCT05112536,has_title,"A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemo"
NCT05112536,has_status,COMPLETED
NCT05112536,has_phase,
NCT05112536,sponsored_by,"G1 Therapeutics, Inc."
NCT05112536,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT05112536,tests,Cylophosphamide
Cylophosphamide,has_type,DRUG
NCT05112536,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT05112536,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT05112536,tests,Carboplatin (Investigator discretion)
Carboplatin (Investigator discretion),has_type,DRUG
NCT05112536,tests,Pembrolizumab (Investigator discretion)
Pembrolizumab (Investigator discretion),has_type,BIOLOGICAL
NCT00998036,has_title,"Phase I Study of Combined Temsirolimus, Erlotinib and Cisplatin in Advanced Solid Tumors"
NCT00998036,has_status,COMPLETED
NCT00998036,has_phase,
NCT00998036,sponsored_by,Columbia University
NCT00998036,tests,Temsirolimus
Temsirolimus,has_type,DRUG
NCT00998036,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT00998036,tests,Erlotinib
Erlotinib,has_type,DRUG
NCT00892736,has_title,"A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated"
NCT00892736,has_status,COMPLETED
NCT00892736,has_phase,
NCT00892736,sponsored_by,National Cancer Institute (NCI)
NCT00892736,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT00892736,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT00892736,tests,Veliparib
Veliparib,has_type,DRUG
NCT03829436,has_title,"A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or "
NCT03829436,has_status,COMPLETED
NCT03829436,has_phase,
NCT03829436,sponsored_by,Tempest Therapeutics
NCT03829436,tests,Part 1 TPST-1120
Part 1 TPST-1120,has_type,DRUG
NCT03829436,tests,Part 2 TPST-1120 + nivolumab
Part 2 TPST-1120 + nivolumab,has_type,DRUG
NCT03829436,tests,Part 3 TPST-1120
Part 3 TPST-1120,has_type,DRUG
NCT03829436,tests,Part 4 TPST-1120 + nivolumab
Part 4 TPST-1120 + nivolumab,has_type,DRUG
NCT02035813,has_title,"DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Me"
NCT02035813,has_status,COMPLETED
NCT02035813,has_phase,
NCT02035813,sponsored_by,Prof. Wolfgang Janni
NCT02035813,tests,Ribociclib
Ribociclib,has_type,DRUG
NCT02035813,tests,Eribulin
Eribulin,has_type,DRUG
NCT04234113,has_title,A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101
NCT04234113,has_status,TERMINATED
NCT04234113,has_phase,
NCT04234113,sponsored_by,SOTIO Biotech AG
NCT04234113,tests,Nanrilkefusp alfa
Nanrilkefusp alfa,has_type,DRUG
NCT04234113,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT01150513,has_title,Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant
NCT01150513,has_status,COMPLETED
NCT01150513,has_phase,
NCT01150513,sponsored_by,Chinese Academy of Medical Sciences
NCT01150513,tests,EC-T
EC-T,has_type,DRUG
NCT01150513,tests,TP
TP,has_type,DRUG
NCT02498613,has_title,A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613,has_status,ACTIVE_NOT_RECRUITING
NCT02498613,has_phase,
NCT02498613,sponsored_by,National Cancer Institute (NCI)
NCT02498613,tests,18F-Fluoromisonidazole
18F-Fluoromisonidazole,has_type,OTHER
NCT02498613,tests,Cediranib Maleate
Cediranib Maleate,has_type,DRUG
NCT02498613,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02498613,tests,Olaparib
Olaparib,has_type,DRUG
NCT02498613,tests,Positron Emission Tomography
Positron Emission Tomography,has_type,PROCEDURE
NCT04468113,has_title,"Prospective, Multicenter Registry Study Evaluating the Feasibility of Ultrasound-guided Clipping of "
NCT04468113,has_status,COMPLETED
NCT04468113,has_phase,
NCT04468113,sponsored_by,Kliniken Essen-Mitte
NCT04468113,tests,Tumark® Vision clip
Tumark® Vision clip,has_type,DEVICE
NCT02203513,has_title,A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated
NCT02203513,has_status,TERMINATED
NCT02203513,has_phase,
NCT02203513,sponsored_by,National Cancer Institute (NCI)
NCT02203513,tests,LY2606368
LY2606368,has_type,DRUG
NCT05757232,has_title,Construction of an Ultrasound Profile and a Mammography Profile Corresponding to the Different Molec
NCT05757232,has_status,COMPLETED
NCT05757232,has_phase,
NCT05757232,sponsored_by,Elsan
NCT00640861,has_title,MUC1/HER-2/Neu Peptide Based Immunotherapeutic Vaccines for Breast Adenocarcinomas
NCT00640861,has_status,COMPLETED
NCT00640861,has_phase,
NCT00640861,sponsored_by,Mayo Clinic
NCT00640861,tests,CpG oligodeoxynucleotide
CpG oligodeoxynucleotide,has_type,BIOLOGICAL
NCT00640861,tests,HER-2/neu peptide vaccine
HER-2/neu peptide vaccine,has_type,BIOLOGICAL
NCT00640861,tests,MUC-1 peptide vaccine
MUC-1 peptide vaccine,has_type,BIOLOGICAL
NCT00640861,tests,incomplete Freund's adjuvant
incomplete Freund's adjuvant,has_type,BIOLOGICAL
NCT00640861,tests,sargramostim
sargramostim,has_type,BIOLOGICAL
NCT00640861,tests,immunoenzyme technique
immunoenzyme technique,has_type,OTHER
NCT00640861,tests,immunologic technique
immunologic technique,has_type,OTHER
NCT05203445,has_title,Phase II of Neoadjuvant Olaparib in Combination with Pembrolizumab in Patients with Triple Negative 
NCT05203445,has_status,ACTIVE_NOT_RECRUITING
NCT05203445,has_phase,
NCT05203445,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT05203445,tests,Olaparib
Olaparib,has_type,DRUG
NCT05203445,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03623945,has_title,Autoantibodies in Breast Cancer Detection
NCT03623945,has_status,TERMINATED
NCT03623945,has_phase,
NCT03623945,sponsored_by,Sanford Health
NCT03623945,tests,Collection of blood
Collection of blood,has_type,OTHER
NCT02543645,has_title,"A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezoli"
NCT02543645,has_status,TERMINATED
NCT02543645,has_phase,
NCT02543645,sponsored_by,Celldex Therapeutics
NCT02543645,tests,Combination of Varlilumab and Atezolizumab
Combination of Varlilumab and Atezolizumab,has_type,DRUG
NCT04639245,has_title,ATTAMAGE-A1.: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affini
NCT04639245,has_status,TERMINATED
NCT04639245,has_phase,
NCT04639245,sponsored_by,Fred Hutchinson Cancer Center
NCT04639245,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04639245,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04639245,tests,Fludarabine
Fludarabine,has_type,DRUG
NCT04639245,tests,MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells,has_type,BIOLOGICAL
NCT04639245,tests,PD1 Inhibitor
PD1 Inhibitor,has_type,BIOLOGICAL
NCT03750240,has_title,Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
NCT03750240,has_status,TERMINATED
NCT03750240,has_phase,
NCT03750240,sponsored_by,NYU Langone Health
NCT03750240,tests,Sodium (Na) Magnetic Resonance Imaging (MRI)
Sodium (Na) Magnetic Resonance Imaging (MRI),has_type,DIAGNOSTIC_TEST
NCT03750240,tests,Dynamic Contrast- Enhanced (DCE) MRI
Dynamic Contrast- Enhanced (DCE) MRI,has_type,DIAGNOSTIC_TEST
NCT04489940,has_title,"A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants Wit"
NCT04489940,has_status,TERMINATED
NCT04489940,has_phase,
NCT04489940,sponsored_by,"EMD Serono Research & Development Institute, Inc."
NCT04489940,tests,Bintrafusp alfa
Bintrafusp alfa,has_type,DRUG
NCT03207867,has_title,"A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Sele"
NCT03207867,has_status,TERMINATED
NCT03207867,has_phase,
NCT03207867,sponsored_by,Novartis Pharmaceuticals
NCT03207867,tests,NIR178
NIR178,has_type,DRUG
NCT03207867,tests,PDR001
PDR001,has_type,DRUG
NCT02307240,has_title,"Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Or"
NCT02307240,has_status,COMPLETED
NCT02307240,has_phase,
NCT02307240,sponsored_by,"Curis, Inc."
NCT02307240,tests,CUDC-907
CUDC-907,has_type,DRUG
NCT02854644,has_title,Study of the Anti-tumoral Immune Response T Cells Cluster of Differentiation 4 (TCD4): Proof of the 
NCT02854644,has_status,COMPLETED
NCT02854644,has_phase,
NCT02854644,sponsored_by,Centre Hospitalier Universitaire de Besancon
NCT02854644,tests,additional blood sample
additional blood sample,has_type,OTHER
NCT03838367,has_title,A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metasta
NCT03838367,has_status,ACTIVE_NOT_RECRUITING
NCT03838367,has_phase,
NCT03838367,sponsored_by,"CytoDyn, Inc."
NCT03838367,tests,350 mg leronlimab
350 mg leronlimab,has_type,DRUG
NCT03838367,tests,525 mg leronlimab
525 mg leronlimab,has_type,DRUG
NCT03838367,tests,700 mg leronlimab
700 mg leronlimab,has_type,DRUG
NCT03838367,tests,AUC 5 Carboplatin
AUC 5 Carboplatin,has_type,DRUG
NCT03838367,tests,Maximum Tolerated Dose (MTD) of leronlimab
Maximum Tolerated Dose (MTD) of leronlimab,has_type,DRUG
NCT03435640,has_title,"A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combin"
NCT03435640,has_status,TERMINATED
NCT03435640,has_phase,
NCT03435640,sponsored_by,Nektar Therapeutics
NCT03435640,tests,NKTR-262
NKTR-262,has_type,DRUG
NCT03435640,tests,bempegaldesleukin
bempegaldesleukin,has_type,DRUG
NCT03435640,tests,nivolumab
nivolumab,has_type,DRUG
NCT03199040,has_title,A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvaluma
NCT03199040,has_status,TERMINATED
NCT03199040,has_phase,
NCT03199040,sponsored_by,Washington University School of Medicine
NCT03199040,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03199040,tests,Neoantigen DNA vaccine
Neoantigen DNA vaccine,has_type,BIOLOGICAL
NCT03199040,tests,TDS-IM system (Inchor Medical Systems)
TDS-IM system (Inchor Medical Systems),has_type,DEVICE
NCT03199040,tests,Peripheral blood draw
Peripheral blood draw,has_type,PROCEDURE
NCT02593227,has_title,A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Va
NCT02593227,has_status,COMPLETED
NCT02593227,has_phase,
NCT02593227,sponsored_by,"Marker Therapeutics, Inc."
NCT02593227,tests,Low dose FRα vaccine
Low dose FRα vaccine,has_type,BIOLOGICAL
NCT02593227,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02593227,tests,High dose FRα vaccine
High dose FRα vaccine,has_type,BIOLOGICAL
NCT02154776,has_title,A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treat
NCT02154776,has_status,COMPLETED
NCT02154776,has_phase,
NCT02154776,sponsored_by,Novartis Pharmaceuticals
NCT02154776,tests,LEE011
LEE011,has_type,DRUG
NCT02154776,tests,Buparlisib
Buparlisib,has_type,DRUG
NCT02154776,tests,Letrozole
Letrozole,has_type,DRUG
NCT02624973,has_title,PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
NCT02624973,has_status,ACTIVE_NOT_RECRUITING
NCT02624973,has_phase,
NCT02624973,sponsored_by,Haukeland University Hospital
NCT02624973,tests,Neoadjuvant tamoxifen + goserelin (premenopausal women)
Neoadjuvant tamoxifen + goserelin (premenopausal women),has_type,DRUG
NCT02624973,tests,Neoadjuvant letrozole (postmenopausal women)
Neoadjuvant letrozole (postmenopausal women),has_type,DRUG
NCT02624973,tests,Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone),has_type,DRUG
NCT02624973,tests,Neoadjuvant docetaxel + cyclophosphamide
Neoadjuvant docetaxel + cyclophosphamide,has_type,DRUG
NCT02624973,tests,Neoadjuvant docetaxel
Neoadjuvant docetaxel,has_type,DRUG
NCT02624973,tests,Neoadjuvant docetaxel + trastuzumab + pertuzumab
Neoadjuvant docetaxel + trastuzumab + pertuzumab,has_type,DRUG
NCT02624973,tests,Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab
Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab,has_type,DRUG
NCT02624973,tests,Neoadjuvant olaparib
Neoadjuvant olaparib,has_type,DRUG
NCT02624973,tests,Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)
Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone),has_type,DRUG
NCT02624973,tests,Breast conserving surgery or mastectomy + SNB/axillary dissection
Breast conserving surgery or mastectomy + SNB/axillary dissection,has_type,PROCEDURE
NCT02624973,tests,Postoperative radiotherapy breast/chest wall + regional lymph nodes
Postoperative radiotherapy breast/chest wall + regional lymph nodes,has_type,RADIATION
NCT02624973,tests,Adjuvant trastuzumab
Adjuvant trastuzumab,has_type,DRUG
NCT02624973,tests,Adjuvant letrozole (postmenopausal women)
Adjuvant letrozole (postmenopausal women),has_type,DRUG
NCT02624973,tests,Adjuvant tamoxifen + goserelin (premenopausal women)
Adjuvant tamoxifen + goserelin (premenopausal women),has_type,DRUG
NCT02624973,tests,Adjuvant palbociclib (if palbociclib given neoadjuvant)
Adjuvant palbociclib (if palbociclib given neoadjuvant),has_type,DRUG
NCT02624973,tests,Adjuvant Epirubicin+ Cyclophosphamide
Adjuvant Epirubicin+ Cyclophosphamide,has_type,DRUG
NCT03982173,has_title,A Phase II Whole Exome Sequencing-based Basket Trial for Combination Therapy With Durvalumab (Anti-P
NCT03982173,has_status,WITHDRAWN
NCT03982173,has_phase,
NCT03982173,sponsored_by,"Gustave Roussy, Cancer Campus, Grand Paris"
NCT03982173,tests,Tremelimumab
Tremelimumab,has_type,DRUG
NCT03982173,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT02413320,has_title,Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus P
NCT02413320,has_status,COMPLETED
NCT02413320,has_phase,
NCT02413320,sponsored_by,Priyanka Sharma
NCT02413320,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02413320,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02413320,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02413320,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02413320,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT02227082,has_title,Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph 
NCT02227082,has_status,COMPLETED
NCT02227082,has_phase,
NCT02227082,sponsored_by,The Netherlands Cancer Institute
NCT02227082,tests,radiotherapy
radiotherapy,has_type,RADIATION
NCT02227082,tests,olaparib
olaparib,has_type,DRUG
NCT03102320,has_title,Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expr
NCT03102320,has_status,COMPLETED
NCT03102320,has_phase,
NCT03102320,sponsored_by,Bayer
NCT03102320,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03102320,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT03102320,tests,Anetumab ravtansine (BAY94-9343)
Anetumab ravtansine (BAY94-9343),has_type,DRUG
NCT05113966,has_title,"A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-h"
NCT05113966,has_status,TERMINATED
NCT05113966,has_phase,
NCT05113966,sponsored_by,"G1 Therapeutics, Inc."
NCT05113966,tests,Trilaciclib
Trilaciclib,has_type,DRUG
NCT05113966,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT02833766,has_title,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Pos
NCT02833766,has_status,TERMINATED
NCT02833766,has_phase,
NCT02833766,sponsored_by,Swiss Group for Clinical Cancer Research
NCT02833766,tests,anti-EGFR-IL-dox
anti-EGFR-IL-dox,has_type,DRUG
NCT05491226,has_title,IIT2021-01-Shiao-CSF1Ri: Reinvigorating TNBC Response to Immunotherapy with Combination Myeloid Inhi
NCT05491226,has_status,ACTIVE_NOT_RECRUITING
NCT05491226,has_phase,
NCT05491226,sponsored_by,Stephen Shiao
NCT05491226,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05491226,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT05491226,tests,Axatilimab
Axatilimab,has_type,DRUG
NCT01986426,has_title,"A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Mono"
NCT01986426,has_status,COMPLETED
NCT01986426,has_phase,
NCT01986426,sponsored_by,Lytix Biopharma AS
NCT01986426,tests,LTX-315 consecutive lesions
LTX-315 consecutive lesions,has_type,DRUG
NCT01986426,tests,LTX-315
LTX-315,has_type,DRUG
NCT01986426,tests,LTX-315 + ipilimumab
LTX-315 + ipilimumab,has_type,DRUG
NCT01986426,tests,LTX-315 + pembrolizumab
LTX-315 + pembrolizumab,has_type,DRUG
NCT05255666,has_title,Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Neg
NCT05255666,has_status,WITHDRAWN
NCT05255666,has_phase,
NCT05255666,sponsored_by,Washington University School of Medicine
NCT05255666,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT05255666,tests,Liposomal Irinotecan
Liposomal Irinotecan,has_type,DRUG
NCT04140526,has_title,"Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pem"
NCT04140526,has_status,ACTIVE_NOT_RECRUITING
NCT04140526,has_phase,
NCT04140526,sponsored_by,"OncoC4, Inc."
NCT04140526,tests,ONC-392
ONC-392,has_type,DRUG
NCT04140526,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04140526,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01525966,has_title,Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Loca
NCT01525966,has_status,ACTIVE_NOT_RECRUITING
NCT01525966,has_phase,
NCT01525966,sponsored_by,City of Hope Medical Center
NCT01525966,tests,carboplatin
carboplatin,has_type,DRUG
NCT01525966,tests,paclitaxel albumin-stabilized nanoparticle formulation
paclitaxel albumin-stabilized nanoparticle formulation,has_type,DRUG
NCT01525966,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT00618657,has_title,"A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzuma"
NCT00618657,has_status,COMPLETED
NCT00618657,has_phase,
NCT00618657,sponsored_by,"University of California, Irvine"
NCT00618657,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00618657,tests,paclitaxel albumin-stabilized nanoparticle formulation
paclitaxel albumin-stabilized nanoparticle formulation,has_type,DRUG
NCT00618657,tests,bevacizumab
bevacizumab,has_type,DRUG
NCT00618657,tests,trastuzumab
trastuzumab,has_type,DRUG
NCT00618657,tests,magnetic resonance imaging
magnetic resonance imaging,has_type,PROCEDURE
NCT00618657,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT02555657,has_title,A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemothera
NCT02555657,has_status,COMPLETED
NCT02555657,has_phase,
NCT02555657,sponsored_by,Merck Sharp & Dohme LLC
NCT02555657,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT02555657,tests,capecitabine
capecitabine,has_type,DRUG
NCT02555657,tests,eribulin
eribulin,has_type,DRUG
NCT02555657,tests,gemcitabine
gemcitabine,has_type,DRUG
NCT02555657,tests,vinorelbine
vinorelbine,has_type,DRUG
NCT01112826,has_title,Phase III Study of Adjuvant Capecitabine Metronomic Chemotherapy in Triple-negative Operable Breast 
NCT01112826,has_status,COMPLETED
NCT01112826,has_phase,
NCT01112826,sponsored_by,Sun Yat-sen University
NCT01112826,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT04432857,has_title,An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients Wit
NCT04432857,has_status,ACTIVE_NOT_RECRUITING
NCT04432857,has_phase,
NCT04432857,sponsored_by,"Adlai Nortye Biopharma Co., Ltd."
NCT04432857,tests,AN0025
AN0025,has_type,DRUG
NCT04432857,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT04985357,has_title,Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Dru
NCT04985357,has_status,WITHDRAWN
NCT04985357,has_phase,
NCT04985357,sponsored_by,Travera Inc
NCT02456857,has_title,"Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and"
NCT02456857,has_status,COMPLETED
NCT02456857,has_phase,
NCT02456857,sponsored_by,M.D. Anderson Cancer Center
NCT02456857,tests,Bevacizumab
Bevacizumab,has_type,BIOLOGICAL
NCT02456857,tests,Everolimus
Everolimus,has_type,DRUG
NCT02456857,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02456857,tests,Pegylated Liposomal Doxorubicin Hydrochloride
Pegylated Liposomal Doxorubicin Hydrochloride,has_type,DRUG
NCT03797326,has_title,"A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) i"
NCT03797326,has_status,COMPLETED
NCT03797326,has_phase,
NCT03797326,sponsored_by,Merck Sharp & Dohme LLC
NCT03797326,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03797326,tests,Lenvatinib
Lenvatinib,has_type,DRUG
NCT03071757,has_title,"A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacoki"
NCT03071757,has_status,COMPLETED
NCT03071757,has_phase,
NCT03071757,sponsored_by,AbbVie
NCT03071757,tests,ABBV-368
ABBV-368,has_type,DRUG
NCT03071757,tests,ABBV-181
ABBV-181,has_type,DRUG
NCT02316457,has_title,First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID f
NCT02316457,has_status,COMPLETED
NCT02316457,has_phase,
NCT02316457,sponsored_by,BioNTech SE
NCT02316457,tests,IVAC_W_bre1_uID
IVAC_W_bre1_uID,has_type,BIOLOGICAL
NCT02316457,tests,IVAC_W_bre1_uID/IVAC_M_uID
IVAC_W_bre1_uID/IVAC_M_uID,has_type,BIOLOGICAL
NCT03719326,has_title,A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Particip
NCT03719326,has_status,COMPLETED
NCT03719326,has_phase,
NCT03719326,sponsored_by,"Arcus Biosciences, Inc."
NCT03719326,tests,Etrumadenant
Etrumadenant,has_type,DRUG
NCT03719326,tests,IPI-549
IPI-549,has_type,DRUG
NCT03719326,tests,Pegylated liposomal doxorubicin (PLD)
Pegylated liposomal doxorubicin (PLD),has_type,DRUG
NCT03719326,tests,nanoparticle albumin-bound paclitaxel (NP)
nanoparticle albumin-bound paclitaxel (NP),has_type,DRUG
NCT03218826,has_title,A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mut
NCT03218826,has_status,ACTIVE_NOT_RECRUITING
NCT03218826,has_phase,
NCT03218826,sponsored_by,National Cancer Institute (NCI)
NCT03218826,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT03218826,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT03218826,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT03218826,tests,PI3Kbeta Inhibitor AZD8186
PI3Kbeta Inhibitor AZD8186,has_type,DRUG
NCT01984866,has_title,Complete Pathological Response Prediction After Neoadjuvant Treatment Using Excisional Biopsy By Rad
NCT01984866,has_status,TERMINATED
NCT01984866,has_phase,
NCT01984866,sponsored_by,Hospital General Universitario Gregorio Marañon
NCT05325866,has_title,"A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzum"
NCT05325866,has_status,ACTIVE_NOT_RECRUITING
NCT05325866,has_phase,
NCT05325866,sponsored_by,Amgen
NCT05325866,tests,Bemarituzumab
Bemarituzumab,has_type,DRUG
NCT03487666,has_title,OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy 
NCT03487666,has_status,COMPLETED
NCT03487666,has_phase,
NCT03487666,sponsored_by,Georgetown University
NCT03487666,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03487666,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT05539365,has_title,A Phase II Study of Intratumorally Injected Autologous Dendritic Cells (DCs) in PD-L1-Negative Treat
NCT05539365,has_status,WITHDRAWN
NCT05539365,has_phase,
NCT05539365,sponsored_by,Roswell Park Cancer Institute
NCT05539365,tests,Alpha-type-1 Polarized Dendritic Cells
Alpha-type-1 Polarized Dendritic Cells,has_type,BIOLOGICAL
NCT05539365,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT05539365,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT05539365,tests,Leukapheresis
Leukapheresis,has_type,PROCEDURE
NCT05539365,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT05539365,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT03355066,has_title,"A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetic"
NCT03355066,has_status,TERMINATED
NCT03355066,has_phase,
NCT03355066,sponsored_by,"Biosplice Therapeutics, Inc."
NCT03355066,tests,SM08502
SM08502,has_type,DRUG
NCT05134194,has_title,"A Muti-center, Open-label, Randomized, Phase III Study of Camrelizumab Plus Treatment of Physician C"
NCT05134194,has_status,TERMINATED
NCT05134194,has_phase,
NCT05134194,sponsored_by,"Suzhou Suncadia Biopharmaceuticals Co., Ltd."
NCT05134194,tests,Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine
Camrelizumab、Capecitabine/eribulin/gemcitabine/vinorelbine,has_type,DRUG
NCT05134194,tests,Capecitabine/eribulin/gemcitabine/vinorelbine
Capecitabine/eribulin/gemcitabine/vinorelbine,has_type,DRUG
NCT02365662,has_title,A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated L
NCT02365662,has_status,TERMINATED
NCT02365662,has_phase,
NCT02365662,sponsored_by,AbbVie
NCT02365662,tests,ABBV-221
ABBV-221,has_type,DRUG
NCT03075462,has_title,"An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib "
NCT03075462,has_status,COMPLETED
NCT03075462,has_phase,
NCT03075462,sponsored_by,"Jiangsu HengRui Medicine Co., Ltd."
NCT03075462,tests,Fluzoparib
Fluzoparib,has_type,DRUG
NCT03075462,tests,Apatinib
Apatinib,has_type,DRUG
NCT03289962,has_title,"A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a"
NCT03289962,has_status,COMPLETED
NCT03289962,has_phase,
NCT03289962,sponsored_by,"Genentech, Inc."
NCT03289962,tests,Autogene cevumeran
Autogene cevumeran,has_type,DRUG
NCT03289962,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02698176,has_title,"A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Ex"
NCT02698176,has_status,TERMINATED
NCT02698176,has_phase,
NCT02698176,sponsored_by,Merck Sharp & Dohme LLC
NCT02698176,tests,Birabresib
Birabresib,has_type,DRUG
NCT03310957,has_title,"Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Lin"
NCT03310957,has_status,COMPLETED
NCT03310957,has_phase,
NCT03310957,sponsored_by,Seagen Inc.
NCT03310957,tests,ladiratuzumab vedotin
ladiratuzumab vedotin,has_type,DRUG
NCT03310957,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT01982448,has_title,A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Nega
NCT01982448,has_status,COMPLETED
NCT01982448,has_phase,
NCT01982448,sponsored_by,Dana-Farber Cancer Institute
NCT01982448,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01982448,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01116648,has_title,Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serou
NCT01116648,has_status,ACTIVE_NOT_RECRUITING
NCT01116648,has_phase,
NCT01116648,sponsored_by,National Cancer Institute (NCI)
NCT01116648,tests,Biopsy Procedure
Biopsy Procedure,has_type,PROCEDURE
NCT01116648,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT01116648,tests,Cediranib Maleate
Cediranib Maleate,has_type,DRUG
NCT01116648,tests,Computed Tomography
Computed Tomography,has_type,PROCEDURE
NCT01116648,tests,Echocardiography Test
Echocardiography Test,has_type,PROCEDURE
NCT01116648,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT01116648,tests,Multigated Acquisition Scan
Multigated Acquisition Scan,has_type,PROCEDURE
NCT01116648,tests,Olaparib
Olaparib,has_type,DRUG
NCT01695057,has_title,A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases
NCT01695057,has_status,WITHDRAWN
NCT01695057,has_phase,
NCT01695057,sponsored_by,University of Southern California
NCT01695057,tests,vorinostat
vorinostat,has_type,DRUG
NCT01695057,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT01695057,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT02489448,has_title,Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Na
NCT02489448,has_status,COMPLETED
NCT02489448,has_phase,
NCT02489448,sponsored_by,Yale University
NCT02489448,tests,MEDI4736
MEDI4736,has_type,DRUG
NCT03000257,has_title,"A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combinat"
NCT03000257,has_status,COMPLETED
NCT03000257,has_phase,
NCT03000257,sponsored_by,AbbVie
NCT03000257,tests,Venetoclax
Venetoclax,has_type,DRUG
NCT03000257,tests,Rovalpituzumab Tesirine
Rovalpituzumab Tesirine,has_type,DRUG
NCT03000257,tests,ABBV-181
ABBV-181,has_type,DRUG
NCT00031681,has_title,A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part
NCT00031681,has_status,COMPLETED
NCT00031681,has_phase,
NCT00031681,sponsored_by,National Cancer Institute (NCI)
NCT00031681,tests,7-hydroxystaurosporine
7-hydroxystaurosporine,has_type,DRUG
NCT00031681,tests,irinotecan hydrochloride
irinotecan hydrochloride,has_type,DRUG
NCT00031681,tests,diagnostic laboratory biomarker analysis
diagnostic laboratory biomarker analysis,has_type,OTHER
NCT02743910,has_title,"Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer"
NCT02743910,has_status,ACTIVE_NOT_RECRUITING
NCT02743910,has_phase,
NCT02743910,sponsored_by,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02743910,tests,ptDNA
ptDNA,has_type,OTHER
NCT02743910,tests,Tissue sample
Tissue sample,has_type,OTHER
NCT00789581,has_title,Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Pacl
NCT00789581,has_status,COMPLETED
NCT00789581,has_phase,
NCT00789581,sponsored_by,"SCRI Development Innovations, LLC"
NCT00789581,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT00789581,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00789581,tests,Ixabepilone (Ixempra)
Ixabepilone (Ixempra),has_type,DRUG
NCT00789581,tests,Paclitaxel (Taxol)
Paclitaxel (Taxol),has_type,DRUG
NCT02978495,has_title,Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study (NACATRINE T
NCT02978495,has_status,COMPLETED
NCT02978495,has_phase,
NCT02978495,sponsored_by,Barretos Cancer Hospital
NCT02978495,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02978495,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02978495,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02978495,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02762981,has_title,Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
NCT02762981,has_status,COMPLETED
NCT02762981,has_phase,
NCT02762981,sponsored_by,Corcept Therapeutics
NCT02762981,tests,Relacorilant with nab-paclitaxel
Relacorilant with nab-paclitaxel,has_type,DRUG
NCT02427581,has_title,A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long 
NCT02427581,has_status,WITHDRAWN
NCT02427581,has_phase,
NCT02427581,sponsored_by,Washington University School of Medicine
NCT02427581,tests,Personalized synthetic long peptide vaccine (Poly ICLC)
Personalized synthetic long peptide vaccine (Poly ICLC),has_type,BIOLOGICAL
NCT02427581,tests,Poly ICLC
Poly ICLC,has_type,DRUG
NCT03206203,has_title,A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Neg
NCT03206203,has_status,COMPLETED
NCT03206203,has_phase,
NCT03206203,sponsored_by,Vanderbilt-Ingram Cancer Center
NCT03206203,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03206203,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03206203,tests,Laboratory Biomarker
Laboratory Biomarker,has_type,OTHER
NCT03206203,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT02981303,has_title,"A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced "
NCT02981303,has_status,COMPLETED
NCT02981303,has_phase,
NCT02981303,sponsored_by,"HiberCell, Inc."
NCT02981303,tests,Imprime PGG
Imprime PGG,has_type,BIOLOGICAL
NCT02981303,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02792114,has_title,A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Ant
NCT02792114,has_status,ACTIVE_NOT_RECRUITING
NCT02792114,has_phase,
NCT02792114,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02792114,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02792114,tests,Mesothelin-targeted T cells
Mesothelin-targeted T cells,has_type,BIOLOGICAL
NCT02792114,tests,AP1903
AP1903,has_type,DRUG
NCT01281150,has_title,A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Adva
NCT01281150,has_status,COMPLETED
NCT01281150,has_phase,
NCT01281150,sponsored_by,National Cancer Institute (NCI)
NCT01281150,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01281150,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01281150,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT01281150,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT01281150,tests,Veliparib
Veliparib,has_type,DRUG
NCT01849250,has_title,A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Canc
NCT01849250,has_status,COMPLETED
NCT01849250,has_phase,
NCT01849250,sponsored_by,National Cancer Institute (NCI)
NCT01849250,tests,Docosahexaenoic Acid
Docosahexaenoic Acid,has_type,DRUG
NCT01849250,tests,Placebo
Placebo,has_type,OTHER
NCT01677455,has_title,An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Br
NCT01677455,has_status,COMPLETED
NCT01677455,has_phase,
NCT01677455,sponsored_by,Synta Pharmaceuticals Corp.
NCT01677455,tests,ganetespib
ganetespib,has_type,DRUG
NCT06618014,has_title,"A Single-Arm Phase II Trial of Neoadjuvant Toripalimab, Docetaxel, Plus Carboplatin in Patients With"
NCT06618014,has_status,COMPLETED
NCT06618014,has_phase,
NCT06618014,sponsored_by,Sun Yat-sen University
NCT06618014,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT06618014,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT06618014,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT06833723,has_title,Construction and Validation of a Multi-omics Prediction Model to Assess Immunotherapy Efficacy in Pa
NCT06833723,has_status,ACTIVE_NOT_RECRUITING
NCT06833723,has_phase,
NCT06833723,sponsored_by,"Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences"
NCT06833723,tests,Retrospective Data Collection and Analysis
Retrospective Data Collection and Analysis,has_type,OTHER
NCT04584255,has_title,A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BR
NCT04584255,has_status,ACTIVE_NOT_RECRUITING
NCT04584255,has_phase,
NCT04584255,sponsored_by,Dana-Farber Cancer Institute
NCT04584255,tests,Niraparib
Niraparib,has_type,DRUG
NCT04584255,tests,Dostarlimab
Dostarlimab,has_type,DRUG
NCT02779855,has_title,A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple
NCT02779855,has_status,ACTIVE_NOT_RECRUITING
NCT02779855,has_phase,
NCT02779855,sponsored_by,H. Lee Moffitt Cancer Center and Research Institute
NCT02779855,tests,Talimogene laherparepvec
Talimogene laherparepvec,has_type,BIOLOGICAL
NCT02779855,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02476955,has_title,An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic Agents in Subjects 
NCT02476955,has_status,TERMINATED
NCT02476955,has_phase,
NCT02476955,sponsored_by,"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)"
NCT02476955,tests,ARQ 092 + carboplatin + paclitaxel (Closed)
ARQ 092 + carboplatin + paclitaxel (Closed),has_type,DRUG
NCT02476955,tests,ARQ 092 + paclitaxel (Closed)
ARQ 092 + paclitaxel (Closed),has_type,DRUG
NCT02476955,tests,ARQ 092 + anastrozole
ARQ 092 + anastrozole,has_type,DRUG
NCT00483223,has_title,A Phase II Study of Cisplatin or Carboplatin for Triple-Negative Metastatic Breast Cancer and Evalua
NCT00483223,has_status,COMPLETED
NCT00483223,has_phase,
NCT00483223,sponsored_by,Massachusetts General Hospital
NCT00483223,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT00483223,tests,carboplatin
carboplatin,has_type,DRUG
NCT01738438,has_title,A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer
NCT01738438,has_status,COMPLETED
NCT01738438,has_phase,
NCT01738438,sponsored_by,Dana-Farber Cancer Institute
NCT01738438,tests,Cabozantinib
Cabozantinib,has_type,DRUG
NCT03369223,has_title,A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced S
NCT03369223,has_status,COMPLETED
NCT03369223,has_phase,
NCT03369223,sponsored_by,Bristol-Myers Squibb
NCT03369223,tests,BMS-986249
BMS-986249,has_type,BIOLOGICAL
NCT03369223,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT03369223,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT01333423,has_title,A Phase I With Dose Expansion to Determine the Maximum Tolerated Dose of Liposomal Doxorubicin in Co
NCT01333423,has_status,WITHDRAWN
NCT01333423,has_phase,
NCT01333423,sponsored_by,M.D. Anderson Cancer Center
NCT01333423,tests,Liposomal Doxorubicin
Liposomal Doxorubicin,has_type,DRUG
NCT01333423,tests,Seliciclib
Seliciclib,has_type,DRUG
NCT03390608,has_title,"Prognosis, Prognostic Factors and Predictive Factors in Centimeter or Subcentimeter Node-negative Br"
NCT03390608,has_status,COMPLETED
NCT03390608,has_phase,
NCT03390608,sponsored_by,Karolinska Institutet
NCT03390608,tests,Endocrine therapy
Endocrine therapy,has_type,DRUG
NCT03390608,tests,Radiotherapy
Radiotherapy,has_type,RADIATION
NCT03390608,tests,Herceptin
Herceptin,has_type,DRUG
NCT03390608,tests,Chemotherapy
Chemotherapy,has_type,DRUG
NCT03390608,tests,Type of breast cancer surgery
Type of breast cancer surgery,has_type,PROCEDURE
NCT03390608,tests,Age at diagnosis
Age at diagnosis,has_type,OTHER
NCT03390608,tests,Screen detected tumor
Screen detected tumor,has_type,OTHER
NCT03390608,tests,Menopausal status at diagnosis
Menopausal status at diagnosis,has_type,OTHER
NCT03390608,tests,Tumor size
Tumor size,has_type,OTHER
NCT03390608,tests,Estrogen receptor (ER) status
Estrogen receptor (ER) status,has_type,OTHER
NCT03390608,tests,Tumor grade
Tumor grade,has_type,OTHER
NCT03390608,tests,HER2-status
HER2-status,has_type,OTHER
NCT03390608,tests,Intrinsic subgroups of breast cancer
Intrinsic subgroups of breast cancer,has_type,OTHER
NCT03390608,tests,Nodal status
Nodal status,has_type,OTHER
NCT00603408,has_title,Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Br
NCT00603408,has_status,TERMINATED
NCT00603408,has_phase,
NCT00603408,sponsored_by,Washington University School of Medicine
NCT00603408,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT00603408,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT00603408,tests,Mastectomy
Mastectomy,has_type,PROCEDURE
NCT03997123,has_title,A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclita
NCT03997123,has_status,ACTIVE_NOT_RECRUITING
NCT03997123,has_phase,
NCT03997123,sponsored_by,AstraZeneca
NCT03997123,tests,Capivasertib
Capivasertib,has_type,DRUG
NCT03997123,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03997123,tests,Placebo
Placebo,has_type,DRUG
NCT01957514,has_title,Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Tri
NCT01957514,has_status,TERMINATED
NCT01957514,has_phase,
NCT01957514,sponsored_by,University of Washington
NCT01957514,tests,Cytology Specimen Collection Procedure
Cytology Specimen Collection Procedure,has_type,OTHER
NCT01957514,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT01957514,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT01957514,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT05082610,has_title,"A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy "
NCT05082610,has_status,ACTIVE_NOT_RECRUITING
NCT05082610,has_phase,
NCT05082610,sponsored_by,Hummingbird Bioscience
NCT05082610,tests,HMBD-002
HMBD-002,has_type,DRUG
NCT05082610,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02348281,has_title,"A Prospective, Single Center, Phase II Study of Bicalutamide as A Treatment in Androgen Receptor (AR"
NCT02348281,has_status,TERMINATED
NCT02348281,has_phase,
NCT02348281,sponsored_by,Fudan University
NCT02348281,tests,Bicalutamide
Bicalutamide,has_type,DRUG
NCT03126110,has_title,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination Wit"
NCT03126110,has_status,COMPLETED
NCT03126110,has_phase,
NCT03126110,sponsored_by,Incyte Biosciences International Sàrl
NCT03126110,tests,INCAGN01876
INCAGN01876,has_type,DRUG
NCT03126110,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT03126110,tests,Ipilimumab
Ipilimumab,has_type,DRUG
NCT05008510,has_title,Phase 2 Clinical Efficacy and Safety Study of Sabizabulin (VERU-111) Monotherapy and Sacituzumab Gov
NCT05008510,has_status,WITHDRAWN
NCT05008510,has_phase,
NCT05008510,sponsored_by,Veru Inc.
NCT05008510,tests,Sabizabulin
Sabizabulin,has_type,DRUG
NCT05008510,tests,Sacituzumab Govitecan-hziy
Sacituzumab Govitecan-hziy,has_type,DRUG
NCT05008510,tests,Sabizabulin/Sacituzumab govitecan-hziy Combo
Sabizabulin/Sacituzumab govitecan-hziy Combo,has_type,DRUG
NCT01612910,has_title,"A Pilot Study of BR-DIM in Women With Stage II-III, Triple Negative, and Androgen Receptor Positive,"
NCT01612910,has_status,WITHDRAWN
NCT01612910,has_phase,
NCT01612910,sponsored_by,Barbara Ann Karmanos Cancer Institute
NCT01612910,tests,oral microencapsulated diindolylmethane
oral microencapsulated diindolylmethane,has_type,DRUG
NCT01612910,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT04111510,has_title,A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Me
NCT04111510,has_status,COMPLETED
NCT04111510,has_phase,
NCT04111510,sponsored_by,Yale University
NCT04111510,tests,Tumor infiltrating lymphocytes (TIL) LN-145
Tumor infiltrating lymphocytes (TIL) LN-145,has_type,DRUG
NCT02202746,has_title,"A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF"
NCT02202746,has_status,TERMINATED
NCT02202746,has_phase,
NCT02202746,sponsored_by,"Clovis Oncology, Inc."
NCT02202746,tests,Lucitanib
Lucitanib,has_type,DRUG
NCT03303846,has_title,Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology
NCT03303846,has_status,ACTIVE_NOT_RECRUITING
NCT03303846,has_phase,
NCT03303846,sponsored_by,City of Hope Medical Center
NCT03303846,tests,Magnetic Resonance Imaging
Magnetic Resonance Imaging,has_type,PROCEDURE
NCT03303846,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT03303846,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT00754312,has_title,"A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in S"
NCT00754312,has_status,TERMINATED
NCT00754312,has_phase,
NCT00754312,sponsored_by,Syndax Pharmaceuticals
NCT00754312,tests,SNDX-275
SNDX-275,has_type,DRUG
NCT03893955,has_title,"A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, an"
NCT03893955,has_status,ACTIVE_NOT_RECRUITING
NCT03893955,has_phase,
NCT03893955,sponsored_by,AbbVie
NCT03893955,tests,ABBV-927
ABBV-927,has_type,DRUG
NCT03893955,tests,ABBV-368
ABBV-368,has_type,DRUG
NCT03893955,tests,ABBV-181
ABBV-181,has_type,DRUG
NCT03893955,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03893955,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04052555,has_title,A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resist
NCT04052555,has_status,ACTIVE_NOT_RECRUITING
NCT04052555,has_phase,
NCT04052555,sponsored_by,National Cancer Institute (NCI)
NCT04052555,tests,Berzosertib
Berzosertib,has_type,DRUG
NCT04052555,tests,Biospecimen Collection
Biospecimen Collection,has_type,PROCEDURE
NCT04052555,tests,Quality-of-Life Assessment
Quality-of-Life Assessment,has_type,OTHER
NCT04052555,tests,Questionnaire Administration
Questionnaire Administration,has_type,OTHER
NCT04052555,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT02574455,has_title,"An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Ver"
NCT02574455,has_status,COMPLETED
NCT02574455,has_phase,
NCT02574455,sponsored_by,Gilead Sciences
NCT02574455,tests,Sacituzumab govitecan
Sacituzumab govitecan,has_type,DRUG
NCT02574455,tests,Eribulin
Eribulin,has_type,DRUG
NCT02574455,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02574455,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02574455,tests,Vinorelbine
Vinorelbine,has_type,DRUG
NCT02322814,has_title,"A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobi"
NCT02322814,has_status,TERMINATED
NCT02322814,has_phase,
NCT02322814,sponsored_by,Hoffmann-La Roche
NCT02322814,tests,Cobimetinib
Cobimetinib,has_type,DRUG
NCT02322814,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02322814,tests,Placebo
Placebo,has_type,DRUG
NCT02322814,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT02322814,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT03761914,has_title,A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Sel
NCT03761914,has_status,COMPLETED
NCT03761914,has_phase,
NCT03761914,sponsored_by,Sellas Life Sciences Group
NCT03761914,tests,galinpepimut-S
galinpepimut-S,has_type,BIOLOGICAL
NCT03761914,tests,pembrolizumab
pembrolizumab,has_type,BIOLOGICAL
NCT03761914,tests,Montanide
Montanide,has_type,OTHER
NCT03761914,tests,GM-CSF
GM-CSF,has_type,BIOLOGICAL
NCT02575781,has_title,A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors
NCT02575781,has_status,COMPLETED
NCT02575781,has_phase,
NCT02575781,sponsored_by,Sanofi
NCT02575781,tests,SAR428926
SAR428926,has_type,DRUG
NCT02201381,has_title,"A Non Randomised, Non Blinded Real World Trial of the Safety, Tolerability and Effectiveness of Meta"
NCT02201381,has_status,WITHDRAWN
NCT02201381,has_phase,
NCT02201381,sponsored_by,Health Clinics Limited
NCT02201381,tests,Metabolic treatment
Metabolic treatment,has_type,DRUG
NCT04131881,has_title,The Consistency of Drug Sensitivity in Vitro and Neoadjuvant Chemotherapy Results in Vivo for Early 
NCT04131881,has_status,COMPLETED
NCT04131881,has_phase,
NCT04131881,sponsored_by,Peking University People's Hospital
NCT01698281,has_title,"A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Met"
NCT01698281,has_status,TERMINATED
NCT01698281,has_phase,
NCT01698281,sponsored_by,AEterna Zentaris
NCT01698281,tests,AEZS-108
AEZS-108,has_type,DRUG
NCT01698281,tests,SCCC
SCCC,has_type,DRUG
NCT01698281,tests,Dexamethasone
Dexamethasone,has_type,DRUG
NCT02788981,has_title,"A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclita"
NCT02788981,has_status,ACTIVE_NOT_RECRUITING
NCT02788981,has_phase,
NCT02788981,sponsored_by,University of Chicago
NCT02788981,tests,Mifepristone
Mifepristone,has_type,DRUG
NCT02788981,tests,Placebo
Placebo,has_type,OTHER
NCT02788981,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT02419495,has_title,Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard C
NCT02419495,has_status,TERMINATED
NCT02419495,has_phase,
NCT02419495,sponsored_by,M.D. Anderson Cancer Center
NCT02419495,tests,Capecitabine
Capecitabine,has_type,DRUG
NCT02419495,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT02419495,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02419495,tests,Doxorubicin
Doxorubicin,has_type,DRUG
NCT02419495,tests,Eribulin
Eribulin,has_type,DRUG
NCT02419495,tests,Fluorouracil
Fluorouracil,has_type,DRUG
NCT02419495,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT02419495,tests,Irinotecan Hydrochloride
Irinotecan Hydrochloride,has_type,DRUG
NCT02419495,tests,Leucovorin Calcium
Leucovorin Calcium,has_type,DRUG
NCT02419495,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT02419495,tests,Olaparib
Olaparib,has_type,DRUG
NCT02419495,tests,Oxaliplatin
Oxaliplatin,has_type,DRUG
NCT02419495,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT02419495,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT02419495,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT02419495,tests,Selinexor
Selinexor,has_type,DRUG
NCT02419495,tests,Topotecan
Topotecan,has_type,DRUG
NCT03401385,has_title,"Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subje"
NCT03401385,has_status,ACTIVE_NOT_RECRUITING
NCT03401385,has_phase,
NCT03401385,sponsored_by,"Daiichi Sankyo Co., Ltd."
NCT03401385,tests,Datopotamab Deruxtecan (Dato-DXd)
Datopotamab Deruxtecan (Dato-DXd),has_type,DRUG
NCT03401385,tests,Steroid Containing Mouthwash
Steroid Containing Mouthwash,has_type,DRUG
NCT03401385,tests,Non-Steroid Containing Mouthwash
Non-Steroid Containing Mouthwash,has_type,OTHER
NCT01363232,has_title,"A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered "
NCT01363232,has_status,COMPLETED
NCT01363232,has_phase,
NCT01363232,sponsored_by,"Array Biopharma, now a wholly owned subsidiary of Pfizer"
NCT01363232,tests,BKM120 + MEK162
BKM120 + MEK162,has_type,DRUG
NCT04726332,has_title,A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent an
NCT04726332,has_status,TERMINATED
NCT04726332,has_phase,
NCT04726332,sponsored_by,Exelixis
NCT04726332,tests,XL102
XL102,has_type,DRUG
NCT04726332,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT04726332,tests,Abiraterone
Abiraterone,has_type,DRUG
NCT04726332,tests,Prednisone
Prednisone,has_type,DRUG
NCT01306032,has_title,Phase II Randomized Trial of ABT-888 in Combination With Metronomic Oral Cyclophosphamide in Refract
NCT01306032,has_status,COMPLETED
NCT01306032,has_phase,
NCT01306032,sponsored_by,National Cancer Institute (NCI)
NCT01306032,tests,ABT-888
ABT-888,has_type,DRUG
NCT01306032,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT02078752,has_title,"A FIRST-IN-HUMAN PHASE 1, DOSE ESCALATION, SAFETY AND PHARMACOKINETIC STUDY OF PF-06647263 IN ADULT "
NCT02078752,has_status,TERMINATED
NCT02078752,has_phase,
NCT02078752,sponsored_by,Pfizer
NCT02078752,tests,PF-06647263
PF-06647263,has_type,DRUG
NCT02078752,tests,PF-06647263
PF-06647263,has_type,DRUG
NCT04296942,has_title,"A Phase 1b Trial of Sequential Combinations of BN-Brachyury, Entinostat, Ado-trastuzuamb Emtansine a"
NCT04296942,has_status,TERMINATED
NCT04296942,has_phase,
NCT04296942,sponsored_by,National Cancer Institute (NCI)
NCT04296942,tests,Brachyury-TRICOM
Brachyury-TRICOM,has_type,BIOLOGICAL
NCT04296942,tests,Entinostat
Entinostat,has_type,DRUG
NCT04296942,tests,M7824
M7824,has_type,BIOLOGICAL
NCT04296942,tests,Ado-trastuzumab emtansine
Ado-trastuzumab emtansine,has_type,BIOLOGICAL
NCT03504488,has_title,"A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and "
NCT03504488,has_status,COMPLETED
NCT03504488,has_phase,
NCT03504488,sponsored_by,"BioAtla, Inc."
NCT03504488,tests,CAB-ROR2-ADC
CAB-ROR2-ADC,has_type,BIOLOGICAL
NCT03504488,tests,PD-1 inhibitor
PD-1 inhibitor,has_type,BIOLOGICAL
NCT02984683,has_title,Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 
NCT02984683,has_status,TERMINATED
NCT02984683,has_phase,
NCT02984683,sponsored_by,Sanofi
NCT02984683,tests,SAR566658 (ACT14884)
SAR566658 (ACT14884),has_type,DRUG
NCT02971761,has_title,A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulat
NCT02971761,has_status,COMPLETED
NCT02971761,has_phase,
NCT02971761,sponsored_by,City of Hope Medical Center
NCT02971761,tests,Enobosarm
Enobosarm,has_type,DRUG
NCT02971761,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02971761,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT04574583,has_title,"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activ"
NCT04574583,has_status,COMPLETED
NCT04574583,has_phase,
NCT04574583,sponsored_by,National Cancer Institute (NCI)
NCT04574583,tests,SX-682
SX-682,has_type,DRUG
NCT04574583,tests,M7824
M7824,has_type,DRUG
NCT04574583,tests,MVA-BN-CV301
MVA-BN-CV301,has_type,BIOLOGICAL
NCT04574583,tests,recombinant fowlpox viral (FPV)-CV301
recombinant fowlpox viral (FPV)-CV301,has_type,BIOLOGICAL
NCT01653561,has_title,"A Multi-institutional, Open-label, Single Arm Study of Apatinib in Non-triple-negative Metastatic Br"
NCT01653561,has_status,COMPLETED
NCT01653561,has_phase,
NCT01653561,sponsored_by,Fudan University
NCT01653561,tests,Apatinib
Apatinib,has_type,DRUG
NCT03881605,has_title,Routine MRI Screening Versus Symptom-directed Surveillance for Brain Metastases Among Patients with 
NCT03881605,has_status,ACTIVE_NOT_RECRUITING
NCT03881605,has_phase,
NCT03881605,sponsored_by,Sunnybrook Health Sciences Centre
NCT03881605,tests,MRI screening
MRI screening,has_type,DIAGNOSTIC_TEST
NCT02365805,has_title,"Randomized Open-label, Multicentric, Phase II Clinical Trial to Evaluate the Efficacy of a Neoadjuva"
NCT02365805,has_status,COMPLETED
NCT02365805,has_phase,
NCT02365805,sponsored_by,Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT02365805,tests,Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel,has_type,DRUG
NCT02365805,tests,Epirubicin + Cisplatin + Fluorouracil
Epirubicin + Cisplatin + Fluorouracil,has_type,DRUG
NCT02365805,tests,Docetaxel + Ciclofosfamide
Docetaxel + Ciclofosfamide,has_type,DRUG
NCT02183805,has_title,Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therap
NCT02183805,has_status,TERMINATED
NCT02183805,has_phase,
NCT02183805,sponsored_by,Sun Yat-sen University
NCT02183805,tests,"Abraxane,Cyclophosphamide,Carboplatin"
"Abraxane,Cyclophosphamide,Carboplatin",has_type,DRUG
NCT02129205,has_title,A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06650808 IN PATIENTS WI
NCT02129205,has_status,TERMINATED
NCT02129205,has_phase,
NCT02129205,sponsored_by,Pfizer
NCT02129205,tests,PF-06650808
PF-06650808,has_type,DRUG
NCT02129205,tests,PF-06650808
PF-06650808,has_type,DRUG
NCT03872505,has_title,A Randomized Phase II Study Evaluating Pathologic Response Rates Following Pre-operAtive Non-Anthrac
NCT03872505,has_status,WITHDRAWN
NCT03872505,has_phase,
NCT03872505,sponsored_by,Cedars-Sinai Medical Center
NCT03872505,tests,Durvalumab
Durvalumab,has_type,DRUG
NCT03872505,tests,Radiation Therapy
Radiation Therapy,has_type,RADIATION
NCT03872505,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03872505,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03197805,has_title,Prospective Study Assessing the Impact of RNA Genomic Profile Defined by a Genomic Test on Treatment
NCT03197805,has_status,TERMINATED
NCT03197805,has_phase,
NCT03197805,sponsored_by,Centre Jean Perrin
NCT03197805,tests,PAM 50 test
PAM 50 test,has_type,DIAGNOSTIC_TEST
NCT03330405,has_title,A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE PO
NCT03330405,has_status,TERMINATED
NCT03330405,has_phase,
NCT03330405,sponsored_by,Pfizer
NCT03330405,tests,Avelumab Phase 1b
Avelumab Phase 1b,has_type,DRUG
NCT03330405,tests,Talazoparib Phase 1b
Talazoparib Phase 1b,has_type,DRUG
NCT03330405,tests,Avelumab Phase 2
Avelumab Phase 2,has_type,DRUG
NCT03330405,tests,Talazoparib Phase 2
Talazoparib Phase 2,has_type,DRUG
NCT01173497,has_title,"A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Trea"
NCT01173497,has_status,COMPLETED
NCT01173497,has_phase,
NCT01173497,sponsored_by,Sanofi
NCT01173497,tests,INIPARIB + irinotecan
INIPARIB + irinotecan,has_type,DRUG
NCT03205761,has_title,A Phase II Clinical Trial to Analyse Olaparib Response in Patients With BRCA1 and/or 2 Promoter Meth
NCT03205761,has_status,COMPLETED
NCT03205761,has_phase,
NCT03205761,sponsored_by,Spanish Breast Cancer Research Group
NCT03205761,tests,Olaparib
Olaparib,has_type,DRUG
NCT03911453,has_title,Window of Opportunity Trial to Evaluate Change in PD-L1 Expression in Triple Negative Breast Tumors 
NCT03911453,has_status,COMPLETED
NCT03911453,has_phase,
NCT03911453,sponsored_by,University of Arizona
NCT03911453,tests,Rucaparib
Rucaparib,has_type,DRUG
NCT01770353,has_title,"A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tum"
NCT01770353,has_status,COMPLETED
NCT01770353,has_phase,
NCT01770353,sponsored_by,Ipsen
NCT01770353,tests,Ferumoxytol
Ferumoxytol,has_type,DRUG
NCT01770353,tests,MM-398
MM-398,has_type,DRUG
NCT02723877,has_title,"An Open Label, Non Randomized, Multicenter Phase 1/2b Study Investigating Safety and Efficacy of PQR"
NCT02723877,has_status,COMPLETED
NCT02723877,has_phase,
NCT02723877,sponsored_by,PIQUR Therapeutics AG
NCT02723877,tests,PQR309
PQR309,has_type,DRUG
NCT02723877,tests,Eribulin
Eribulin,has_type,DRUG
NCT05071677,has_title,Determinants of Treatment Decision Making in African American Women Diagnosed With Triple Negative B
NCT05071677,has_status,COMPLETED
NCT05071677,has_phase,
NCT05071677,sponsored_by,M.D. Anderson Cancer Center
NCT05071677,tests,Discussion
Discussion,has_type,PROCEDURE
NCT05071677,tests,Interview
Interview,has_type,OTHER
NCT05071677,tests,Survey Administration
Survey Administration,has_type,OTHER
NCT03891953,has_title,"A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PD"
NCT03891953,has_status,ACTIVE_NOT_RECRUITING
NCT03891953,has_phase,
NCT03891953,sponsored_by,Novartis Pharmaceuticals
NCT03891953,tests,DKY709
DKY709,has_type,DRUG
NCT03891953,tests,PDR001
PDR001,has_type,DRUG
NCT02834247,has_title,A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid T
NCT02834247,has_status,TERMINATED
NCT02834247,has_phase,
NCT02834247,sponsored_by,"Calithera Biosciences, Inc"
NCT02834247,tests,TAK-659
TAK-659,has_type,DRUG
NCT02834247,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT01596751,has_title,Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macropha
NCT01596751,has_status,COMPLETED
NCT01596751,has_phase,
NCT01596751,sponsored_by,"Hope Rugo, MD"
NCT01596751,tests,PLX3397
PLX3397,has_type,DRUG
NCT01596751,tests,Eribulin
Eribulin,has_type,DRUG
NCT03876951,has_title,Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assist
NCT03876951,has_status,ACTIVE_NOT_RECRUITING
NCT03876951,has_phase,
NCT03876951,sponsored_by,Centre Georges Francois Leclerc
NCT03876951,tests,Vacuum-assisted biopsy
Vacuum-assisted biopsy,has_type,DIAGNOSTIC_TEST
NCT03281954,has_title,"A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab o"
NCT03281954,has_status,ACTIVE_NOT_RECRUITING
NCT03281954,has_phase,
NCT03281954,sponsored_by,NSABP Foundation Inc
NCT03281954,tests,Placebo
Placebo,has_type,DRUG
NCT03281954,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT00576654,has_title,"A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, N"
NCT00576654,has_status,COMPLETED
NCT00576654,has_phase,
NCT00576654,sponsored_by,National Cancer Institute (NCI)
NCT00576654,tests,Irinotecan Hydrochloride
Irinotecan Hydrochloride,has_type,DRUG
NCT00576654,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT00576654,tests,Pharmacological Study
Pharmacological Study,has_type,OTHER
NCT00576654,tests,Veliparib
Veliparib,has_type,DRUG
NCT03396445,has_title,A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With
NCT03396445,has_status,COMPLETED
NCT03396445,has_phase,
NCT03396445,sponsored_by,Merck Sharp & Dohme LLC
NCT03396445,tests,Boserolimab
Boserolimab,has_type,DRUG
NCT03396445,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03396445,tests,Pemetrexed
Pemetrexed,has_type,DRUG
NCT03396445,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03396445,tests,Nab-paclitaxel
Nab-paclitaxel,has_type,DRUG
NCT04418154,has_title,Neoadjuvant Anthracycline Followed by Toripalimab Combined With Nab-paclitaxel in Patients With Earl
NCT04418154,has_status,ACTIVE_NOT_RECRUITING
NCT04418154,has_phase,
NCT04418154,sponsored_by,Fudan University
NCT04418154,tests,epirubicin hydrochloride
epirubicin hydrochloride,has_type,DRUG
NCT04418154,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT04418154,tests,Albumin bound paclitaxel
Albumin bound paclitaxel,has_type,DRUG
NCT04418154,tests,Toripalimab
Toripalimab,has_type,DRUG
NCT03096054,has_title,A Cancer Research UK (CR-UK) Phase I Trial of LY3143921 a Cdc7 Inhibitor in Adult Patients with Adva
NCT03096054,has_status,ACTIVE_NOT_RECRUITING
NCT03096054,has_phase,
NCT03096054,sponsored_by,Cancer Research UK
NCT03096054,tests,LY3143921 hydrate
LY3143921 hydrate,has_type,DRUG
NCT05253053,has_title,"A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the S"
NCT05253053,has_status,COMPLETED
NCT05253053,has_phase,
NCT05253053,sponsored_by,"TransThera Sciences (Nanjing), Inc."
NCT05253053,tests,TT-00420
TT-00420,has_type,DRUG
NCT05253053,tests,Combination Product: Atezolizumab
Combination Product: Atezolizumab,has_type,DRUG
NCT05253053,tests,Combination Product: Nab-Paclitaxel
Combination Product: Nab-Paclitaxel,has_type,DRUG
NCT03193853,has_title,Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (H
NCT03193853,has_status,COMPLETED
NCT03193853,has_phase,
NCT03193853,sponsored_by,Joyce O'Shaughnessy
NCT03193853,tests,Tak-228 & Tak-117
Tak-228 & Tak-117,has_type,DRUG
NCT03193853,tests,Cisplatin & Nab Paclitaxel
Cisplatin & Nab Paclitaxel,has_type,DRUG
NCT05001347,has_title,A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With 
NCT05001347,has_status,COMPLETED
NCT05001347,has_phase,
NCT05001347,sponsored_by,I-Mab Biopharma US Limited
NCT05001347,tests,TJ004309
TJ004309,has_type,DRUG
NCT03454451,has_title,"A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AG"
NCT03454451,has_status,COMPLETED
NCT03454451,has_phase,
NCT03454451,sponsored_by,"Corvus Pharmaceuticals, Inc."
NCT03454451,tests,CPI-006
CPI-006,has_type,DRUG
NCT03454451,tests,CPI-006 + ciforadenant
CPI-006 + ciforadenant,has_type,DRUG
NCT03454451,tests,CPI-006 + pembrolizumab
CPI-006 + pembrolizumab,has_type,DRUG
NCT03454451,tests,CPI-006
CPI-006,has_type,DRUG
NCT03454451,tests,CPI-006 + ciforadenant
CPI-006 + ciforadenant,has_type,DRUG
NCT03454451,tests,CPI-006 + pembrolizumab
CPI-006 + pembrolizumab,has_type,DRUG
NCT04266353,has_title,Mechanisms in IGF2 Induced Chemoresistance and Mitochondrial Regulation in Triple Negative Breast Ca
NCT04266353,has_status,WITHDRAWN
NCT04266353,has_phase,
NCT04266353,sponsored_by,Loma Linda University
NCT04266353,tests,Resveratrol (RSV)
Resveratrol (RSV),has_type,DIETARY_SUPPLEMENT
NCT03012477,has_title,A Phase II Study of Cisplatin + AZD1775 in Metastatic Triple-negative Breast Cancer and Evaluation o
NCT03012477,has_status,COMPLETED
NCT03012477,has_phase,
NCT03012477,sponsored_by,Dana-Farber Cancer Institute
NCT03012477,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT03012477,tests,AZD1775
AZD1775,has_type,DRUG
NCT01289353,has_title,Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks)
NCT01289353,has_status,COMPLETED
NCT01289353,has_phase,
NCT01289353,sponsored_by,NYU Langone Health
NCT01289353,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT01289353,tests,3D-RT or IMRT
3D-RT or IMRT,has_type,RADIATION
NCT02744053,has_title,Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Tri
NCT02744053,has_status,ACTIVE_NOT_RECRUITING
NCT02744053,has_phase,
NCT02744053,sponsored_by,M.D. Anderson Cancer Center
NCT02744053,tests,Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Dynamic Contrast-Enhanced Magnetic Resonance Imaging,has_type,PROCEDURE
NCT02744053,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02744053,tests,Scintimammography
Scintimammography,has_type,RADIATION
NCT02744053,tests,Technetium Tc-99m Sestamibi
Technetium Tc-99m Sestamibi,has_type,DRUG
NCT02309177,has_title,"A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (Bms-936558) in Combination With Nab-p"
NCT02309177,has_status,COMPLETED
NCT02309177,has_phase,
NCT02309177,sponsored_by,Celgene
NCT02309177,tests,nab-Paclitaxel
nab-Paclitaxel,has_type,DRUG
NCT02309177,tests,Nivolumab
Nivolumab,has_type,DRUG
NCT02309177,tests,Gemcitabine
Gemcitabine,has_type,DRUG
NCT02309177,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT03599453,has_title,Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhanc
NCT03599453,has_status,COMPLETED
NCT03599453,has_phase,
NCT03599453,sponsored_by,Roswell Park Cancer Institute
NCT03599453,tests,Biopsy
Biopsy,has_type,PROCEDURE
NCT03599453,tests,Chemokine Modulation Therapy
Chemokine Modulation Therapy,has_type,PROCEDURE
NCT03599453,tests,Celecoxib
Celecoxib,has_type,DRUG
NCT03599453,tests,Recombinant Interferon Alfa-2b
Recombinant Interferon Alfa-2b,has_type,BIOLOGICAL
NCT03599453,tests,Rintatolimod
Rintatolimod,has_type,DRUG
NCT03599453,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT01676753,has_title,A Phase 1b Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizum
NCT01676753,has_status,COMPLETED
NCT01676753,has_phase,
NCT01676753,sponsored_by,Jo Chien
NCT01676753,tests,Dinaciclib
Dinaciclib,has_type,DRUG
NCT01676753,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03915951,has_title,"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small "
NCT03915951,has_status,ACTIVE_NOT_RECRUITING
NCT03915951,has_phase,
NCT03915951,sponsored_by,Pfizer
NCT03915951,tests,encorafenib
encorafenib,has_type,DRUG
NCT03915951,tests,binimetinib
binimetinib,has_type,DRUG
NCT00679783,has_title,"Phase II, Open Label, Non-Randomized Study of AZD2281 in the Treatment of Patients With Known BRCA o"
NCT00679783,has_status,COMPLETED
NCT00679783,has_phase,
NCT00679783,sponsored_by,AstraZeneca
NCT00679783,tests,AZD2281
AZD2281,has_type,DRUG
NCT03601897,has_title,"An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel"
NCT03601897,has_status,TERMINATED
NCT03601897,has_phase,
NCT03601897,sponsored_by,"Deciphera Pharmaceuticals, LLC"
NCT03601897,tests,Rebastinib
Rebastinib,has_type,DRUG
NCT03601897,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04835597,has_title,Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT04835597,has_status,TERMINATED
NCT04835597,has_phase,
NCT04835597,sponsored_by,M.D. Anderson Cancer Center
NCT04835597,tests,Behavioral Assessment
Behavioral Assessment,has_type,BEHAVIORAL
NCT04835597,tests,Electronic Health Record Review
Electronic Health Record Review,has_type,OTHER
NCT04158583,has_title,"An Open-Label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pha"
NCT04158583,has_status,TERMINATED
NCT04158583,has_phase,
NCT04158583,sponsored_by,Hoffmann-La Roche
NCT04158583,tests,RO7296682
RO7296682,has_type,DRUG
NCT03586297,has_title,Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in
NCT03586297,has_status,ACTIVE_NOT_RECRUITING
NCT03586297,has_phase,
NCT03586297,sponsored_by,Hackensack Meridian Health
NCT05891197,has_title,A Biomarker Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Saf
NCT05891197,has_status,TERMINATED
NCT05891197,has_phase,
NCT05891197,sponsored_by,"Lyell Immunopharma, Inc."
NCT01857193,has_title,A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment o
NCT01857193,has_status,COMPLETED
NCT01857193,has_phase,
NCT01857193,sponsored_by,Novartis Pharmaceuticals
NCT01857193,tests,ribociclib (LEE011)
ribociclib (LEE011),has_type,DRUG
NCT01857193,tests,Exemestane
Exemestane,has_type,DRUG
NCT01857193,tests,Everolimus (RAD001)
Everolimus (RAD001),has_type,DRUG
NCT03363893,has_title,"A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability"
NCT03363893,has_status,COMPLETED
NCT03363893,has_phase,
NCT03363893,sponsored_by,Carrick Therapeutics Limited
NCT03363893,tests,CT7001
CT7001,has_type,DRUG
NCT03363893,tests,Fulvestrant
Fulvestrant,has_type,DRUG
NCT03164993,has_title,ALICE: a Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined with Immunoge
NCT03164993,has_status,COMPLETED
NCT03164993,has_phase,
NCT03164993,sponsored_by,Oslo University Hospital
NCT03164993,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03164993,tests,Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin,has_type,DRUG
NCT03164993,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT03164993,tests,Placebo
Placebo,has_type,OTHER
NCT04185311,has_title,"A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Loca"
NCT04185311,has_status,TERMINATED
NCT04185311,has_phase,
NCT04185311,sponsored_by,Jonsson Comprehensive Cancer Center
NCT04185311,tests,Ipilimumab
Ipilimumab,has_type,BIOLOGICAL
NCT04185311,tests,Nivolumab
Nivolumab,has_type,BIOLOGICAL
NCT04185311,tests,Talimogene Laherparepvec
Talimogene Laherparepvec,has_type,BIOLOGICAL
NCT01216111,has_title,A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF
NCT01216111,has_status,COMPLETED
NCT01216111,has_phase,
NCT01216111,sponsored_by,Fudan University
NCT01216111,tests,Paclitaxel Cisplatin
Paclitaxel Cisplatin,has_type,DRUG
NCT01216111,tests,fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T),has_type,DRUG
NCT02482311,has_title,"A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and"
NCT02482311,has_status,COMPLETED
NCT02482311,has_phase,
NCT02482311,sponsored_by,AstraZeneca
NCT02482311,tests,AZD 1775
AZD 1775,has_type,DRUG
NCT06231693,has_title,Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-worl
NCT06231693,has_status,TERMINATED
NCT06231693,has_phase,
NCT06231693,sponsored_by,AstraZeneca
NCT06231693,tests,Trastuzumab deruxtecan
Trastuzumab deruxtecan,has_type,DRUG
NCT06067061,has_title,"""neoBREASTIM"": A Phase 2 Study of Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant S"
NCT06067061,has_status,TERMINATED
NCT06067061,has_phase,
NCT06067061,sponsored_by,Institut Curie
NCT06067061,tests,Atezolizumab + RP1
Atezolizumab + RP1,has_type,COMBINATION_PRODUCT
NCT01292083,has_title,A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacitidine on ER and PR Expression 
NCT01292083,has_status,WITHDRAWN
NCT01292083,has_phase,
NCT01292083,sponsored_by,University of Southern California
NCT01292083,tests,azacitidine
azacitidine,has_type,DRUG
NCT01292083,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,OTHER
NCT01292083,tests,immunohistochemistry staining method
immunohistochemistry staining method,has_type,OTHER
NCT01292083,tests,polymerase chain reaction
polymerase chain reaction,has_type,GENETIC
NCT01292083,tests,western blotting
western blotting,has_type,GENETIC
NCT01292083,tests,nucleic acid sequencing
nucleic acid sequencing,has_type,GENETIC
NCT01292083,tests,therapeutic conventional surgery
therapeutic conventional surgery,has_type,PROCEDURE
NCT03411161,has_title,Phase I/II Trial of S 81694 Administered Intravenously in Combination With Paclitaxel to Evaluate th
NCT03411161,has_status,COMPLETED
NCT03411161,has_phase,
NCT03411161,sponsored_by,Institut de Recherches Internationales Servier
NCT03411161,tests,Combination therapy (S81694 + paclitaxel) phase I
Combination therapy (S81694 + paclitaxel) phase I,has_type,DRUG
NCT03411161,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03411161,tests,Combination therapy (S81694 + paclitaxel) phase II
Combination therapy (S81694 + paclitaxel) phase II,has_type,DRUG
NCT06965361,has_title,Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Tripl
NCT06965361,has_status,COMPLETED
NCT06965361,has_phase,
NCT06965361,sponsored_by,Ziauddin University
NCT06965361,tests,carboplatin
carboplatin,has_type,DRUG
NCT06965361,tests,carboplatin
carboplatin,has_type,DEVICE
NCT01009983,has_title,A Phase II Clinical Trial of Weekly Paclitaxel and Carboplatin in Combination With Panitumumab in Me
NCT01009983,has_status,TERMINATED
NCT01009983,has_phase,
NCT01009983,sponsored_by,Wake Forest University Health Sciences
NCT01009983,tests,panitumumab
panitumumab,has_type,BIOLOGICAL
NCT01009983,tests,paclitaxel
paclitaxel,has_type,DRUG
NCT01009983,tests,carboplatin
carboplatin,has_type,DRUG
NCT01009983,tests,laboratory biomarker analysis
laboratory biomarker analysis,has_type,PROCEDURE
NCT01009983,tests,immunohistochemistry staining method
immunohistochemistry staining method,has_type,PROCEDURE
NCT03004183,has_title,Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Vi
NCT03004183,has_status,COMPLETED
NCT03004183,has_phase,
NCT03004183,sponsored_by,The Methodist Hospital Research Institute
NCT03004183,tests,ADV/HSV-tk
ADV/HSV-tk,has_type,BIOLOGICAL
NCT03004183,tests,Valacyclovir
Valacyclovir,has_type,DRUG
NCT03004183,tests,SBRT
SBRT,has_type,RADIATION
NCT03004183,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT02648477,has_title,MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients Wi
NCT02648477,has_status,COMPLETED
NCT02648477,has_phase,
NCT02648477,sponsored_by,City of Hope Medical Center
NCT02648477,tests,Anastrozole
Anastrozole,has_type,DRUG
NCT02648477,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT02648477,tests,Exemestane
Exemestane,has_type,DRUG
NCT02648477,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02648477,tests,Letrozole
Letrozole,has_type,DRUG
NCT02648477,tests,Pembrolizumab
Pembrolizumab,has_type,BIOLOGICAL
NCT03225547,has_title,Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Canc
NCT03225547,has_status,ACTIVE_NOT_RECRUITING
NCT03225547,has_phase,
NCT03225547,sponsored_by,University of Chicago
NCT03225547,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03225547,tests,Mifepristone
Mifepristone,has_type,DRUG
NCT04099277,has_title,A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
NCT04099277,has_status,TERMINATED
NCT04099277,has_phase,
NCT04099277,sponsored_by,Eli Lilly and Company
NCT04099277,tests,LY3435151
LY3435151,has_type,DRUG
NCT04099277,tests,Pembrolizumab
Pembrolizumab,has_type,DRUG
NCT03330847,has_title,"A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents T"
NCT03330847,has_status,ACTIVE_NOT_RECRUITING
NCT03330847,has_phase,
NCT03330847,sponsored_by,AstraZeneca
NCT03330847,tests,Olaparib Continuous (28-Day cycle) 300 mg BD.
Olaparib Continuous (28-Day cycle) 300 mg BD.,has_type,DRUG
NCT03330847,tests,Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).,has_type,DRUG
NCT03330847,tests,Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).,has_type,DRUG
NCT03106077,has_title,Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients 
NCT03106077,has_status,COMPLETED
NCT03106077,has_phase,
NCT03106077,sponsored_by,M.D. Anderson Cancer Center
NCT03106077,tests,Mirvetuximab Soravtansine
Mirvetuximab Soravtansine,has_type,BIOLOGICAL
NCT03654547,has_title,"A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult P"
NCT03654547,has_status,ACTIVE_NOT_RECRUITING
NCT03654547,has_phase,
NCT03654547,sponsored_by,"TransThera Sciences (Nanjing), Inc."
NCT03654547,tests,TT-00420
TT-00420,has_type,DRUG
NCT01920061,has_title,A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212
NCT01920061,has_status,COMPLETED
NCT01920061,has_phase,
NCT01920061,sponsored_by,Pfizer
NCT01920061,tests,PF-05212384 (gedatolisib)
PF-05212384 (gedatolisib),has_type,DRUG
NCT01920061,tests,Docetaxel
Docetaxel,has_type,DRUG
NCT01920061,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT01920061,tests,Dacomitinib
Dacomitinib,has_type,DRUG
NCT00448305,has_title,"An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1"
NCT00448305,has_status,COMPLETED
NCT00448305,has_phase,
NCT00448305,sponsored_by,MediGene
NCT00448305,tests,EndoTAG-1 + paclitaxel
EndoTAG-1 + paclitaxel,has_type,DRUG
NCT00448305,tests,EndoTAG-1
EndoTAG-1,has_type,DRUG
NCT00448305,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT03752398,has_title,A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With
NCT03752398,has_status,COMPLETED
NCT03752398,has_phase,
NCT03752398,sponsored_by,"Xencor, Inc."
NCT03752398,tests,XmAb®23104
XmAb®23104,has_type,BIOLOGICAL
NCT03752398,tests,Yervoy® (ipilimumab)
Yervoy® (ipilimumab),has_type,BIOLOGICAL
NCT06782698,has_title,Home-Based Physical Exercise During Neoadjuvant Treatment for Improving Fatigue and Quality of Life 
NCT06782698,has_status,ACTIVE_NOT_RECRUITING
NCT06782698,has_phase,
NCT06782698,sponsored_by,Centro Hospitalar Universitário de Santo António
NCT06782698,tests,Home-based exercise program
Home-based exercise program,has_type,BEHAVIORAL
NCT06782698,tests,Promotion of Healthy Physical Activity
Promotion of Healthy Physical Activity,has_type,BEHAVIORAL
NCT02595905,has_title,Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Met
NCT02595905,has_status,COMPLETED
NCT02595905,has_phase,
NCT02595905,sponsored_by,National Cancer Institute (NCI)
NCT02595905,tests,Cisplatin
Cisplatin,has_type,DRUG
NCT02595905,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT02595905,tests,Placebo Administration
Placebo Administration,has_type,OTHER
NCT02595905,tests,Veliparib
Veliparib,has_type,DRUG
NCT02422498,has_title,A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Rec
NCT02422498,has_status,COMPLETED
NCT02422498,has_phase,
NCT02422498,sponsored_by,Memorial Sloan Kettering Cancer Center
NCT02422498,tests,external beam radiation therapy
external beam radiation therapy,has_type,RADIATION
NCT02422498,tests,cisplatin
cisplatin,has_type,DRUG
NCT02422498,tests,Biopsy of Target Tumor
Biopsy of Target Tumor,has_type,PROCEDURE
NCT03961698,has_title,"Ph 2, Multi-arm, Multicenter, Open-label Study to Evaluate Efficacy and Safety of IPI-549 Administer"
NCT03961698,has_status,ACTIVE_NOT_RECRUITING
NCT03961698,has_phase,
NCT03961698,sponsored_by,"Infinity Pharmaceuticals, Inc."
NCT03961698,tests,IPI-549 (eganelisib)
IPI-549 (eganelisib),has_type,DRUG
NCT03961698,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03961698,tests,nab-paclitaxel
nab-paclitaxel,has_type,DRUG
NCT03961698,tests,Bevacizumab
Bevacizumab,has_type,DRUG
NCT03981705,has_title,Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
NCT03981705,has_status,COMPLETED
NCT03981705,has_phase,
NCT03981705,sponsored_by,"Masonic Cancer Center, University of Minnesota"
NCT03981705,tests,Standard Trimodality Breast Imaging
Standard Trimodality Breast Imaging,has_type,RADIATION
NCT00861705,has_title,Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuv
NCT00861705,has_status,ACTIVE_NOT_RECRUITING
NCT00861705,has_phase,
NCT00861705,sponsored_by,National Cancer Institute (NCI)
NCT00861705,tests,Bevacizumab
Bevacizumab,has_type,BIOLOGICAL
NCT00861705,tests,Carboplatin
Carboplatin,has_type,DRUG
NCT00861705,tests,Cyclophosphamide
Cyclophosphamide,has_type,DRUG
NCT00861705,tests,Doxorubicin Hydrochloride
Doxorubicin Hydrochloride,has_type,DRUG
NCT00861705,tests,Laboratory Biomarker Analysis
Laboratory Biomarker Analysis,has_type,OTHER
NCT00861705,tests,Paclitaxel
Paclitaxel,has_type,DRUG
NCT04148911,has_title,"An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab"
NCT04148911,has_status,COMPLETED
NCT04148911,has_phase,
NCT04148911,sponsored_by,Hoffmann-La Roche
NCT04148911,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT04148911,tests,Nab-Paclitaxel
Nab-Paclitaxel,has_type,DRUG
NCT03538028,has_title,"A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants "
NCT03538028,has_status,COMPLETED
NCT03538028,has_phase,
NCT03538028,sponsored_by,Incyte Biosciences International Sàrl
NCT03538028,tests,INCAGN02385
INCAGN02385,has_type,BIOLOGICAL
NCT00940498,has_title,A Phase 1 Study Of Pf-05212384 (Also Known As Pki-587) Administered As An Intravenous Infusion To Pa
NCT00940498,has_status,COMPLETED
NCT00940498,has_phase,
NCT00940498,sponsored_by,Pfizer
NCT00940498,tests,PF-05212384 (also known as PKI-587)
PF-05212384 (also known as PKI-587),has_type,DRUG
NCT03756298,has_title,"Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adj"
NCT03756298,has_status,ACTIVE_NOT_RECRUITING
NCT03756298,has_phase,
NCT03756298,sponsored_by,"National Cancer Center, Korea"
NCT03756298,tests,Atezolizumab
Atezolizumab,has_type,DRUG
NCT03756298,tests,Capecitabine
Capecitabine,has_type,DRUG
Pembrolizumab,targets_gene,PD-1
Nivolumab,targets_gene,PD-1
Atezolizumab,targets_gene,PD-L1
Olaparib,targets_gene,BRCA1
Olaparib,targets_gene,BRCA2
NCT03639948,has_trial_type,"CHEMO, IMMUNO"
NCT03414684,has_trial_type,"CHEMO, IMMUNO"
NCT01094184,has_trial_type,"CHEMO, TARGETED"
NCT04067102,has_trial_type,CHEMO
NCT04514484,has_trial_type,IMMUNO
NCT03125902,has_trial_type,"CHEMO, IMMUNO"
NCT03742102,has_trial_type,"CHEMO, TARGETED"
NCT04521621,has_trial_type,IMMUNO
NCT04849364,has_trial_type,IMMUNO
NCT00203502,has_trial_type,TARGETED
NCT02124902,has_trial_type,CHEMO
NCT01207102,has_trial_type,CHEMO
NCT02876302,has_trial_type,CHEMO
NCT04925284,has_trial_type,"IMMUNO, TARGETED"
NCT04927884,has_trial_type,IMMUNO
NCT01250379,has_trial_type,TARGETED
NCT00691379,has_trial_type,"CHEMO, TARGETED"
NCT03777579,has_trial_type,"CHEMO, IMMUNO"
NCT01779479,has_trial_type,CHEMO
NCT02161679,has_trial_type,CHEMO
NCT05252390,has_trial_type,TARGETED
NCT03449108,has_trial_type,IMMUNO
NCT00733408,has_trial_type,"CHEMO, TARGETED"
NCT02370238,has_trial_type,CHEMO
NCT05809895,has_trial_type,"CHEMO, IMMUNO"
NCT02263495,has_trial_type,CHEMO
NCT03301350,has_trial_type,CHEMO
NCT04690855,has_trial_type,IMMUNO
NCT03098550,has_trial_type,IMMUNO
NCT03775850,has_trial_type,IMMUNO
NCT02838823,has_trial_type,IMMUNO
NCT04177108,has_trial_type,"CHEMO, IMMUNO"
NCT03752723,has_trial_type,IMMUNO
NCT02658214,has_trial_type,CHEMO
NCT02423603,has_trial_type,CHEMO
NCT04508803,has_trial_type,TARGETED
NCT03002103,has_trial_type,CHEMO
NCT04031703,has_trial_type,CHEMO
NCT02734290,has_trial_type,"CHEMO, IMMUNO"
NCT05609903,has_trial_type,"CHEMO, IMMUNO"
NCT03577743,has_trial_type,TARGETED
NCT05889390,has_trial_type,CHEMO
NCT01969643,has_trial_type,TARGETED
NCT04584112,has_trial_type,"CHEMO, IMMUNO"
NCT05374512,has_trial_type,CHEMO
NCT01031446,has_trial_type,CHEMO
NCT02447003,has_trial_type,IMMUNO
NCT03801369,has_trial_type,TARGETED
NCT02957968,has_trial_type,"CHEMO, IMMUNO, TARGETED"
NCT03849469,has_trial_type,IMMUNO
NCT04664972,has_trial_type,CHEMO
NCT02644369,has_trial_type,IMMUNO
NCT02513472,has_trial_type,IMMUNO
NCT02755272,has_trial_type,"CHEMO, IMMUNO"
NCT04770272,has_trial_type,"CHEMO, IMMUNO"
NCT05194072,has_trial_type,IMMUNO
NCT03917381,has_trial_type,IMMUNO
NCT05390710,has_trial_type,CHEMO
NCT05093387,has_trial_type,"CHEMO, IMMUNO"
NCT01251874,has_trial_type,"CHEMO, TARGETED"
NCT05333874,has_trial_type,TARGETED
NCT02000882,has_trial_type,TARGETED
NCT03621982,has_trial_type,IMMUNO
NCT01975831,has_trial_type,IMMUNO
NCT02689427,has_trial_type,CHEMO
NCT02929576,has_trial_type,CHEMO
NCT04085276,has_trial_type,CHEMO
NCT05756166,has_trial_type,IMMUNO
NCT02535026,has_trial_type,TARGETED
NCT03175666,has_trial_type,"CHEMO, TARGETED"
NCT03911973,has_trial_type,TARGETED
NCT01750073,has_trial_type,"CHEMO, TARGETED"
NCT02474173,has_trial_type,CHEMO
NCT04556773,has_trial_type,"CHEMO, TARGETED"
NCT03970382,has_trial_type,IMMUNO
NCT03109080,has_trial_type,TARGETED
NCT03168880,has_trial_type,CHEMO
NCT02041429,has_trial_type,CHEMO
NCT02620280,has_trial_type,CHEMO
NCT02708680,has_trial_type,IMMUNO
NCT04595565,has_trial_type,CHEMO
NCT00479674,has_trial_type,"CHEMO, TARGETED"
NCT04464174,has_trial_type,CHEMO
NCT02622074,has_trial_type,"CHEMO, IMMUNO"
NCT05062174,has_trial_type,TARGETED
NCT02954874,has_trial_type,IMMUNO
NCT00912444,has_trial_type,CHEMO
NCT02125344,has_trial_type,"CHEMO, TARGETED"
NCT05209529,has_trial_type,TARGETED
NCT02530489,has_trial_type,"CHEMO, IMMUNO"
NCT06371989,has_trial_type,TARGETED
NCT03644589,has_trial_type,"CHEMO, IMMUNO"
NCT02657889,has_trial_type,IMMUNO
NCT03367689,has_trial_type,TARGETED
NCT04216472,has_trial_type,CHEMO
NCT01421472,has_trial_type,"CHEMO, TARGETED"
NCT03292172,has_trial_type,IMMUNO
NCT00608972,has_trial_type,"CHEMO, TARGETED"
NCT00528567,has_trial_type,TARGETED
NCT02488967,has_trial_type,CHEMO
NCT01745367,has_trial_type,CHEMO
NCT03829501,has_trial_type,IMMUNO
NCT01045304,has_trial_type,CHEMO
NCT02768701,has_trial_type,IMMUNO
NCT03256344,has_trial_type,IMMUNO
NCT04434040,has_trial_type,IMMUNO
NCT01910844,has_trial_type,CHEMO
NCT03366844,has_trial_type,IMMUNO
NCT01930292,has_trial_type,CHEMO
NCT01167192,has_trial_type,CHEMO
NCT04464967,has_trial_type,TARGETED
NCT04331067,has_trial_type,"CHEMO, IMMUNO"
NCT04249167,has_trial_type,"CHEMO, IMMUNO"
NCT02157792,has_trial_type,CHEMO
NCT03101280,has_trial_type,IMMUNO
NCT01208480,has_trial_type,"CHEMO, TARGETED"
NCT04762901,has_trial_type,CHEMO
NCT02484404,has_trial_type,TARGETED
NCT01617668,has_trial_type,CHEMO
NCT01057069,has_trial_type,CHEMO
NCT01194869,has_trial_type,CHEMO
NCT01201265,has_trial_type,"CHEMO, TARGETED"
NCT05081492,has_trial_type,IMMUNO
NCT05888831,has_trial_type,IMMUNO
NCT02260531,has_trial_type,TARGETED
NCT04373031,has_trial_type,IMMUNO
NCT03483012,has_trial_type,IMMUNO
NCT02435680,has_trial_type,CHEMO
NCT03945604,has_trial_type,IMMUNO
NCT00930930,has_trial_type,CHEMO
NCT03952325,has_trial_type,IMMUNO
NCT01145430,has_trial_type,CHEMO
NCT03012230,has_trial_type,IMMUNO
NCT05177796,has_trial_type,"CHEMO, IMMUNO"
NCT01069796,has_trial_type,"CHEMO, TARGETED"
NCT03498716,has_trial_type,"CHEMO, IMMUNO"
NCT02978716,has_trial_type,CHEMO
NCT04083963,has_trial_type,CHEMO
NCT01818063,has_trial_type,CHEMO
NCT01560663,has_trial_type,CHEMO
NCT01377363,has_trial_type,TARGETED
NCT01931163,has_trial_type,CHEMO
NCT00516724,has_trial_type,CHEMO
NCT03337724,has_trial_type,CHEMO
NCT03197935,has_trial_type,"CHEMO, IMMUNO"
NCT00540358,has_trial_type,CHEMO
NCT02546934,has_trial_type,CHEMO
NCT01287624,has_trial_type,CHEMO
NCT01276496,has_trial_type,CHEMO
NCT04348916,has_trial_type,IMMUNO
NCT03267316,has_trial_type,CHEMO
NCT05498896,has_trial_type,"CHEMO, IMMUNO"
NCT05383196,has_trial_type,CHEMO
NCT02315196,has_trial_type,"CHEMO, TARGETED"
NCT04243616,has_trial_type,CHEMO
NCT05233696,has_trial_type,"CHEMO, IMMUNO"
NCT00868634,has_trial_type,TARGETED
NCT04225117,has_trial_type,IMMUNO
NCT04602117,has_trial_type,"CHEMO, TARGETED"
NCT01898117,has_trial_type,"CHEMO, IMMUNO"
NCT04799249,has_trial_type,CHEMO
NCT02366949,has_trial_type,CHEMO
NCT03289819,has_trial_type,"CHEMO, IMMUNO"
NCT01445418,has_trial_type,CHEMO
NCT05750719,has_trial_type,TARGETED
NCT01147016,has_trial_type,"CHEMO, TARGETED"
NCT03667716,has_trial_type,IMMUNO
NCT05620134,has_trial_type,IMMUNO
NCT01953536,has_trial_type,CHEMO
NCT01618136,has_trial_type,CHEMO
NCT03154749,has_trial_type,CHEMO
NCT01848834,has_trial_type,IMMUNO
NCT05585034,has_trial_type,IMMUNO
NCT03371017,has_trial_type,"CHEMO, IMMUNO"
NCT04418219,has_trial_type,IMMUNO
NCT04408118,has_trial_type,"CHEMO, IMMUNO, TARGETED"
NCT04102618,has_trial_type,"IMMUNO, TARGETED"
NCT02162719,has_trial_type,CHEMO
NCT02819518,has_trial_type,"CHEMO, IMMUNO"
NCT01939418,has_trial_type,CHEMO
NCT01623349,has_trial_type,TARGETED
NCT00813956,has_trial_type,CHEMO
NCT02509507,has_trial_type,IMMUNO
NCT04711109,has_trial_type,TARGETED
NCT05504707,has_trial_type,TARGETED
NCT02876107,has_trial_type,CHEMO
NCT03853707,has_trial_type,"CHEMO, IMMUNO"
NCT05145907,has_trial_type,IMMUNO
NCT00707707,has_trial_type,CHEMO
NCT02682693,has_trial_type,"CHEMO, TARGETED"
NCT03918278,has_trial_type,"CHEMO, IMMUNO"
NCT00472693,has_trial_type,TARGETED
NCT03232593,has_trial_type,IMMUNO
NCT02264678,has_trial_type,"CHEMO, TARGETED"
NCT01672671,has_trial_type,"CHEMO, TARGETED"
NCT04268693,has_trial_type,CHEMO
NCT02301988,has_trial_type,CHEMO
NCT00463788,has_trial_type,CHEMO
NCT03036488,has_trial_type,"CHEMO, IMMUNO"
NCT04251533,has_trial_type,CHEMO
NCT05918133,has_trial_type,CHEMO
NCT04332653,has_trial_type,IMMUNO
NCT02641847,has_trial_type,CHEMO
NCT02032277,has_trial_type,CHEMO
NCT02401347,has_trial_type,TARGETED
NCT02983045,has_trial_type,IMMUNO
NCT02547987,has_trial_type,"CHEMO, TARGETED"
NCT03674242,has_trial_type,CHEMO
NCT01815242,has_trial_type,CHEMO
NCT03277352,has_trial_type,IMMUNO
NCT01091454,has_trial_type,CHEMO
NCT01238133,has_trial_type,CHEMO
NCT02441933,has_trial_type,CHEMO
NCT04101851,has_trial_type,TARGETED
NCT04296175,has_trial_type,CHEMO
NCT01674842,has_trial_type,CHEMO
NCT05776875,has_trial_type,"IMMUNO, TARGETED"
NCT02737475,has_trial_type,IMMUNO
NCT00887575,has_trial_type,CHEMO
NCT05383170,has_trial_type,IMMUNO
NCT02593175,has_trial_type,CHEMO
NCT02685059,has_trial_type,"CHEMO, IMMUNO"
NCT02672475,has_trial_type,CHEMO
NCT01104259,has_trial_type,CHEMO
NCT04335006,has_trial_type,CHEMO
NCT04879849,has_trial_type,IMMUNO
NCT02783300,has_trial_type,IMMUNO
NCT02661100,has_trial_type,IMMUNO
NCT05555706,has_trial_type,CHEMO
NCT00674206,has_trial_type,TARGETED
NCT05007106,has_trial_type,"CHEMO, IMMUNO, TARGETED"
NCT05234606,has_trial_type,IMMUNO
NCT01918306,has_trial_type,CHEMO
NCT04491942,has_trial_type,CHEMO
NCT02938442,has_trial_type,CHEMO
NCT06829199,has_trial_type,"CHEMO, IMMUNO, TARGETED"
NCT04060342,has_trial_type,"CHEMO, IMMUNO"
NCT05097599,has_trial_type,TARGETED
NCT03464942,has_trial_type,IMMUNO
NCT02221999,has_trial_type,CHEMO
NCT02789332,has_trial_type,"CHEMO, TARGETED"
NCT01777932,has_trial_type,TARGETED
NCT00546156,has_trial_type,"CHEMO, TARGETED"
NCT03818685,has_trial_type,IMMUNO
NCT01969032,has_trial_type,CHEMO
NCT01333137,has_trial_type,CHEMO
NCT05266937,has_trial_type,"CHEMO, IMMUNO"
NCT02531932,has_trial_type,CHEMO
NCT02637375,has_trial_type,CHEMO
NCT02208375,has_trial_type,TARGETED
NCT01401959,has_trial_type,TARGETED
NCT01074970,has_trial_type,CHEMO
NCT04691375,has_trial_type,IMMUNO
NCT00601159,has_trial_type,CHEMO
NCT01910870,has_trial_type,CHEMO
NCT05629585,has_trial_type,IMMUNO
NCT04958785,has_trial_type,CHEMO
NCT02628132,has_trial_type,"CHEMO, IMMUNO"
NCT04148937,has_trial_type,IMMUNO
NCT04742959,has_trial_type,CHEMO
NCT05673200,has_trial_type,"CHEMO, IMMUNO"
NCT01251900,has_trial_type,TARGETED
NCT01238952,has_trial_type,CHEMO
NCT01075100,has_trial_type,CHEMO
NCT02358200,has_trial_type,CHEMO
NCT06190600,has_trial_type,"CHEMO, TARGETED"
NCT02752685,has_trial_type,"CHEMO, IMMUNO"
NCT03057600,has_trial_type,CHEMO
NCT03499899,has_trial_type,CHEMO
NCT03717415,has_trial_type,CHEMO
NCT03387085,has_trial_type,"CHEMO, TARGETED"
NCT03106415,has_trial_type,IMMUNO
NCT00938652,has_trial_type,CHEMO
NCT03121352,has_trial_type,"CHEMO, IMMUNO"
NCT03095352,has_trial_type,"CHEMO, IMMUNO, TARGETED"
NCT04244552,has_trial_type,"CHEMO, IMMUNO"
NCT03295552,has_trial_type,CHEMO
NCT01165385,has_trial_type,CHEMO
NCT02411656,has_trial_type,IMMUNO
NCT02379585,has_trial_type,"CHEMO, TARGETED"
NCT02445391,has_trial_type,CHEMO
NCT01928394,has_trial_type,IMMUNO
NCT03564691,has_trial_type,"CHEMO, IMMUNO"
NCT05181462,has_trial_type,CHEMO
NCT04734262,has_trial_type,CHEMO
NCT00894504,has_trial_type,CHEMO
NCT06433804,has_trial_type,TARGETED
NCT03197389,has_trial_type,IMMUNO
NCT04081389,has_trial_type,CHEMO
NCT04395989,has_trial_type,"CHEMO, IMMUNO"
NCT02425891,has_trial_type,"CHEMO, IMMUNO"
NCT03362060,has_trial_type,IMMUNO
NCT02993094,has_trial_type,CHEMO
NCT04434560,has_trial_type,IMMUNO
NCT00542191,has_trial_type,CHEMO
NCT03473691,has_trial_type,CHEMO
NCT05852691,has_trial_type,"CHEMO, IMMUNO"
NCT03328494,has_trial_type,CHEMO
NCT03356860,has_trial_type,CHEMO
NCT02499367,has_trial_type,"CHEMO, IMMUNO"
NCT01426880,has_trial_type,CHEMO
NCT01186991,has_trial_type,"CHEMO, TARGETED"
NCT02187991,has_trial_type,CHEMO
NCT04095689,has_trial_type,IMMUNO
NCT02883062,has_trial_type,"CHEMO, IMMUNO"
NCT01307891,has_trial_type,CHEMO
NCT03872791,has_trial_type,CHEMO
NCT03205176,has_trial_type,TARGETED
NCT03010176,has_trial_type,IMMUNO
NCT05358639,has_trial_type,TARGETED
NCT03316586,has_trial_type,IMMUNO
NCT01127763,has_trial_type,CHEMO
NCT03280563,has_trial_type,"IMMUNO, TARGETED"
NCT04191135,has_trial_type,"CHEMO, IMMUNO, TARGETED"
NCT02432963,has_trial_type,IMMUNO
NCT05382286,has_trial_type,"CHEMO, IMMUNO"
NCT01881230,has_trial_type,CHEMO
NCT01111825,has_trial_type,TARGETED
NCT02730130,has_trial_type,IMMUNO
NCT03616886,has_trial_type,CHEMO
NCT02018458,has_trial_type,TARGETED
NCT03594396,has_trial_type,TARGETED
NCT01204125,has_trial_type,CHEMO
NCT03544125,has_trial_type,TARGETED
NCT03241173,has_trial_type,IMMUNO
NCT03326258,has_trial_type,IMMUNO
NCT03184558,has_trial_type,IMMUNO
NCT04224922,has_trial_type,CHEMO
NCT03800836,has_trial_type,"CHEMO, IMMUNO"
NCT01431196,has_trial_type,TARGETED
NCT01929941,has_trial_type,CHEMO
NCT02455141,has_trial_type,CHEMO
NCT02926196,has_trial_type,IMMUNO
NCT02898207,has_trial_type,TARGETED
NCT03554109,has_trial_type,CHEMO
NCT02001519,has_trial_type,CHEMO
NCT03167619,has_trial_type,TARGETED
NCT05112536,has_trial_type,"CHEMO, IMMUNO"
NCT00998036,has_trial_type,CHEMO
NCT00892736,has_trial_type,TARGETED
NCT03829436,has_trial_type,IMMUNO
NCT02035813,has_trial_type,TARGETED
NCT04234113,has_trial_type,IMMUNO
NCT01150513,has_trial_type,CHEMO
NCT02498613,has_trial_type,TARGETED
NCT02203513,has_trial_type,TARGETED
NCT05203445,has_trial_type,"IMMUNO, TARGETED"
NCT02543645,has_trial_type,IMMUNO
NCT04639245,has_trial_type,IMMUNO
NCT03838367,has_trial_type,CHEMO
NCT03435640,has_trial_type,IMMUNO
NCT02624973,has_trial_type,TARGETED
NCT02413320,has_trial_type,CHEMO
NCT02227082,has_trial_type,TARGETED
NCT03102320,has_trial_type,CHEMO
NCT02833766,has_trial_type,CHEMO
NCT05491226,has_trial_type,IMMUNO
NCT01986426,has_trial_type,IMMUNO
NCT05255666,has_trial_type,IMMUNO
NCT04140526,has_trial_type,IMMUNO
NCT01525966,has_trial_type,CHEMO
NCT00618657,has_trial_type,"CHEMO, TARGETED"
NCT02555657,has_trial_type,IMMUNO
NCT04432857,has_trial_type,IMMUNO
NCT02456857,has_trial_type,"CHEMO, TARGETED"
NCT03797326,has_trial_type,IMMUNO
NCT03719326,has_trial_type,CHEMO
NCT03487666,has_trial_type,IMMUNO
NCT05539365,has_trial_type,IMMUNO
NCT03289962,has_trial_type,IMMUNO
NCT03310957,has_trial_type,IMMUNO
NCT01982448,has_trial_type,CHEMO
NCT01116648,has_trial_type,TARGETED
NCT02489448,has_trial_type,IMMUNO
NCT00789581,has_trial_type,CHEMO
NCT02978495,has_trial_type,CHEMO
NCT02762981,has_trial_type,CHEMO
NCT03206203,has_trial_type,"CHEMO, IMMUNO"
NCT02981303,has_trial_type,IMMUNO
NCT01281150,has_trial_type,CHEMO
NCT06618014,has_trial_type,CHEMO
NCT02779855,has_trial_type,CHEMO
NCT02476955,has_trial_type,CHEMO
NCT00483223,has_trial_type,CHEMO
NCT03369223,has_trial_type,IMMUNO
NCT01333423,has_trial_type,CHEMO
NCT03390608,has_trial_type,TARGETED
NCT00603408,has_trial_type,CHEMO
NCT03997123,has_trial_type,CHEMO
NCT05082610,has_trial_type,IMMUNO
NCT03126110,has_trial_type,IMMUNO
NCT03893955,has_trial_type,CHEMO
NCT02322814,has_trial_type,"CHEMO, IMMUNO"
NCT03761914,has_trial_type,IMMUNO
NCT02788981,has_trial_type,CHEMO
NCT02419495,has_trial_type,"CHEMO, IMMUNO, TARGETED"
NCT04296942,has_trial_type,TARGETED
NCT03504488,has_trial_type,IMMUNO
NCT02971761,has_trial_type,IMMUNO
NCT02365805,has_trial_type,CHEMO
NCT02183805,has_trial_type,CHEMO
NCT03872505,has_trial_type,CHEMO
NCT03205761,has_trial_type,TARGETED
NCT03911453,has_trial_type,IMMUNO
NCT02834247,has_trial_type,IMMUNO
NCT03281954,has_trial_type,IMMUNO
NCT03396445,has_trial_type,"CHEMO, IMMUNO"
NCT04418154,has_trial_type,CHEMO
NCT05253053,has_trial_type,"CHEMO, IMMUNO"
NCT03193853,has_trial_type,CHEMO
NCT05001347,has_trial_type,IMMUNO
NCT03454451,has_trial_type,IMMUNO
NCT03012477,has_trial_type,CHEMO
NCT01289353,has_trial_type,CHEMO
NCT02309177,has_trial_type,"CHEMO, IMMUNO"
NCT03599453,has_trial_type,IMMUNO
NCT01676753,has_trial_type,IMMUNO
NCT00679783,has_trial_type,TARGETED
NCT03601897,has_trial_type,CHEMO
NCT03164993,has_trial_type,"CHEMO, IMMUNO"
NCT04185311,has_trial_type,IMMUNO
NCT01216111,has_trial_type,CHEMO
NCT06231693,has_trial_type,TARGETED
NCT06067061,has_trial_type,IMMUNO
NCT03411161,has_trial_type,CHEMO
NCT06965361,has_trial_type,CHEMO
NCT01009983,has_trial_type,CHEMO
NCT03004183,has_trial_type,IMMUNO
NCT02648477,has_trial_type,"CHEMO, IMMUNO"
NCT03225547,has_trial_type,"IMMUNO, TARGETED"
NCT04099277,has_trial_type,IMMUNO
NCT03330847,has_trial_type,TARGETED
NCT01920061,has_trial_type,CHEMO
NCT00448305,has_trial_type,CHEMO
NCT02595905,has_trial_type,CHEMO
NCT02422498,has_trial_type,CHEMO
NCT03961698,has_trial_type,"CHEMO, IMMUNO, TARGETED"
NCT00861705,has_trial_type,"CHEMO, TARGETED"
NCT04148911,has_trial_type,"CHEMO, IMMUNO"
NCT03756298,has_trial_type,IMMUNO
Pembrolizumab,has_trial_type,IMMUNO
Nivolumab,has_trial_type,IMMUNO
Atezolizumab,has_trial_type,IMMUNO
Olaparib,has_trial_type,TARGETED
